Inflammatory mechanisms in acute pancreatitis by de Beaux, Andrew Charles.
Inflammatory mechanisms in
acute pancreatitis
Andrew Charles de Beaux







1. this thesis has been composed by myself;
2. the research work is primarily my own;
3. while I do not hold the degree ofMB ChB from the University of
Edinburgh, all of the work contributing to this thesis was undertaken while
employed as a lecturer by the University of Edinburgh, in the Lister Laboratories,
Royal Infirmary of Edinburgh;
4. this thesis has not been submitted in candidature for any other degree,
diploma or professional qualification.
Mr Andrew Charles de Beaux
Contents
Chapter 1 Page 1
Introduction
1.1 Pathology of acute pancreatitis Page 5
1.2 Pancreatic digestive enzymes Page 6
1.3 Oxygen-derived free radicals Page 9
1.4 Role of the inflammatory cell infiltrate Page 13
1.5 Distal organ damage and the leucocyte Page 14
1.6 Complement system Page 15
1.7 Kallikrein-kinin system Page 16
1.8 Coagulation system Page 17
1.9 Cytokines Page 20
1.10 Platelet-activating factor Page 27
1.11 Acute phase proteins: C-reactive protein Page 29
1.12 Endotoxin Page 31
1.13 Potential biological effects of serum pro- Page 35
inflammatory molecules in acute pancreatitis
1.14 Leucocyte function in acute pancreatitis Page 41
1.15 Study hypothesis Page 43
1.16 Study aims Page 44
Page i
Chapter 2 Page 46
Materials and Methods
2.1 Patients Page 46
2.2 Serum collection Page 47
2.3 Isolation and culture of peripheral blood Page 47
mononuclear cells
2.4 PBMC lymphoproliferation assay Page 48
2.5 Isolation and culture of human umbilical Page 49
vein endothelial cells
2.6 Cytokine and C-reactive protein enzyme- Page 51
linked immunosorbant assays
2.7 Preparation of PBMCs for fluorescence Page 55
activated cell sorter (FACS) analysis
2.8 Conclusion Page 56
Chapter 3 Page 57
Pro-inflammatory cytokine release by peripheral blood mononuclear
cells from patients with acute pancreatitis
3.1 Introduction Page 57
3.2 Patients and methods Page 60
3.3 Results Page 64
3.4 Discussion Page 79
Chapter 4 Page 84
Changes in peripheral blood mononuclear cell pro-inflammatory
cytokine release from patients with acute pancreatitis and correlation
with disease progression
4.1 Introduction Page 84
4.2 Patients and methods Page 85
4.3 Results Page 87
4.4 Discussion Page 92
Page ii
Chapter 5 Page 97
Regulatory control by indomethacin and Type II cytokines of pro¬
inflammatory cytokine release by peripheral blood mononuclear cells
isolated from patients with acute pancreatitis
5.1 Introduction Page 97
5.2 Patients and methods Page 99
5.3 Results Page 101
5.4 Discussion Page 112
Chapter 6 Page 116
Studies on PBMC proliferation and cell sub-types in patients with acute
pancreatitis
6.1 Introduction Page 116
6.2 Patients and methods Page 117
6.3 Results Page 119
6.4 Discussion Page 126
Chapter 7 Page 130
Effect of interleukin-4 and interleukin-10 on human umbilical vein
endothelial cell interleukin-6 and interleukin-8 release
7.1 Introduction Page 130
7.2 Patients and methods Page 132
7.3 Results Page 133
7.4 Discussion Page 142
Chapter 8 Page 145
Serum concentrations of inflammatory mediators in patients with acute
pancreatitis and their relationship to organ failure
8.1 Introduction Page 145
8.2 Patients and methods Page 148
8.3 Results Page 151
8.4 Discussion Page 156
Page iii
Chapter 9 Page 162
A randomized double-blind study of glutamine supplementation of total
parenteral nutrition in patients with severe acute pancreatitis: effect on
peripheral blood mononucler cell pro-inflammatory cytokine release and
proliferative response
9.1 Introduction Page 162
9.2 Patients and methods Page 165
9.3 Results Page 167
9.4 Discussion Page 175
Chapter 10 Page 179
Discussion
Appendix 1 Page 192
References
Appendix 2 Page 235
Scientific presentations and papers resulting from this thesis work
12.1 Presentations Page 235
12.2 Published papers Page 236
12.3 Published abstracts Page 237
Page iv
List of Figures
Figure 1.1 Page 3
Survival by Goris organ failure score in acute pancreatitis
Figure 3.1 Page 66
Effect of foetal calf serum concentration in the culture medium on blood
mononuclear cell IL-6 and IL-8 release
Figure 3.2 Page 67
Effect of lipopolysaccharide concentration in the culture medium on
blood mononuclear cell IL-6 release
Figure 3.3 Page 68
Effect of period of incubation on blood mononuclear cell TNFa, IL-6 and
IL-8 release
Figure 3.4 Page 75
Serum TNFa and IL-6 concentration in patients with acute pancreatitis
Figure 3.5 Page 76
Standard and corrected TNFa release from blood mononuclear cells
isolated from patients with acute pancreatitis
Page v
Figure 3.6 Page 77
Standard and corrected IL-6 release from blood mononuclear cells
isolated from patients with acute pancreatitis
Figure 3.7 Page 78
Standard and corrected IL-8 release from blood mononuclear cells
isolated from patients with acute pancreatitis
Figure 4.1 Page 90
IL-6 release from blood mononuclear cells isolated from volunteers and
patients with acute pancreatitis on day 1 and day 5 of admission
Figure 4.2 Page 91
IL-8 release from blood mononuclear cells isolated from volunteers and
patients with acute pancreatitis on day 1 and day 5 of admission
Figure 5.1 Page 103
Inhibition of spontaneous IL-6 release from blood mononuclear cells
isolated from volunteers and patients with acute pancreatitis by IL-4 and IL-10
Figure 5.2 Page 104
Inhibition of lipopolysaccharide-stimulated IL-6 release from blood
mononuclear cells isolated from volunteers and patients with acute pancreatitis
by IL-4 and IL-10
Figure 5.3 Page 105
Inhibition of spontaneous IL-8 release from blood mononuclear cells
isolated from volunteers and patients with acute pancreatitis by IL-4 and IL-10
Page vi
Figure 5.4 Page 106
Inhibition of lipopolysaccharide-stimulated IL-8 release from blood
mononuclear cells isolated from volunteers and patients with acute pancreatitis
by IL-4 and IL-10
Figure 5.5 Page 107
Effect of period of incubation prior to IL-4 and IL-10 administration on
blood mononuclear cell IL-6 release
Figure 5.6 Page 110
Effect of indomethacin and prostaglandin^ on IL-6 release from blood
mononuclear cells isolated from volunteers and patients with acute pancreatitis
Figure 5.7 Page 111
Effect of indomethacin and prostaglandin-E2 on IL-8 release from blood
mononuclear cells isolated from volunteers and patients with acute pancreatitis
Figure 6.1 Page 122
CD4 to CD8 positive ratios in blood mononuclear cell populations
isolated from volunteers and patients with acute pancreatitis
Figure 6.2 Page 123
(CD4 and CD8) to CD 14 positive ratios in blood mononuclear cell
populations isolated from volunteers and patients with acute pancreatitis
Figure 6.3 Page 124
Flow cytometry scattergrams of blood mononuclear cell populations
isolated from patients with mild and severe acute pancreatitis
Page vii
Figure 6.4 Page 125
Uptake of tritiated thymidine by un-stimulated and phytohaemagglutinin-
stimulated blood mononuclear cells isolated from volunteers and patients with
acute pancreatitis
Figure 7.1 Page 134
Effect of human AB serum concentration in the culture medium on
human umbilical vein endothelial cell IL-6 and IL-8 release
Figure 7.2 Page 135
Effect of period of lipopolysaccharide pulse on human umbilical vein
endothelial cell IL-6 and IL-8 release
Figure 7.3 Page 136
Effect of lipopolysaccharide concentration in the culture medium on
human umbilical vein endothelial cell IL-6 and IL-8 release
Figure 7.4 Page 137
Effect of incubation time period on human umbilical vein endothelial cell
IL-6 and IL-8 release
Figure 7.5 Page 138
Effect of IL-4 on human umbilical vein endothelial cell IL-6 release
Figure 7.6 Page 139
Effect of IL-10 on human umbilical vein endothelial cell IL-6 release
Page viii
Figure 7.7 Page 140
Effect of IL-4 on human umbilical vein endothelial cell IL-8 release
Figure 7.8 Page 141
Effect of IL-10 on human umbilical vein endothelial cell IL-8 release
Figure 8.1 Page 153
Serum TNFa concentration in patients with acute pancreatitis stratified by
disease severity
Figure 8.2 Page 154
Serum soluble TNFa receptor (55 kDa fragment) concentration in
patients with acute pancreatitis stratified by disease severity
Figure 8.3 Page 155
Serum soluble TNFa receptor (75 kDa fragment) concentration in
patients with acute pancreatitis stratified by disease severity
Figure 8.4 Page 157
Serum IL-6 concentration in patients with acute pancreatitis stratified by
disease severity
Figure 8.5 Page 158
Serum C-reactive protein concentration in patients with acute pancreatitis
stratified by disease severity
Page ix
Figure 9.1 Page 170
Changes in the uptake of tritiated thymidine by un-stimulated blood
mononuclear cells isolated from patients with severe acute pancreatitis receiving
glutamine-supplemented or conventional total parenteral nutrition
Figure 9.2 Page 171
Changes in the uptake of tritiated thymidine by phytohaemagglutinin-
stimulated blood mononuclear cells isolated from patients with severe acute
pancreatitis receiving glutamine-supplemented or conventional total parenteral
nutrition
Figure 9.3 Page 172
Changes in TNFa release by blood mononuclear cells isolated from
patients with severe acute pancreatitis receiving glutamine-supplemented or
conventional total parenteral nutrition
Figure 9.4 Page 173
Changes in IL-6 release by blood mononuclear cells isolated from patients
with severe acute pancreatitis receiving glutamine-supplemented or conventional
total parenteral nutrition
Figure 9.5 Page 174
Changes in IL-8 release by blood mononuclear cells isolated from patients




I am indebted to the following for their help, encouragement and advice.
Professor D C Carter, Professor of Surgery, Royal Infirmary of Edinburgh,
Mr K C H Fearon, Reader in Surgery, Royal Infirmary of Edinburgh,
Dr J A Ross, Senior Lecturer, Lister Research Laboratories, Edinburgh and
Mrs J P Maingay, Lister Research Laboratories, Edinburgh.
I am also grateful to the Scottish Office, the Sir Stanley and Lady Davidson
Medical Research Fund, Pharmacia and Upjohn and British Biotech for their
funding which enabled me to research this thesis.
Thanks are due to
MrM O'Riordain for his practical advice in my early laboratory work,
Dr A S Goldie for her advice with the soluble TNFa receptor assay,
Dr Buurman for supplying the antibodies for the soluble TNFa receptor assay,
Mr R G Molloy for his advice regarding prostaglandin mediated control of
peripheral blood mononuclear cell cytokine release,
Miss C Sangster and Mr I Ansell for their practical advice in my laboratory work
and to Mr I Thomson, pharmacist, Royal Infirmary of Edinburgh for his help in the
running of the glutamine total parenteral nutrition study.
I would also like to thank
the medical and nursing staff of the surgical corridor and the intensive care unit,
Royal Infirmary of Edinburgh,
the nursing staff of the labour ward, Simpson Maternity Pavilion, Edinburgh
Page xi
the laboratory staff of the Departments of Clinical Haematology and Biochemistry,
Royal Infirmary of Edinburgh,
and the Department of Statistics, the University of Edinburgh
for their co-operation.
Finally, a very special thanks to all the patients with acute pancreatitis and
the healthy volunteers who kindly and readily agreed to donate samples of their
peripheral venous blood and to participate in the randomised trials.
Page xii
Abstract
Acute pancreatitis is an inflammatory condition. It is associated with a
systemic inflammatory response, the degree of which appears to correlate with the
severity of the illness. The role of circulating leucocytes and their production of
cytokines in the development of severe acute pancreatitis is unknown. Monocytes
are believed to be a major source of pro-inflammatory cytokines, but lymphocytes
and endothelial cells also produce such cytokines. These cell types, in particular
lymphocytes, also produce a variety of down-regulatory signals so that monocytes,
lymphocytes and endothelial cells interact to produce a net systemic inflammatory
signal, influenced further by the varying degree of lymphocyte sub-populations to
undergo blastogenesis in response to inflammation. The focus of this thesis is on
pro-inflammatory cytokines and their release in vitro from peripheral blood
mononuclear cells (PBMCs) isolated from patients with acute pancreatitis.
On admission to hospital, patients with acute pancreatitis demonstrated
increased interleukin-6 and interleukin-8 release but not tumour necrosis factor-a
release from isolated PBMCs compared with healthy volunteers. The severity of the
disease was not related to the level of cytokine release from a standard cell number.
However, when allowance was made for the variation in PBMC numbers in the
blood, the estimated IL-6 and IL-8 release per unit of blood was greater in those
patients with severe disease compared with those with mild disease. Severe disease
is also characterised by a more prolonged duration of increased pro-inflammatory
cytokine release compared with patients with mild disease. Products of the cyclo-
oxygenase pathway play a down-regulatory role in PBMCs in patients with acute
pancreatitis as indomethacin (a cyclo-oxygenase inhibitor) had no significant effect
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on pro-inflammatory cytokine release by PBMCs isolated from healthy volunteers,
but increased IL-6 and IL-8 release by PBMCs isolated from patients with both mild
and severe disease. PBMC pro-inflammatory cytokine release remains sensitive to
the down-regulatory action of the T-cell regulatory cytokines, interleukin-4 and
interleukin-10. Lymphocyte proliferation (as measured by thymidine incorporation)
is impaired in acute pancreatitis and correlates with the severity of the disease.
Following the successful isolation and culture of human umbilical vein endothelial
cells, IL-4 and IL-10 (in contrast to their inhibitory action on PBMCs), produce a
dose dependent increase in endothelial cell IL-6 and IL-8 release. TNFa is often
undetectable in patients with acute pancreatitis on admission, even in severe disease.
However, elevation in the serum concentration of soluble TNFa receptors would
suggest significant TNFa-induced inflammation early in the course of the disease.
Glutamine is a conditionally essential amino acid in patients with severe acute
pancreatitis and is important for immune function. A double blind, randomised
controlled trial of glutamine supplemented versus conventional total parenteral
nutrition in patients with severe acute pancreatitis demonstrated a trend towards
improved lymphocyte proliferation in the glutamine supplemented group.
Furthermore, PBMC IL-8 release but not TNFa and IL-6 release was significantly
reduced over the study period.
Severe acute pancreatitis is associated with prolonged PBMC pro¬
inflammatory cytokine release and impaired lymphocyte proliferation. However,
these cells remain sensitive to the down-regulatory action of T-cell cytokines in
vitro, but the exogenous administration of these cytokines may have an
unpredictable clinical effect because of their different actions on various cell types.
More general methods of immuno-modulation, such as the exogenous





Acute pancreatitis is an acute inflammatory process affecting the pancreas,
with variable involvement of other regional tissues or remote organ systems. It is a
common and potentially lethal disease. Although conservative treatment results in
rapid recovery in the majority of cases, a proportion of patients develop extensive
pancreatic inflammation and necrosis, a systemic inflammatory response, and
subsequent multiple organ failure. This significant minority pose difficult
management problems and they often have a protracted hospital stay, need intensive
care support of their organ failure, and require major surgery to deal with the
consequences of pancreatic necrosis (Carter, 1993; Fenton-Lee, 1993).
While acute pancreatitis remains a dangerous disease, mortality rates appear
to be falling in recent analyses of national statistics. For example, in Finland the
mortality fell from 5.9 % to 2.6 % in the period 1970 to 1989 (Jaakkola, 1993) while
in Scotland it fell from 17.8 % in 1961 to 5.8 % in 1985 (Wilson, 1990). These
trends however, may not be reflected in data from individual surgical units receiving
a high proportion of patients with complicated and severe disease. In an audit of
279 patients with acute pancreatitis managed in the University Department of
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Surgery, Royal Infirmary of Edinburgh, between 1989 and 1993 (de Beaux, 1995)
there were only 4 deaths amongst 210 patients admitted directly to the department, a
mortality rate of 1.9 %. This must be set against the overall mortality rate of 6.1 %
and a mortality rate of 18.8 % (13 deaths) in the 69 patients transferred from other
units for further management of local or systemic complications of the disease. The
overall mortality in this series is similar to that of 7.6 % reported from Leeds for the
years 1985 to 1987 (Larvin, 1989). Severe disease (as defined by the Atlanta
Classification (Bradley, 1993): development of a local pancreatic complication
and/or organ failure) was present in 130 (46.6 %) patients, 74 (35.0 %) in the direct
and 56 (81.0 %) in the transfer group. Ninety (32.3 %) patients developed organ
failure, (scoring 1 or more on the Goris organ failure score (Goris, 1985)), 55 (26.2
%) in the direct and 35 (50.7 %) in the transfer group. The number of patients
surviving or dying in relation to their maximal Goris score is shown in Figure 1.1. It
is of note that not one of the 189 patients with a Goris score of 0 (no organ failure),
died. As the Goris score increased, so did the mortality, rising to a rate of 67 % in
patients with acute pancreatitis with a Goris score of 5 or more. The prevention of
organ failure would thus appear to be of central importance in reducing mortality in
the disease, yet the pathophysiology of the disease is poorly understood. At the
level of the pancreas itself, attempts to explain the varying aetiological agents of
pancreatitis within a unified process has remained elusive. Furthermore, the
sequence of events whereby local inflammation of the pancreas mediates a systemic
inflammatory response, progressing to multiple organ dysfunction and death, is also
unclear.
While progressive organ failure is the common pathway of death in patients
with acute pancreatitis, the timing of onset of this organ failure defines a number of
patient categories. In a number of patients, the onset of acute pancreatitis is






















Survival/non-survival in patients (n=90) with acute pancreatitis as a function
of the worst Goris multiple organ failure score (Goris, 1985) during the illness.
There were no deaths in 189 patients with a score of 0. Survivors (n=73;D) and
non-survivors (n=17;H).
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several days. In a second category, the initial presentation is less dramatic although
the patient continues to be unwell on clinical grounds. Dynamic abdominal
computer tomography scans typically reveal areas of pancreatic necrosis. Many of
these patients will make a slow recovery on conservative treatment but a number
will relapse with ensuing organ dysfunction. The trigger mechanism for this event
are unclear, but may be related to bacterial infection of the once sterile pancreatic
necrosis (Beger, 1986). While this dichotomy in the timing of events exists, it
seems likely the mechanisms responsible for the development of organ failure are
similar in the two groups, arising as a result of the initial pancreatic acinar cell
injury or as a event subsequent to the infected pancreatic necrosis.
In this introduction, the evidence relating to the pathophysiology of acute
pancreatitis is discussed, focusing predominantly on the potential mechanisms
resulting in progression to severe disease and organ dysfunction. Pathological
changes in the pancreas and distal organs are well reported and these are described
briefly. The role of the pancreas as a digestive organ led to the hypothesis that the
pathological changes observed in acute pancreatitis represented a state of auto-
digestion mediated by premature uncontrolled activation of pancreatic digestive
enzymes and that derangement of structure and function in distant organs was a
consequence of such activated enzymes spilling into the circulation. Attempts,
however, to minimise such enzyme activity have enjoyed little clinical success. The
potential role of oxygen-derived free radicals in mediating local and systemic effects
was also recognised although the emphasis now appears to be more on free radical
production from the parenchyma of the pancreas rather than from white blood cells.
A variety of changes in the serum concentrations of a number of factors involved in
the complement, kallikrein-kinin and coagulation cascades have been identified and
point to the development of an acute phase response and a systemic inflammatory
response. However, the demonstration that leucocyte depletion in experimental
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acute pancreatitis attenuated a number of the systemic effects of the disease pointed
to the key role of the leucocyte in mediating end organ damage. Whether leucocytes
mediated such damage as a result of intra-vascular leucocyte activation directly or
by opportunistic exploitation of the damaged endothelium by leucocytes was not
clear from these studies. The evidence leading to the current hypotheses of the
pathogenesis of acute pancreatitis are discussed in turn.
1.1 Pathology of acute pancreatitis
Amongst the earliest descriptions of the pathology associated with acute
pancreatitis were those by Fitz (Fitz, 1889) and Opie (Opie, 1901) towards the end
of the 19th century. They described a number of features associated with severe
pancreatitis including fat necrosis, pancreatic haemorrhage and peri-pancreatic
inflammation. Since then, changes in both the pancreas and other organs in
experimental acute pancreatitis have been described (Becker, 1981). The earliest
microscopic event to be observed appears to occur within the pancreatic acinar cell
with the development of patchy vesiculation of the rough endoplasmic reticulum
(Tardini, 1971; Watanabe, 1984). This progresses to show prominent vacuolation
within the cell with an increased number and heterogeneity of the zymogen granules
(Lombardi, 1975). Following these acinar cell changes, leucocyte congestion within
the post capillary venules is observed proceeding to a marked inflammatory cell
infiltrate into the gland (Aho, 1980). This emigration of leucocytes corresponds to
changes in the micro-circulation including the initial increased fenestration of
capillaries (Kelly, 1993b) progressing to more marked disruption of the endothelium
with time. In-vivo microscopy techniques have demonstrated increased vascular
permeability and reduced capillary blood flow with areas of blood stasis as a
relatively early event (Kusterer, 1991). Micro-corrosion casts of the pancreatic
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micro-vasculature in experimental acute pancreatitis (Kelly, 1993b; McEntree,
1989) show increasing irregularity of capillaries, loss of the typical smooth contour
of vessels, increased tortuosity and abrupt termination of vessels with development
of the local inflammation. Similar findings in the hepatic micro-vasculature
(Andrzejewska, 1985; Delaney, 1990) are observed after a short lag phase behind
the pancreatic changes. Some time later on, similar changes in the pulmonary
micro-vasculature (Kelly, 1991) but not the renal circulation are observed over the
study period (Kelly, 1993a). With increasing severity of the pancreatitis, patchy
areas of acinar cell necrosis coalesce with concomitant haemorrhage, fat necrosis
and oedema with such pathological changes being observed in regional tissues
around the pancreas and in distant organs (Lankisch, 1983a).
1.2 Pancreatic digestive enzymes
1.2.1 Pancreatic enzyme synthesis and transport
Protein synthesis within the pancreas is greater than in any other organ. The
two main enzyme series produced are the digestive enzymes and lysosomal
hydrolases. The synthesis, transport and secretion of these enzymes are common to
protein manufacture in other cell types (Caro, 1964). The protein sequences are
synthesised from messenger RNA on ribosomes attached to the rough endoplasmic
reticulum. The polypeptide chains produced are then transported to the golgi
complex where the pathways of these two enzyme classes diverge: digestive enzyme
proteins are packaged into zymogen granules and lysosomal hydrolases into
lysosomes through an intermediate stage of the condensing vacuole (Steer, 1984).
The mechanism by which the two protein classes are sorted from each other appears
to involve post-translational modification of the lysosomal enzymes (Rosenfield,
1982). Following a secretory signal to the pancreatic acinar cell, for example, by
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pancreozymin, zymogen granules fuse with the cell membrane at the apex of the cell
and discharge their contents into the pancreatic duct, a process termed exocytosis.
1.2.2 Preservation of pancreas integrity
The integrity of the pancreas is protected from the potentially lethal effect of
its enzymes by a number of mechanisms. The enzymes are present as inactive
zymogens sequestered in zymogen granules (Rinderknecht, 1986; Steer, 1984). The
zymogen granule is actively acidified precluding enzyme activity and favouring
enzyme degradation rather than activation (Niederau, 1986). Low intra-granule
calcium concentration promotes a similar environment (Rinderknecht, 1986).
Specific zymogen inhibitors are present in pancreatic secretions and zymogen
granules (Watanabe, 1984). Activation of zymogens normally takes place in the
duodenum, associated with the change in pH, calcium concentration and the
presence of enterokinase, an enzyme released from enterocytes lining the duodenum
that activates trypsin from trypsinogen. Trypsin then appears to be important in the
activation cascade of the remaining pancreatic zymogens (Rinderknecht, 1986).
Whilst the separation, packaging and apical release of these potentially destructive
enzymes would seem to be important for the preservation of the integrity of the
pancreas, derangements in this system have been identified in experimental models
of acute pancreatitis, although their relevance to the disease in man is controversial.
Lombardi and co-workers (Lombardi, 1975) developed a murine model of acute
pancreatitis, by feeding mice a choline-deficient, ethionine-enriched diet. Within
hours of consumption of this diet, the number of zymogen granules present in the
acinar cells rapidly increased suggesting either an accelerated production of these
enzymes or an inhibitory block to granule exocytosis (Steer, 1987). Zymogen
granules then appeared to fuse with the intracellular lysosomes, allowing pancreatic
zymogens to come in contact with lysosomal hydrolases, an event that can mediate
zymogen activation (Rao, 1980).
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In another model of acute pancreatitis, rats were infused with caerulein, a
pancreaozymin analogue (Watanabe, 1984) mediating hyper-stimulation of the
pancreas. Within 30 minutes of caerulein stimulation, large vacuoles appeared in
the acinar cell, shown to contain both digestive enzymes and lysosomal hydrolases.
This intra-vacuole mixing of enzymes is likely to occur as a result of abnormal
condensing vacuole maturation which normally leads to the segregation of
lysosomal hydrolases from digestive enzymes (Baniukiewicz, 1994; Steer, 1984).
Another potentially damaging event, so called 'misdirected' exocytosis, has been
observed in this hyper-stimulation model (Adler, 1982) and in a hyper-stimulation
model of acute pancreatitis in dog (Tardini, 1971). Here the contents of zymogen
granules are released on the basolateral surface of the acinar cell into the interstitium
of the pancreas rather than on the apical surface into the pancreatic ductule.
1.2.3 Role of pancreatic enzymes in systemic organ damage
While pancreatic enzymes are likely to contribute to the local cell damage
observed in acute pancreatitis, their role in the systemic effects of the disease
remains not proven for a number of reasons. Pancreatic hyper-stimulation is not
thought to be play a major role in the initiation of acute pancreatitis in man, except
perhaps in more rare aetiologies of the disease such as following the bite of the
Trinidad scorpion (Bartholomew, 1970) or the ingestion of insecticides with marked
anti-cholinesterase activity (Dressel, 1979). Indeed, active trypsin is rarely found in
more than trace amounts in acute pancreatitis (Mero, 1982) although trypsinogen is
detectable in the serum for several days in patients with acute pancreatitis
(Ventrucci, 1987). Furthermore, homogenates from both normal and inflamed
pancreas have little in the way of proteolytic activity as a number of zymogen and
enzyme inhibitors are released by the pancreas in significant amounts, even in
disease states (Balldin, 1979; Rinderknecht, 1988). The micro-environment
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generated by an inflammatory response tends to be low in calcium and pH, again
reducing the chance of uncontrolled enzyme activation. Finally, therapeutic
intervention to reduce pancreatic stimulation and further enzyme release with
calcitonin (Goebell, 1979), glucagon (Condon, 1973), somatostatin (D'Amico, 1990;
Usadel, 1980), atropine (Cameron, 1979), and nasogastric aspiration (Fuller, 1981)
or by manoeuvres to neutralise activated pancreatic enzymes such as aprotinin
(trasylol) (Imrie, 1978; Trapnell, 1974), gabexate mesilate (Buchler, 1993;
Valderrama 1992), fresh frozen plasma (Goodman, 1986; Leese, 1991) or peritoneal
lavage (Mayer, 1985) have shown no clinical benefit. The exact role of pancreatic
enzymes in mediating distant organ damage is unclear. Infusion of high dose
trypsin and phospholipase A2 in experimental models to reproduce a state of excess
activation has resulted in changes in the blood coagulation system (Kwaan, 1971)
lungs (Nevalainen, 1980; Tahamont, 1982) and brain (Nevalainen, 1980) typical of
the disease. Whether such changes are mediated directly by a toxic effect of
activated pancreatic enzymes in the circulation or by a more indirect mechanism is
unclear. Furthermore, many of the systemic changes in acute pancreatitis are not
specific to the disease, but are evident in other conditions such as those following
major trauma, burns and sepsis where there is no evidence any significant release of
pancreatic enzyme into the circulation.
1.3 Oxygen-derived free radicals
Another avenue of investigation in the pathophysiology of acute pancreatitis
was the potential role of oxygen-derived free radicals, contributing to both
pancreatic cell damage and spillage into the circulation thereby mediating distant
organ damage. Oxygen-derived free radicals are highly charged, toxic intermediates
normally produced in small amounts as a by-product of oxidative metabolism. Such
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by-products are usually rapidly detoxified by endogenous enzymatic free radical
scavengers such as superoxide dismutase, catalase and non-enzymatic free radical
scavengers such as vitamins A, C and E (Reilly, 1991). However, in a number of
pathological conditions, including acute pancreatitis (Scott, 1993), oxygen-derived
free radical production may exceed the scavenging capacity, and tissue injury is
produced largely through the peroxidation of structural lipids in the membranes of
cells and organelles and disruption of membrane transport proteins. Injury of this
nature in pancreatitis is of particular importance, as disruption of lysosomes and
zymogen granules, with the subsequent intracellular release and activation of
lysosomal and granule enzymes, could potentiate the free-radical induced cellular
damage (Bulkley, 1983). It appears however, that pancreatic zymogens as well as
trypsin inhibitors are protected from attack by oxygen-derived free radicals,
resistance that may be conferred by the presence of a hydrogen peroxide-dependent
enzyme in pancreatic juice (Guyan, 1986). Nevertheless, a number of studies using
experimental models of acute pancreatitis have demonstrated a protective effect on
the degree of pancreatic inflammation with the use of oxygen-derived free radical
scavengers such as superoxide dismutase and catalase (Gough, 1990; Sanfey,
1984a), pre-treatment with allopurinol (a xanthine oxidase inhibitor) (Gough, 1990;
Rutledge, 1987; Sanfey, 1985) or administration of a platelet activating factor
antagonist (Dabrowski, 1989). The source of these oxygen-derived free radicals in
acute pancreatitis is believed to be in the pancreas parenchyma, either the acinar
cells or the vascular endothelial cells since leucocyte depletion prior to the induction
of acute pancreatitis (thus removing the leucocyte as a potential source of oxygen-
derived free radicals) had no effect on the degree of pancreatitis induced (Guice,
1989; Sarr, 1987). This finding is perhaps not surprising, as allopurinol was able to
attenuate pancreatic damage in both leucocyte rich and depleted models of acute
pancreatitis. Neutrophils contain little or no xanthine oxidase but generate oxygen-
Page 10
derived free radicals via a membrane-associated NADH oxidase which is not
inhibited by allopurinol (Baboir, 1978).
1.3.1 Xanthine oxidase system
Xanthine oxidase is translated in the form of xanthine dehydrogenase, an
enzyme that is common to most cells and catalyses the terminal oxidation of purines
to uric acid, coupled with the reduction of NAD+ to NADH. Conversion of
xanthine dehydrogenase to xanthine oxidase is by proteolytic cleavage of a 26 kilo
Dalton (kDa) peptide, producing an enzyme which is also able to catalyse the
conversion of purines to uric acid, but now coupled with the reduction of molecular
oxygen. When the extra electron is passed to the oxygen molecule, the highly
reactive superoxide free radical anion is generated. The role of oxygen-derived free
radicals produced by the pancreatic cells is not entirely clear, but they may well
mediate the increased capillary permeability observed early in the course of acute
pancreatitis (Parks, 1983a; Sanfey, 1984b). As well as an effect on capillary
permeability, superoxide appears to catalyse the generation of a cascade of toxic
oxidants (Reilly, 1991) that can signal integrin-mediated adhesion, trapping and
activation of circulating neutrophils by the micro-vascular endothelium (Patel,
1991). It is evident that the recruitment of leucocytes to the tissue by oxygen-
derived free radicals is not unique to acute pancreatitis. Reperfusion of an
ischaemic tissue is associated with an inflammatory cell infiltrate into the previously
ischaemic tissue and such leucocyte emigration is inhibited by allopurinol (Grace,
1994). It has been postulated that cell damage, produced by a noxious agent or
hypoxia, is associated with the rapid conversion of xanthine dehydrogenase to
xanthine oxidase, increased oxygen-derived free radical formation within the
damaged cell, creating an effective mechanism of rapid onset to attract leucocytes to
the vicinity of the cell damage, establishing an area of acute inflammation as part of
the defence mechanism to limit spread of cellular injury to adjacent viable cells and
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to aid in the repair and ultimate healing of the tissue (Bulkley, 1993; Dormandy,
1983). Any additional oxygen-derived free radical production by infiltrating
leucocytes may then act as a second message to potentiate the immune response in
the recruitment of further leucocytes to the area of pancreatic cell damage, perhaps
accounting for the rapid inflammatory cell infiltrate into the gland observed in
models of acute pancreatitis. From this proposal, it is evident that the formation of
free radicals may not necessarily be deleterious to the host, perhaps accounting for
the findings that reducing free radical formation may not alter the clinical outcome
in terms ofmortality in models of acute pancreatitis (Rutledge, 1987). However, to
date, no trials of such therapies in patients with acute pancreatitis have been reported
in the literature.
1.3.2 Role of oxygen-derived free radicals in systemic organ damage
Oxygen-derived free radicals are believed to mediate endothelial cell damage
within the pancreas but can free radicals mediate distant organ damage? Infusion of
intra-vascular hypoxanthine and xanthine oxidase, an oxygen radical generating
system led to increased micro-vascular permeability in distant organs (Parks,
1983b). While oxygen-derived free radicals may account for some of the micro¬
vascular changes in distant organs seen in acute pancreatitis, whether this is a direct
toxic effect (Johnson, 1981; Taylor, 1983) or mediated through the generation of
additional neutrophil chemotactic factors (McCord, 1983), concomitant complement
activation (Willemer, 1991) or intra-vascular leucocyte activation (Guice, 1989) is
not clear. Neutrophils can also damage pulmonary endothelium through their own
oxygen radical production (Guice, 1989), and there is evidence that interaction with
pancreatic enzymes can enhance free radical formation by leucocytes (Tsuji, 1994).
However, Rutledge and co-workers (Rutledge, 1987) found that while treatment
with allopurinol in a model of acute pancreatitis reduced the degree of pancreatic
inflammation, mortality was similar in the treated or untreated groups.
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Nevertheless, Braganza (Braganza, 1995) and co-workers have reported evidence of
oxidative stress that had pervaded the vascular compartment by the time of
admission in patients with acute pancreatitis and the blood micro-nutrient anti¬
oxidant profile at this stage in these patients was consistent with compromised
cellular capacity to withstand further oxidative assault.
1.4 Role of the inflammatory cell infiltrate
The normal function of the infiltrating leucocytes is to remove the offending
material from the site of injury by engulfing it into a phagocytic vacuole where it is
degraded. This process involves the stimulus-secretion coupling of leucocyte
zymogen granules with the phagocytic vacuole (Weissmann, 1982). These granules
contain a variety of proteases, including neutrophil elastase, phospholipase,
DNAase, RNAase, many other lysosomal hydrolases, platelet activating factor, and
also oxidases involved in the production of reactive oxygen species. In a self
limiting disease, tissue damage is minimised and healing follows or is concurrent
with the inflammation leading to recovery. However, circumstances may arise in
which the inflammatory response develops in a direction more damaging to the host
than the initial injury. This can occur when the quantity of material to be digested is
overwhelming (Weissmann, 1971) or when the stimulation of neutrophils and
macrophages is excessive and phagocytosis so vigorous that the granulocyte
contents are spilled into the exterior of the phagocyte before the phagocytic vacuole
has time to close off completely, so called overt secretion (Weissmann, 1982).
Release of lysosomal enzymes, further reactive oxygen metabolites and other tissue
toxic factors into the extra-vascular space will result in additional cell damage,
increasing the intensity of the inflammatory response and initiating a vicious cycle
of leucocyte recruitment, overt secretion, increased tissue injury and further
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leucocyte recruitment. Evidence for this is now recognised in other inflammatory
conditions such as gout and rheumatoid arthritis (Rae, 1982; Rinderknecht, 1988).
It seems reasonable to postulate that in the case of severe initial injury to the
pancreas, or prolonged activation by a noxious agent, the amount of cell debris and
noxious agent to be phagocytosed may become overwhelming, provoking overt
secretion of neutrophil granules into the interstitium of the pancreas. The normally
protective apparatus of both leucocytes and acinar cells is unleashed on a course of
local pancreas destruction. There is increasing indirect evidence that the magnitude
of the inflammatory response may not simply relate to the extent of the initial
pancreatic cell injury, but that the degree of activation of the inflammatory process
may have a significant genetic component (Guillou, 1993; Rinderknecht, 1994).
Thus, the extent or duration of the pancreatic injury coupled with the patient's
idiosyncratic reaction to the presence of pancreatic inflammation that may determine
the progression of the disease to involve distant organs.
1.5 Distant organ damage and the leucocyte
Spillage of a wide variety of products from activated leucocytes, endothelial
cells and damaged parenchymal cells undoubtedly occurs, and many of these
molecules are known to promote a pro-inflammatory effect on vascular beds distant
from the area of initial inflammation. However, Barie and co-workers noted that the
pulmonary sequelae of experimental acute pancreatitis in sheep (in particular the
increased micro-vascular permeability) were prevented by leucocyte depletion prior
to the induction of pancreatitis (Barie, 1982). Similarly, leucocyte depletion
reduced acute lung injury in experimental acute pancreatitis in rats (Guice, 1989;
Willemer, 1991). Furthermore, in other models of acute pancreatitis, pronounced
margination of leucocytes was observed within the capillaries and venules of the
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liver and lungs as an early event in the development of organ dysfunction and failure
(Kelly, 1993b). These observations would suggest that the circulating leucocyte is
an important mediator in the development of the systemic complications of acute
pancreatitis, either interacting with an activated endothelium at the target organ, or
as a consequence of intra-vascular leucocyte activation or as a combination of both
distant endothelial injury and intra-vascular leucocyte activation. The evidence for
these events in man is largely indirect through an interpretation of the changes in
serum complement, kinin and coagulation cascades and the changes in serum
markers of leucocyte activation in patients with acute pancreatitis.
1.6 Complement system
Acute pancreatitis is associated with reduced serum levels of complement
(Foulis, 1982; Goldstein, 1978; Seelig, 1975). Furthermore, patients with severe
disease manifest a greater depletion of serum complement (Goldstein, 1978; Lasson,
1985). This depletion of complement could result from reduced synthesis, but as
complement factors are acute phase proteins (Alper, 1969) and acute pancreatitis is
associated with a significant acute phase protein response, this explanation is
unlikely. The more likely explanation for the depletion of complement is increased
catabolism, either by activation of the classical or alternate complement pathways or
perhaps by direct pancreatic enyme digestion of the factors in the blood. It has been
demonstrated that trypsin and other proteases can cleave C3 and C5 to yield
biologically active fragments (Cochrane, 1968) which are chemotactic for
leucocytes (Ward, 1971), increase capillary permeability, increase the adhesiveness
of neutrophils (Craddock, 1977) and promote the release of lysosomal enzymes
(Goldstein, 1973) from neutrophils. The possibility exists that inappropriate
complement activation in patients with acute pancreatitis is sufficient to generate
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humoral mediators of inflammation and tissue injury within the circulation. Indeed,
there is evidence to support the role of complement activation in the development of
acute lung injury (Craddock, 1977; Hammerschmidt, 1980). Hammerschmidt and
co-workers demonstrated that serum C5a levels correlated with the development of
acute lung injury (Hammerschmidt, 1980). Neutrophils aggregate in response to
activated complement such as C5a (Craddock, 1977) and intra-vascular leucocyte
aggregation, with the resultant formation of leucocyte emboli, has been postulated to
mediate organ damage (Jacob, 1978). Indeed, C5a induced leuco-embolism has
been observed by intra-vital microscopy of rat mesenteries (Hammerschidt, 1978).
1.7 Kallikrein-kinin system
There is depletion of prekallikrein and kininogen in both the serum and
peritoneal fluid of patients with acute pancreatitis, and this depletion is most marked
in patients with severe disease (Lasson, 1984a; Lasson, 1984b; Orlov, 1978).
Conversely, kallikrein activation in blood and especially peritoneal fluid is enhanced
in patients with acute pancreatitis while the ability of the patient's serum to inhibit
kallikrein activity is markedly reduced, being abolished in patients with severe
disease (Lasson, 1984a). O'Brodovich and co-workers (O'Brodovich, 1981)
demonstrated that pulmonary artery bradykinin levels rose in a sheep model of acute
lung injury and suggested that bradykinin may contribute to the increased
pulmonary endothelial permeability observed in their model.
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1.8 Coagulation system
The initial change in the coagulation cascade in patients with acute
pancreatitis is the development of a hyper-coagulable state (Goodhead, 1969;
Murphy, 1977; Shinowara, 1963). Platelet count, fibrinogen, factor V and factor
VIII concentrations rise as part of the acute phase response (Imrie, 1988). However,
progression to a consumptive coagulopathy and disseminated intra-vascular
coagulation in severe acute pancreatitis is manifest by decreased platelet count
(Byrne, 1971), reduced serum levels of prothrombin, fibrinogen, clotting factors,
anti-thrombin III (the main inhibitor of thrombin) (Innerfield, 1952; Lasson 1986)
and evidence of increased fibrinolysis by reduced levels of fibrinogen and raised
levels of fibrin degradation products (Agarwal, 1982; Ranson, 1977). Ranson and
co-workers (Ranson, 1977) demonstrated that early changes in the serum of such
coagulation factors correlated with respiratory, renal and hepatic dysfunction in
patients with acute pancreatitis, and postulated that pancreatic enzyme mediated
intra-vascular coagulation might be implicated in the pathogenesis of the systemic
features of acute pancreatitis. Indeed, a consumptive coagulopathy similar to that
seen in acute pancreatitis can be induced in dogs by the intravenous infusion of
trypsin (Kwaan, 1971). Intra-vascular coagulation and fibrin micro-embolism
involving the pulmonary micro-circulation has been implicated in the pathogenesis
of acute lung injury (Blaisdell, 1970). Indeed, fibrinogen levels were elevated in 80
% of patients with acute pancreatitis on admission and there was a negative
correlation between these levels and the arterial partial pressure of oxygen (Berry,
1981). Saldeen (Saldeen, 1976) suggested that inhibition of normal fibrinolysis in
the lungs might lead to pulmonary fibrin deposition. However the mechanism
whereby fibrin deposition leads to pulmonary damage is not understood. It has been
suggested that fibrin degradation may cause a local increase in capillary
permeability (Belew, 1978). Peptides such as fibrinopeptide-A produced during the
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conversion of fibrinogen to fibrin are also known to cause local pulmonary damage
(Bayley, 1967). Thrombin, itself, has been demonstrated to enhance interleukin-lp
and tumour necrosis factor a-induced polymorphonuclear leucocyte migration
across endothelium (Drake, 1992).
Although changes in the serum complement, kallikrein-kinin and
coagulation cascades described above are likely to play a role in the pathogenesis of
end organ damage, perhaps through endothelial cell activation promoting leucocyte
attraction, it is clear from the work by Barie (Barie, 1982), Guice (Guice, 1989) and
Willemer (Willemer, 1991) that the presence of the leucocyte is imperative in the
production of end organ damage, manifest clinically as organ failure. Furthermore,
in a rat model of acid aspiration, leucocyte depletion showed a protective effect on
multiple organ oedema normally observed in this model (Goldman, 1992).
Similarly, in a guinea pig model of sepsis, granulocyte depletion prevented tumour
necrosis factor mediated acute lung injury (Stephens, 1988). However, a key
question that remains unanswered is do leucocytes merely exploit an activated or
damaged endothelium allowing their migration into the tissues or is there associated
intra-vascular leucocyte activation in patients with acute pancreatitis?
Rinderknecht (Rinderknecht, 1988) proposed that the systemic sequelae of
acute pancreatitis arose following excessive leucocyte activation within the pancreas
with the release of secondary mediators of inflammation such as the pro¬
inflammatory cytokines, tumour necrosis factor-a and interleukin-6 into the
circulation which in turn, promoted intra-vascular leucocyte activation. Indirect
evidence to support this hypothesis has come from the measurement of serum
concentrations of neutrophil elastase in patients with acute pancreatitis and other
inflammatory conditions. The capacity of neutrophils to cause tissue damage has
been attributed to the effects of their lysosomal proteases, especially elastase, and to
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the production by the phagocytic cell of oxygen-derived free radicals. Neutrophil
elastase is released into the extra-cellular space during phagocytosis and is rapidly
complexed in the circulation by ai-protinase inhibitor (Banks, 1991b). Levels of
this complex are elevated in the sera of patients with a number of inflammatory
conditions such as sepsis, rheumatoid arthritis and inflammatory bowel disease
(Adeyemi, 1985; Duswald, 1985) and are thought to be a crude marker of neutrophil
activation. Circulating levels of neutrophil elastase-ai-protinase inhibitor complex
are raised in patients with acute pancreatitis (Banks, 1991a; Domxnguez-Munoz,
1991; Gross, 1990) and the increase in the concentration of this complex has been
shown to reflect the severity of the attack. Banks and co-workers (Banks, 1991a)
found that on the first day of admission, there was no significant difference in the
level of neutrophil elastase-ai-protinase inhibitor complex between patients with
mild or severe disease. However, over the subsequent 4 days, levels of the complex
remained high in the severe group but fell towards the normal range in the mild
group. From day 5 onwards, once again, there was no significant difference
between the two groups. Similar findings were observed in two further similar
studies (Domfnguez-Munoz, 1991; Gross, 1990) suggesting that severe acute
pancreatitis is associated with a prolonged period of neutrophil activation compared
with mild disease.
A multitude of molecules with either pro-inflammatory actions or produced
as a result of such pro-inflammatory stimulation are now recognised in acute
pancreatitis including members of the cytokine family, platelet activating factor,
acute phase proteins and endotoxin. Their appearance or increase in concentration
within the circulation can be measured giving an indication of inflammatory events
including leucocyte activation. The character of such compounds along with their




Cytokines, such as tumour necrosis factor, interleukin-6 and interleukin-8,
are members of a large family of endogenous polypeptides or glycoproteins
produced by leucocytes and in many cases, other cell types. They are capable of
mediating a wide range of biological effects on diverse cell types, many of which
are particularly essential to the hosts' metabolic, haemodynamic, immunologic and
wound healing responses to injury and infection. The production and secretion of
these cytokines is of limited duration and basal production is usually absent or
occurs at low levels. Furthermore, most cytokines are not stored as preformed
molecules and their production requires new gene transcription and translation in
response to a stimulus (Lowry, 1993). The transcription of many cytokine genes
results in an unstable messenger RNA providing a potential mechanism for tight
regulation of their appearance.
All cytokines exert their action by binding to specific cell-surface receptors.
As opposed to many other peptide hormones, cytokine activity is generally exerted
over a short radius via binding to the cell of its origin (autocrine activity), or to a
neighbouring target cell (paracrine activity). Some cytokines do exert an influence
on distal target cells (endocrine activity) although in most cases the detection of
such proteins in the circulation more likely reflects excessive activity of these
mediators at the tissue level (Tracey, 1990). Once bound to the target cell, the post-
receptor actions of cytokines are exerted through second messenger systems. Such
events usually result in altered patterns of gene expression with new messenger
RNA transcription. Many of these activities include some component of altered cell
proliferation, differentiation or differentiated function and movement at nanomolar
to picomolar concentrations.
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Individually, cytokines are potent molecules. Redundant functions are
demonstrated, at least in vitro, but it is clear that there are likely to be no
circumstances in vivo in which cytokines are produced individually. Rather they are
produced together with other cytokines in patterns characteristic of the particular
stimulus or disease. Cytokine interactions are complex so that the ultimate cellular
events elicited by the sequential or simultaneous presence of several cytokines is not
always predictable. Thus, the potency of cytokines and their potential for
amplification and damage which excessive cytokine production carries, has resulted
in elaborate controls on cytokine production and action. The current view of
cytokine biology is of a network of positive and negative cytokines, and cytokine
inhibitors and inducers, which combine to give an overall biological or clinical
response. While this complex interrelationship of cytokines (and a multitude of
secondary mediators) stimulates inflammatory responses designed to protect the
host, in some circumstances the deleterious effects of these factors may
predominate.
1.9.1 Tumour Necrosis Factor-a
Tumour necrosis factor-a (TNFa) was first identified for its anti-cancer
activity hence its name. The gene for TNFa exists on chromosome 6 within the
major histocompatibility complex (Nedwin, 1985). The expression of TNFa
messenger RNA encodes a precursor of 233 amino acids that is processed to a
mature 157 amino acid protein of 17 300 Da. TNFa is normally secreted as a
homotrimer; monomeric TNFa is not biologically active (Callard, 1994). While the
major source of this cytokine is believed to be from macrophages, many other cell
types including monocytes and lymphocytes produce TNFa. Challenge with
endotoxin appears to be the classical induction agent for the release of TNFa. Other
stimuli will release TNFa such as the binding of immune complexes, phagocytosis
by mononuclear phagocytes, interferon gamma, interleukin-2 and viruses
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(Semenzato, 1990). Prostaglandins have demonstrated a suppressive effect on the
release of macrophage derived TNFa production (Kunkel, 1988) and
glucocorticoids suppress the transcription of TNFa (Remick, 1989).
TNFa receptors are present on nearly all cell types with few exceptions such
as erythrocytes and resting T cells. Two receptors are described, Type I and Type
II, both members of the nerve growth factor release superfamily found on
chromosome 12 and chromosome 1 respectively. Soluble forms of both receptors
are detectable in the serum and urine and are derived from the extra-cellular domain
of each receptor. The two receptors have less than 25 % homology and have no
more homology to each other than to other members of the superfamily.
Furthermore, there is no significant homology between the intracellular domains of
the two TNFa receptors indicating different signalling mechanisms. Receptor
cross-linking by the TNFa trimer is important for signal transduction although the
exact signalling mechanism is not clear. However, it seems likely that the two
TNFa receptors are coupled to distinct signal transduction pathways. Mice, for
example, with type I receptor gene deletion are resistant to TNFa-mediated toxicity
(Rothe, 1993).
TNFa has multiple biological activities (Semenzato, 1990). It serves as the
most proximal cytokine mediator of the natural immune response to bacterial
lipopolysaccharide and to activate inflammatory neutrophils and monocytes to affect
microbial killing, stimulation of T- and B-cell function, and expression of class 1
major histocompatibility complex molecules. TNFa further stimulates the
production of other pro-inflammatory cytokines, such as IL-6 and IL-8, and
enhances endothelial cell adhesiveness for leucocytes, thereby contributing to the
recruitment of these activated cells to sites of inflammation. In higher
concentrations in the systemic circulation, TNFa can contribute to haemodynamic
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collapse through reduced vascular smooth muscle tone, reduced myocardial
contractility and activation of the coagulation cascade with associated intra-vascular
thrombosis. The toxicity of TNFa, as well as other cytokines, is synergistically
enhanced by other factors (Tracey, 1991). For example, interleukin-1 by itself, even
when administered at high doses, is minimally toxic, yet when co-administered with
normally non toxic doses of TNFa, the combination becomes lethal. Endotoxin,
along with platelet-activating factor and interleukin-6 also increase TNFa toxicity.
The central role of TNFa in orchestrating the early inflammatory responses
in patients with severe sepsis is well established (Dinarello, 1993b). Elevated levels
of TNFa have been documented in the sera of patients with sepsis (Damas, 1989;
Debets, 1989; Dofferhoff, 1992) and following exposure to endotoxin (Cannon,
Tompkins, 1990; Hesse, 1988; Michie, 1988b). However, TNFa is often
undetectable in the serum of patients with acute pancreatitis, even in those with
severe disease (Banks, 1991a; Domfnguez-Munoz, 1993; Exley, 1992). This may
be due to the short serum half life of TNFa, binding of TNFa to other proteins,
difficulties with the various methods ofmeasuring TNFa in serum or breakdown of
TNFa in the sample by neutrophil elastase (Van Kessel, 1991). Alternatively, it
may be that TNFa is only transiently and repetitively produced and thus the peak
concentration of TNFa could easily be missed by infrequent blood sampling, or
only occasionally spills over into the circulation. In support of the role of TNFa in
the pathogenesis of acute pancreatitis, messenger RNA for TNFa and TNFa itself
have been demonstrated in the pancreatic acinar cell in an experimental model of
acute pancreatitis (Formela, 1993). TNFa has also been demonstrated in
pneumatocytes in the lung tissue of patients with acute pancreatitis dying from acute
lung injury (Nash, 1991), including patients with acute pancreatitis. An additional
factor in the interpretation of serum levels of TNFa relates to the soluble TNFa
receptors. Shedding of TNFa receptors by the target cell may be a process whereby
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the target cell down-regulates itself to a further TNFa related stimulus (Coyle, 1993;
Tartaglia, 1992). However, these soluble TNFa receptors may bind free TNFa
within the circulation or tissues, thereby reducing the bioavailability of TNFa,
preventing TNFa related stimulation of more distant target cells. It is not
inconceivable, also, that the TNFa/TNFa receptor complex has important biological
activity of its own.
1.9.2 Interleukin-6
Interleukin-6 (IL-6) is the accepted term for hepatocyte stimulating factor, a
substance found in the supernatant of leucocytes that could induce an acute phase
protein response in hepatocyte cultures. The human IL-6 gene is located on the
short arm of chromosome 7 (Heinrich, 1990). This gene translates into a 212 amino
acid precursor protein with a molecular mass of 26 kDa. Following removal of a 28
amino acid signal peptide, the resulting protein is glycosylated and phosphorylated
at varying sites. Although the unglycosylated IL-6 is biologically active, these post-
translational modifications may play a role in tissue-specific functions. IL-6 is
synthesised by a number of cells including monocytes/macrophages, fibroblasts,
endothelial cells and lymphocytes. IL-6 production by these cells can be triggered
by a number of stimuli. Monocytes/macrophages are preferentially triggered by
bacterial lipopolysaccharide, while fibroblasts and endothelial cells respond better to
endogenous cytokines such as TNFa. TNFa is also produced by
monocytes/macrophages suggesting that these cells play a key role in the production
of IL-6.
IL-6 has a multitude of actions. It is a major growth factor for the
proliferation and differentiation of B-cell and T-cell lymphocytes. In contrast, IL-6
appears to be inhibitory on the growth of fibroblasts and endothelial cells, perhaps
mediated in a negative autocrine feedback loop. IL-6 has been demonstrated to
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increase endothelial permeability in-vitro (Maruo, 1992). However, the major
target organ for IL-6 would seem to be the liver. Twenty minutes following an
injection of radio-labelled, human recombinant IL-6 into rats, about 80 % had
disappeared from the circulation and was found in the liver (Castell, 1989).
Furthermore, it was exclusively localised on the surface of the liver parenchymal
cells suggesting the existence of a membrane bound IL-6 receptor (IL-6R). This
receptor is now characterised and is made up of 2 trans-membrane subunits (Callard,
1994). The IL-6R a chain subunit binds IL-6 but does not signal. The 13 subunit
(gpl30) does not itself bind IL-6 but interacts with the a chain/IL-6 complex and is
responsible for signal transduction (Kishimoto, 1992). In the case of the hepatocyte,
this signal transduction brings about the synthesis and release of the acute phase
proteins. The nature and role of such proteins with regard to inflammation is
described in section 1.12.
While many pro-inflammatory cytokines have significant cardiovascular
effects (Reidy, 1993), the intravenous infusion of IL-6 into an animal has little in the
way of haemodynamic change (Casey, 1993). However, IL-6 is now recognised as
an endogenous pyrogen, and intravenous infusion of human recombinant IL-6 into
rabbits leads to a rapid onset of fever (Heinrich, 1990).
In contrast to TNFa (section 1.9.1) IL-6 is commonly detected in the sera of
patients with acute pancreatitis, particularly during the early course of the disease.
Both the serum concentration of IL-6 on admission and the peak level of IL-6
correlate to a degree with the severity of the disease (Heath, 1993; Leser, 1991;
Viedma, 1992; Windsor, 1993). IL-6 has also been shown in other conditions
associated with an inflammatory response to correlate with the severity of the
disease, including sepsis (Damas, 1992), thermal injury (Drost, 1993) and the
development of organ failure in patients with intra-abdominal sepsis (Patel, 1994),
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trauma (Hoch, 1993) and following cardio-pulmonary bypass in cardiac surgery
(Casey, 1993).
1.9.3 Interleukin-8
Interleukin-8 (IL-8) belongs to a family of pro-inflammatory molecules
called chemokines (Horuk, 1994). Prior to the introduction of interleukin
nomenclature, a variety of descriptive terms were applied to molecules, often
isolated from monocyte cultures, that could activate or were chemotactic for
neutrophils (Callard, 1994). These molecules were subsequently found to be
identical, i.e. IL-8. IL-8 is produced by multiple cell types, including monocytes,
lymphocytes, granulocytes, fibroblasts, endothelial cells, bronchial epithelial cell
and hepatocytes. Following stimulation of such cells, the production of IL-8 tends
to lag behind that of TNFa or IL-6, although the production of IL-8 results from
similar stimuli, for example, bacterial lipopolysaccharide in the case of monocytes
and TNFa in the case of endothelial cells (Casey, 1993).
The gene for IL-8 is found on chromosome 4. It is generated as a 99 amino
acid polypeptide. While IL-8 shows no significant sequence homology with other
cytokines, it manifests considerable sequence homology with peptides secreted by
platelets and macrophages that have similar activating and chemotactic effects on
immune competent cells.
In common with other cytokines, IL-8 interacts with its target cell via
surface bound receptors, and a number of these are described (Horuk, 1994; Rot,
1992). Two specific IL-8 receptors have been described, IL-8RA and IL-8RB
(Callard, 1994). Both are seven transmembrane spanning, G-protein-linked
receptors of the rhodopsin superfamily. Neutrophils, basophils and lymphocytes are
the main cell types recognised to express these functional receptors. In contrast to
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the narrow ligand specificity of IL-8RA and IL-8RB, receptors expressed by human
erythrocytes have a broad specificity for chemokine attachment. This multi-specific
receptor, designated the erythrocyte chemokine receptor has been identified as the
Duffy blood group antigen, which is also the receptor for the human malarial
parasite, Plasmodium vivax (Horuk, 1994). The role of this receptor is unclear but it
is postulated that this receptor acts as a sink for IL-8 that may enter the circulation
(Tilg, 1993). At least to date, binding of IL-8 to this receptor has not been shown to
influence any of the physiological functions of erythrocytes.
IL-8 is thought to exert predominately pro-inflammatory activity and is
present in the sera of patients with sepsis (van Zee, 1991) as well as those with acute
pancreatitis (Galloway, 1994; Gross, 1992). The serum IL-8 concentration also
tends to correlate with the severity of disease in acute pancreatitis. Furthermore, the
concentration of IL-8 in bronchoalveolar lavage fluid, obtained on the first day of
admission from patients with acute pancreatitis was shown to be greater in those
patients who subsequently developed acute lung injury compared with those who




phosphocholine) is an ether phospholipid molecule that is stored in precursor form
within cell membranes of a number of cell types including endothelial cells,
leucocytes and pancreatic acinar cells. PAF is produced by de novo synthesis or by
remodelling with the consecutive enzymatic action of phospholipase A2 and acetyl
transferase on l-Q-alkyl-2-acyl-sn-glycero-3-phosphocholine. (In the remodelling
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pathway, phospholipase A2 is the rate-limiting enzyme. This enzyme is known to
be elevated in patients with acute pancreatitis and the highest serum levels tend to be
found in those with severe disease (Bird, 1989; Nevalainen, 1993; Schroder, 1980).
A multitude of stimuli for the production of PAF exist and include vasoactive
agonists such as thrombin, histamine and bradykinin as well as cytokines such as
TNFa and interleukin-l(3 , and there is evidence that PAF itself, may induce PAF
synthesis (Heller, 1992).
PAF exerts its action via a cell surface receptor and is believed to play a role
in a large number of cell signalling mechanisms involved with inflammation (Chao,
1993). These transmemembrane spanning receptors, functionally linked to G-
proteins are found on a variety of cell types including most leucocytes, platelets,
macrophages, including Kupffer cells and alveolar macrophages, and endothelial
cells throughout the body. The regulatory factors on PAF receptors is unclear,
although PAF itself has been shown to down-regulate its own receptor.
The term platelet-activating factor is somewhat of a misnomer, as platelet
activation is just one of its many functions. PAF is able to evoke neutrophil
activation causing chemotaxis, aggregation, superoxide release and degranulation.
PAF also increases neutrophil adhesiveness to endothelial cells (Kubes, 1993) and
increases both endothelial permeability and leucocyte migration across the
endothelium (Heller, 1992; Zimmerman, 1992). An additional, important action of
PAF in inflammation is in arachidonic acid metabolism. Various cell types release
arachidonic acid when PAF is synthesised as well as in response to PAF stimulation
(Chao, 1993). The production of leukotrienes, thromboxanes and prostaglandins
from arachidonic acid may amplify and/or mediate the actions of PAF.
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Emanuelli and co-workers (Emanuelli, 1989) demonstrated that the injection
of PAF into the superior pancreatico-duodenal artery of rabbits increased serum
amylase and induced the morphological changes typical of acute pancreatitis. Since
then a number of groups have demonstrated a protective effect on pancreatic cell
damage by pre-treatment with PAF receptor-antagonists in animal models of acute
pancreatitis (Dabrowski, 1989; Fujimura, 1992; Hirano, 1992; Jancar, 1988;
Konturek, 1992; Zhou, 1993). These PAF receptor-antagonists are chemically
similar to PAF but do not initiate a biological response following binding with the
PAF receptor. Treatment with such PAF receptor-antagonists after the initiation of
acute pancreatitis appears to be less successful (Leonhardt, 1992). Nevertheless,
pre-treatment with PAF receptor-antagonists in experimental acute pancreatitis has
also been demonstrated to attenuate a number of systemic effects typical of the
disease such as haemodynamic upset (Ais, 1992) and acute lung injury (Zhou,
1992). Indeed, a PAF receptor-antagonist is currently undergoing clinical trials in
patients with acute pancreatitis.
1.11 Acute phase proteins: C reactive protein
The acute phase proteins are a group of proteins synthesised by the liver in
response to a variety of stimuli such as tissue trauma, ischaemia, inflammation,
infection and malignancy. They include C-reactive protein, serum amyloid A,
haptoglobin, transferrin, ceruloplasmin, a i-anti-trypsin, ai-anti-chymotrypsin,
fibrinogen (see section 1.4) and a number of the complement proteins (see section
1.6). The concentration of these acute phase proteins in the serum can rise 20 to 100
fold following hepatocyte stimulation (Stahl, 1987). The chief messenger in this
respect is considered to be IL-6, exerting its effect at the level of transcription of the
acute phase protein genes (Marinkovic, 1989; Morrone, 1988). Interleukin-ip and
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TNFa also influence the acute phase protein response, perhaps indirectly by
stimulating IL-6 production, and directly at the level of acute phase protein gene
translation (Mazlam, 1994). Glucocorticoids also have a positive feedback on this
response (Castell, 1989). In addition, unknown control mechanisms must regulate
acute phase proteins individually to allow the varying acute phase protein profiles
seen in differing diseases.
The acute phase proteins possess wide ranging functions including
modulation of the host response at the site of inflammation and the binding of toxins
such as bacterial products and proteolytic enzymes released from the sites of
inflammation. C-reactive protein (CRP) was discovered in 1930 as a substance
which precipitated pneumococcal C-polysaccharide (Tillett, 1930), hence its name.
CRP acts as an opsonin, recognising and binding in a calcium dependent manner to
molecular groups found on a wide variety of bacteria and fungi. This process can
activate complement and enhance phagocytosis. Haptoglobin's main action is to
bind free haemoglobin in the plasma. It also binds free iron and by reducing the free
iron concentration in the plasma or tissues may act as a bacteriostat as most bacteria
require a level of free iron in the tissues in order to proliferate (Eaton, 1982).
Transferrin is also an important iron carrying molecule and may contribute to the
iron control system attempting to minimise bacterial proliferation. An additional
function of transferrin is in host cell proliferation. Many human cells express
receptors to transferrin on the cell surface before undergoing cell division. The
availability of sufficient transferrin may be a requirement for the proliferation of
many cell types, including T-cell lymphocytes (Tormey, 1972). The primary
function of ceruloplasmin is as a copper transport protein. However, its action as a
circulating antioxidant has been demonstrated (Goldstein, 1982). a i-anti-trypsin
and ai-anti-chymotrypsin, as there names suggest, are important anti-proteases,
complexing out proteolytic enzymes released from damaged parenchymal cells and
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leucocytes at sites of inflammation. The acute phase protein response is clearly
important to the host but in some cases will contribute significantly to the hyper¬
metabolism associated with a systemic inflammatory response which is believed to
drive the development of organ failure in critical illness (Cerra, 1987).
CRP is the most rapidly detectable of the acute phase proteins and has
proved a useful marker of disease activity in a variety of inflammatory conditions.
Serum CRP concentrations are elevated in patients with acute pancreatitis and both
overall and peak CRP level have been shown to distinguish mild from severe
disease (Mayer, 1984; Puolakkainen, 1987; Wilson, 1989). The rise in serum CRP
lags behind the peak in serum IL-6 concentration by some 24 to 36 hours (Colley,
1983; Windsor, 1993).
1.12 Endotoxin
The terms endotoxin and bacterial lipopolysaccharide are often used
synonymously, although more precisely, endotoxin refers to the impure extract of
lipopolysaccharide found in combination with different proteins. Endotoxin is
derived from the cell wall of Gram-negative and some Gram-positive bacteria
following bacterial lysis. The bacterial cell wall is made up of a
mucopolysaccharide-peptidoglycan layer, a phospholipid layer and an outermost
lipopolysaccharide layer. Lipopolysaccharide serves as a selective permeability
barrier and controls the transport of molecules into and out of the cell and it aids in
the interaction of the bacterium with its environment (Watson, 1994). The
lipopolysaccharide molecule consists of a polysaccharide chain that extrudes into
the environment and shows marked heterogeneity among different bacterial strains.
The inner part of the polysaccharide chain, called the core region is more conserved
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and anti-core antibodies may therefore recognise endotoxin derived from different
bacteria. The best conserved part of the molecule is the lipid moiety, termed lipid
A. This is bound covalently to the polysaccharide chain and serves to anchor the
lipopolysaccharide molecule in the bacterial membrane (Kimmings, 1994). It is the
lipid A component that contains virtually all the biological activity of endotoxin.
Endotoxaemia is a feature of acute pancreatitis (Exley, 1992; Foulis, 1982;
Kivilaakso, 1984). Foulis and co-workers (Foulis, 1982) detected endotoxin in the
serum of 50 % (13/26) of patients with acute pancreatitis. More recently, Windsor
and co-workers (Windsor, 1993) have shown a significant fall in the serum levels of
endogenous anti-endotoxin core antibodies in 28 of 33 cases, implying exposure to
endotoxin. Furthermore, severe disease was associated with a greater depletion of
antibody. The source of endotoxin may be from an infective focus but is more
likely to come from the gut, as a result of increasing intestinal permeability in
response to the stress of the disease (Roumen, 1993; van Deventer, 1988). Exposure
to bacterial lipopolysaccharide (LPS) results in monocyte and tissue macrophage
activation, and indeed, LPS is used as a standard stimulus of such cells in vitro.
While monocytes are able to recognise LPS directly (Dentener, 1993), activation is
potentiated when LPS form a complex with serum proteins such as LPS-binding
protein (a glycoprotien synthesised by the liver as an acute phase protein) (Mathison
1992) which then interact with the CD14 receptor on the surface of the monocyte
(Wright, 1990). Such cellular activation includes the increased synthesis and release
of pro-inflammatory cytokines such as TNFoc, IL-lp , IL-6 and IL-8 (Andersson,
1992). Monocytes in turn, down-regulate their responsiveness by shedding their
surface CD 14 receptor (Bazil, 1991).
Endotoxaemia is observed in a number of conditions and it is unlikely to be
the primary event in the pathogenesis of acute pancreatitis. Nevertheless, its
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presence could contribute to intra-vascular monocyte activation and the subsequent
development of the systemic inflammatory response syndrome associated with the
disease. Endotoxin is recognised to activate the complement system and may be
responsible for changes in the complement system described above (Foulis, 1982;
Goldstein, 1978). Endotoxin is also able to induce endothelial cell activation,
possibly directly or mediated via LPS interaction with the soluble CD 14 receptor
(Arditi, 1993; Issekutz, 1993). Exposure to LPS has also been implicated in
mediating increased neutrophil adhesiveness by activation of the CR3 receptor
(Wright, 1991). Furthermore, endotoxin appears not only to stimulate the
production of pro-inflammatory cytokines, but may also potentiate their action at the
target cell.
An extension to the endotoxin story is the presence of pancreatic sepsis
complicating the acute inflammation. The presence of proven clinical pancreatic
sepsis is recognised as a risk factor for increased morbidity and mortality in acute
pancreatitis (Beger, 1986; Widdison, 1993). The method of infection is not fully
established but may be haematogenous or may represent bacterial translocation from
the gut. Such a phenomenon has been demonstrated in a rat (Tarpila, 1993) and a
feline (Widdison, 1994b) model of acute pancreatitis but its relevance as a
mechanism of pancreatic infection in human disease is unclear. Furthermore, a
randomised multi-centre clinical trial of antibiotic prophylaxis in patients with acute
pancreatitis while reducing septic complications had no effect on the incidence of
multiple organ failure or mortality (Pederzoli, 1993). Nevertheless, it is now clear
that during critical illness, including acute pancreatitis, structural and functional
changes occur throughout the intestinal tract that serve to reduce the integrity of the
gut (Lacey, 1990). The mechanisms for such aleration in gut integrity include
ischaemia, hypoxia and malnutrition (Saadia, 1990), and indeed may be exacerbated
by the presence of pancreatic enzymes within the gut lumen (Bounous, 1977). The
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state of nutrition at the level of the gut during illness is of current interest and
research. The amino-acid glutamine, is now recognised to be an important energy
substrate for the gut, and indeed, most rapidly dividing cells such as the immune
system. (Glutamine and its role in gut and immune function is discussed more fully
in Chapter 9). However, this non-essential amino-acid in health, becomes
conditionally essential during illness as its requirement appears to exceed synthesis
at such times manifest by a fall in glutamine concentration in both plasma and the
intracellular free amino acid pool (Lacey 1990). There is increasing evidence to
suggest that the exogenous administration of glutamine, either by the enteral or
parenteral route, may have beneficial effects on gut and immune cell function (van
der Hulst, 1993; O'Riordain, 1994).
The findings of scientific research presented in this introduction so far have
indicated that severe acute pancreatitis is associated with increased levels of serum
markers of a systemic inflammatory response compared with patients with mild
disease. However, the serum markers measured may have been derived from the
tissues, endothelial cells or leucocytes but the source of such mediators cannot be
identified from these studies. Nevertheless, the findings reflect the host systemic
response to pancreatic inflammation and suggest an up-regulated inflammatory
response contributing to, if not mediating, systemic organ dysfunction and
eventually failure. The next section, continues to explore the role of such
inflammatory mediators in the pathogenesis of acute pancreatitis, both at the level of
the pancreas itself and in particular, the development of distant organ injury.
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1.13 Potential biological effects of serum pro-inflammatory
molecules in acute pancreatitis
Acute pancreatitis, by definition, involves acute inflammation. Acute
inflammation is a process that occurs when living tissue is damaged whereby the
surrounding areas undergo a series of changes which result in phagocytic cells and
elements of circulating plasma entering the damaged area. The aim is to limit
further tissue injury and at the same time is a mechanism of repair and healing. The
presence of pro-inflammatory cytokines, platelet-activating factor, acute phase
proteins and other vasoactive substances within the region of pancreatic
inflammation during acute pancreatitis is generally considered beneficial, acting as
messengers or signals to recruit and activate immune competent cells to the site of
pancreatic injury. And thus, in the majority of patients with acute pancreatitis, it is a
self-limiting condition and unlikely to reoccur if the precipitating factor is identified
and removed. However, a proportion of patients, as already discussed, can develop
a lethal, fulminant systemic illness often associated with the development of
multiorgan failure. This has been attributed to a reaction to infection of pancreatic
necrosis but these life threatening events can also occur in the absence of any
identifiable focus of infection (Allardyce, 1987). While the patients may appear
septic, they do not all have an underlying infection and dead or injured pancreatic
tissue can replace bacteria as the stimulus for the septic or systemic inflammatory
response (Rinderknecht, 1988).
It is now realised that in the development of a systemic inflammatory
response, the host is not an innocent bystander whose tissues are being directly
ravaged by products of injured tissue, but instead is an active participant in this
destructive process (Deitch, 1992). A number of hypotheses have been put forward
to explain these events which contain overlapping elements but the basic element is
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an uncontrolled or persistent immuno-inflammatory response (Border, 1988).
Clearly, an initiating clinical event is required, in this case acute pancreatitis, which
effects multiple normal homeostatic mechanisms. These altered, normally well
controlled, homeostatic systems interact to amplify or modulate each other. For
example, tissue hypoxia within the pancreatic inflammation, activates resident
macrophages and circulating monocytes and neutrophils and multiple humoral
plasma protein cascades. Products of these activated leucocytes and protein
cascades may in turn further impair oxygen delivery by their effects on the micro¬
circulation. Further leucocyte recruitment to the site of inflammation occurs and
this vicious cycle continues.
1.13.1 Macrophage hypothesis
In the macrophage hypothesis, excessive or prolonged activation or
stimulation of macrophages ultimately results in excessive production, surface
expression and liberation of cytokines and other products, which exert initially local
and then systemic deleterious effects. In other words, the inflammatory response
can escape the local environment and induce a generalised systemic response,
resulting in the activation of multiple inflammatory effector cells such as
macrophages, neutrophils and lymphocytes as well as the intra-vascular activation of
humoral protein cascades. Through this uncontrolled intra-vascular response, the
vascular endothelium may be damaged, thereby further potentiating distant organ
injury. Ultimately, systemic inflammation may become self-perpetuating because of
both the continued leak or spill-over of locally or systemically produced
inflammatory mediators into the circulation and inadequate regulation of the
inflammatory response by the host. Thus, while inflammation aids the host at the
tissue level, systemic activation can represent a major potential host liability. This
hypothesis, that distant organ injury is related to an uncontrolled or persistent
inflammatory state is consistent with the post-mortem study of Nuytinck and co-
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workers (Nuytinck, 1986) who found an association between the presence of acute
lung injury and histologic evidence of organ inflammation in patients with major
trauma.
Support for this hypothesis is based on the recognition that macrophage
activation and cytokine release can produce a systemic inflammatory response,
indistinguishable from severe infection. Elevation of serum TNFa, IL-6 and IL-8
levels in patients with acute pancreatitis have been discussed in section 1.9.
Furthermore, the injection of TNFa into human volunteers produces many of the
systemic and immunologic signs associated with the systemic inflammatory
response (Michie, 1988a). While TNFa may mediate some of its damaging effects
directly, evidence is pointing towards other mediators, downstream of TNFa, as key
mediators. One of these mediators could be IL-8.
IL-8 is a potent chemo-attractant for circulating leucocytes to sites of acute
inflammation (Baggiolini, 1989; Kuijpers, 1992; Nourshargh, 1992). Endothelial
surface-bound IL-8 is known to promote the CD11-CD18 integrin-mediated
adhesion between neutrophils and endothelial cells (Huber, 1991; Lo, 1989;
Tanaka, 1993). In addition, IL-8 induces neutrophil shape change and the shedding
of L-selectin from the surface of neutrophils adhered to endothelial cells, events that
are essential for neutrophil emigration (Burns, 1994; Smith, 1991). However,
several groups (Gimbrone, 1989; Luscinskas, 1992; Moser, 1993) have shown that
while certain inflammatory stimuli render cultured human endothelial cells hyper-
adhesive for neutrophils, this state is transient and reversible. The mechanism for
the attenuation of endothelial cell-neutrophil interaction was attributed in part to the
secretion by activated endothelial cells of a soluble leucocyte adhesion inhibitor,
identified as IL-877, the extended amino-terminal IL-8 variant (Gimbrone, 1989).
Furthermore, recombinant human IL-8 inhibited neutrophil adhesion to IL-1-
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activated endothelial monolayers, protecting the monolayers from neutrophil-
mediated damage (Gimbrone, 1989). One explanation for the observations reported
by Gimbrone and others is that IL-8, like all chemo-attractants, is an ineffective
promoter of neutrophil invasion if the stimulus is distributed equally between apical
and basal compartments thereby destroying the concentration gradient. Under
normal conditions of blood flow through a vessel, the IL-8 released by endothelial
cells from the lumenal surface may be bound to antibodies and red cells and
removed (Horuk, 1994; Tilg, 1993). However, if neutrophils come into contact with
soluble blood-borne IL-8, they may undergo shape change and shedding of the L-
selectin receptor before their initial contact with endothelial cells, thus losing their
ability to effectively adhere to activated endothelium and migrate (Moser, 1993;
Rot, 1992). Support for this hypothesis is demonstrated in a mouse model where
neutrophils activated in vitro did not home in to inflammatory sites in vivo (Jutila,
1989). These prematurely intra-vascular activated neutrophils, because of their
shape change or via complement induced aggregation, loose their deformability and
thus cannot pass through capillary beds. They are thus carried in the circulation to
sequester in the next micro-circulation they encounter (Hechtmann, 1991). This
sequence of events such as this may account for the findings described earlier of
prominent leucocyte margination in the liver and then the lungs in models of acute
pancreatitis (Kelly, 1991).
1.13.2 Micro-circulatory hypothesis
In essence, the micro-circulatory hypothesis of multiple organ failure
proposes that organ injury is related to ischaemia or vascular endothelial cell injury.
Inadequate oxygen delivery (Cain, 1991), ischaemia-reperfusion injury (Grace,
1994; Metinko, 1992) and tissue injury due to endothelial-leucocyte interactions
(Osborn, 1990) contribute to the local and systemic tissue destruction. However, the
micro-circulatory and macrophage hypotheses overlap as systemic inflammation
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adversely affects the micro-circulation whereas ischaemia can exaggerate the host's
inflammatory response to subsequent stimuli by activating neutrophils and priming
macrophages (Pober, 1990).
Endothelial cells are active participants in the regulation of blood flow,
coagulation and inflammation. TNFa (and to a lesser extent other cytokines) are
able to induce a change in endothelial phenotype from a non-inflammatory to a pro¬
inflammatory, pro-coagulant phenotype (Pober, 1990). The endothelial cells
express tissue factor, can bind factor VII a and thus activate the extrinsic clotting
pathway. In addition, these endothelial cells express surface receptors that promote
leucocyte adherence and secrete leucocyte-activating factors such as PAF and IL-8.
This shift in endothelial phenotype ultimately results in focal micro-vascular
thrombosis and leucocyte-mediated endothelial cell injury. If widespread, this
phenomenon can progress to tissue ischaemia and ultimately organ failure.
1.13.3 Gut hypothesis
In this hypothesis, intestinally derived bacteria or endotoxin serve as triggers
to initiate or perpetuate or exacerbate the septic state. Bacteria and endotoxin from
the gut efficiently induce cytokine secretion by resident tissue macrophages,
promote a pro-inflammatory endothelial cell phenotype, stimulate neutrophil
protease and oxidant production and activate multiple humoral protein cascades. In
acute pancreatitis, the gut hypothesis is unlikely to be the primary initiating event of
the systemic inflammatory response observed in patients with severe disease.
However, this response is associated with impaired gut perfusion which will
increase intestinal permeability, potentiate endotoxin translocation and feedback in a
positive manner to the systemic inflammatory response state (Saadia, 1990). Once
this cycle is initiated, it can become self-sustaining with progression of the systemic
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inflammatory response, perhaps independent at this stage from the initial pancreatic
cell injury.
The finding of elevated serum levels of pro-inflammatory cytokines and
other inflammatory molecules from activated leucocytes does not in itself, confirm
their role as mediators of the systemic inflammatory responses. More compelling
evidence comes from interventional animal studies, and in particular, those
employing antibodies to such cytokines. An antibody to endotoxin in conjunction
with the antibiotic gentamycin decreased TNFa production which correlated with
survival in a mouse model of Gram-negative sepsis (Mayoral, 1990). Anti-TNFa
monoclonal antibodies have been shown to reduce lethality from endotoxaemia in
rats (Sheppard, 1989) and baboons (Hinshaw, 1990; Tracey, 1987) although this is
not a universal finding (Eskandari, 1992). Anti-TNFa antibodies reduced the
pulmonary micro-vascular permeability but not pulmonary neutrophil sequestration
following intestinal ischaemia-reperfusion in a rat model (Caty, 1989). In a porcine
model of endotoxaemia, anti-TNFa antibodies attenuated the pulmonary micro¬
vascular leak as well as pulmonary neutrophil sequestration (Windsor, 1994). Anti-
IL-6 monoclonal antibodies also protect against lethal Escherichia coli infection and
lethal TNFa challenge in mice (Starnes, 1990). An anti-TNFa antibody in a rat
model of acute pancreatitis attenuated the serum changes in amylase, calcium and
glucose concentration as well as reducing the volume of ascites and fall in
haematocrit (Grewal, 1994). While pancreatic inflammation as assessed by
histological scores was unchanged, the lung scores were improved in the antibody
treated group compared with the untreated group.
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1.14 Leucocyte function in acute pancreatitis
A large body of evidence to support the presence of a systemic inflammatory
response in patients with acute pancreatitis has been presented above. Furthermore,
the greater the response (as determined by the serum concentration of a variety of
inflammatory mediators including pro-inflammatory cytokines) the more likely the
patients will progress to severe diseases characterised by pancreatic necrosis and
organ dysfunction. While such serum changes would point to a state of leucocyte
activation, there is little direct evidence to support the presence of generalised intra¬
vascular leucocyte activation in patients with acute pancreatitis. Larvin and co¬
workers (Larvin, 1993) measured the clearance of trypsin from the plasma as an
index of phagocytic function in patients with acute pancreatitis. Those patients with
severe disease had significantly prolonged clearance of trypsin compared with
patients with mild disease and healthy volunteers suggestive of impaired phagocytic
function in such patients. In the same study, monocytes and polymorphonuclear
leucocytes were isolated from peripheral blood and the in vitro zymosan-stimulated
phagocytic index measured. There was a step wise reduction in median monocyte
phagocytosis between healthy volunteers, patients with mild disease and those with
severe disease. In contrast, there was no significant difference in
polymorphonuclear leucocyte phagocytosis between the three groups. In another
study (Widdison, 1994c), in vitro neutrophil chemotaxis in patients with either mild
or severe acute pancreatitis was no different from controls while random motility
(reflecting increased metabolic activity) was reduced in patients with severe disease
but not mild disease compared with controls. Antibody independent opsonisation
was similar for the three groups while chemiluminescence (an indirect measure of
bactericidal oxidative metabolism) was increased in patients with severe disease but
not mild disease compared with controls.
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1.12.1 CD4-positive T helper lymphocyte dysfunction in acute
pancreatitis
T helper cells are important lymphocytes which control and modulate the
development of immune responses. They express a 62 kDa glycoprotein, the CD
(cluster designation) 4 antibody, in contrast to the 76 kDa glycoprotein on CD8
positive T cells that defines the T cytotoxic/suppresser cell population. T helper
cells produce a number of cytokines, in particular interleukin-4 and interleukin-10.
These cytokines have major down-regulatory effects on other lymphocytes as well
as macrophage cytokine synthesis and effector function (Sher, 1992). Reduced T
helper cell numbers and T cell proliferation occur in patients with burns and trauma
and correlate with the incidence of sepsis and outcome (Curley, 1993). It is possible
that the presence of T helper cell suppression, in conditions manifesting a systemic
inflammatory response (and associated elevated serum levels of pro-inflammatory
cytokines) such as burns, trauma and acute pancreatitis, may contribute to excessive
macrophage activation, and pro-inflammatory cytokine production.
Curley and co-workers (Curley, 1993) have demonstrated a depletion of
CD4-positive T helper lymphocytes in patients with acute pancreatitis with the
greatest depletion occurring in those with severe disease. At the same time, it was
observed that these patients with severe disease had significantly higher serum IL-6
levels compared with those patients with mild disease. Following resolution of the
pancreatitis and recovery of the patient, the CD4-helper population returned towards
normal values. In this study, CD8-positive suppresser lymphocytes numbers were
not measured to allow determination of the CD4/CD8 ratio. It is not clear whether
the CD4/CD8 ratio or the absolute numbers of CD4 positive cells is more important
in determining a more useful index of lymphocyte imbalance. Nevertheless, similar
findings have been reported for CD4-positive T helper cell depletion following
thermal injury (O-Mahony, 1985) and trauma (Faist, 1987). It is postulated that this
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depletion of CD4-positive T helper cells causes an imbalance in the regulatory
control of the immune response early in inflammatory conditions such as acute
pancreatitis, effectively diminishing the brake on leucocyte activation and allowing
deregulated leucocyte activation (Casey, 1993). In the case of monocytes and
macrophages, this would allow up-regulation of pro-inflammatory cytokine
production which could mediate progression of the disease to multiple organ failure
as discussed above.
1.15 Study hypothesis
In view of the reported changes in inflammatory mediators in the serum of
patients with acute pancreatitis, in particular IL-6 but also TNFa, IL-8 and other
pro-inflammatory molecules, severe acute pancreatitis appears to be associated with
a greater systemic inflammatory response compared with patients with mild disease.
Local leucocyte as well as endothelial cell activation within the pancreas in response
to the pancreatic cell injury are likely to be the main source of these inflammatory
mediators. It is hypothesised, that in some cases of the disease, perhaps if the
pancreatic injury is large, or if there is an idiosyncratic reaction to the pancreatic
injury, spill over of these inflammatory mediators into the portal and systemic
circulation can induce and propagate a generalised state of leucocyte and endothelial
cell activation. This generalised inflammatory cell activation is responsible not only
for the degree of pancreatic damage but also mediates distant organ dysfunction,
potentiating further systemic inflammatory responses which in turn correlate with
the severity of the disease.
The working hypothesis of this thesis is that the release of pro-inflammatory
cytokines from peripheral blood mononuclear cells (isolated from patients with
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acute pancreatitis) is increased in patients with acute pancreatitis early in the course
of the disease and that this increased cytokine release contributes to the severity of
the disease. Peripheral blood mononuclear cells are a mixed cell population
comprising monocytes and lymphocytes. Both cell populations are recognised to
produce pro-inflammatory cytokines such as TNFa, IL-6 and IL-8. PBMCs are an
important cell population involved early in acute inflammation in the recognition of
cellular damage and the presence of foreign antigenic material such as endotoxin.
These cell types participate in inter-cellular signalling which can significantly
modify each others cell function when incubated as co-cultures in comparison with
cell function when incubated as monocultures (Mattern, 1994; Oka, 1993). Thus co-
culture ofmononuclear cells is important as this may more accurately reflect the net
effect of their respective actions in vivo.
1.16 Study aims
The aim of this thesis was to examine a number of inflammatory-related
events occurring in the systemic circulation in patients with acute pancreatitis and to
relate these events to the severity of the disease. The pilot study was to compare in
vitro pro-inflammatory cytokine release from peripheral blood mononuclear cells
isolated from healthy volunteers and patients with acute pancreatitis shortly after
their admission to hospital. Leading on from this, pro-inflammatory cytokine
release over the early course of the disease along with the influence of known
peripheral blood mononuclear cell regulatory factors (such as the T helper cell
cytokines, interleukin-4 and interleukin-10, and prostaglandins) was investigated in
vitro. T-cell function, in particular, blastogenesis was also studied over a similar
time period.
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Endothelial cells are also responsible for pro-inflammatory cytokine
production. The potential regulatory role of T helper cell cytokines on endothelial
cytokine release is investigated. TNFa is often undetectable in the sera of patients
with acute pancreatitis. An additional aim of this study was to investigate serum
levels of soluble TNFa receptors in patients with acute pancreatitis and to relate
these findings to the severity of the disease. The final aim was to investigate in a
double blind randomised controlled manner, the effect of glutamine supplemented
total parenteral nutrition compared to conventional nutrition on peripheral blood
mononuclear cell pro-inflammatory cytokine release and T-cell blastogenesis in





2.1.1 Patients with acute pancreatitis
The diagnosis of acute pancreatitis was based on the presence of appropriate
clinical or radiographic (abdominal ultrasound or computed tomography) evidence
accompanied by a serum amylase concentration greater than 1 000 units/1
(Phadebas; Pharmacia Daignostics, Uppsala, Sweden; normal range 70-300 units/1).
All such patients were admitted and cared for by named consultant surgeons in the
Royal Infirmary of Edinburgh.
2.1.2 Healthy volunteers
Control subjects were healthy volunteers, on no medication and with no
known pancreatic or inflammatory disease.
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2.2 Serum collection
Blood was collected for the separation of serum as follows: 10 mis of blood
was removed from a peripheral vein under aseptic conditions into plain tubes
(Sarstedt, Niimbrecht, Germany) through a 21 G needle (Sarstedt, Numbrecht,
Germany). The blood was transported on ice before being centrifuged (1 400 x g
for 10 minutes) and the serum aliquoted into 1 ml apex tubes (Alpha Laboratories
Ltd, Eastleigh, U.K.). Samples were stored within 1 hour of collection at -70 °C
until subsequent batch analysis.
2.3 Isolation and culture of peripheral blood
mononuclear cells
2.3.1 Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood (20 mis) was collected from patients and volunteers under
aseptic conditions into non-pyrogenic lithium heparin tubes (Sarstedt, Numbrecht,
Germany). The blood was layered onto an equal volume of Histopaque®
(polysucrose/sodium diatrizoate)(Sigma Chemicals, Poole, U.K.) in a 50 ml
polypropylene tube (Costar , Cambridge, U.S.A.) and centrifuged at 600 x g for 30
minutes. The cells at the interface were removed and washed 3 times by
centrifugation in RPMI1640 (ICN Flow Laboratories, Irvine, U.K.). The cell pellet
was resuspended in RPMI 1640 medium supplemented with penicillin (50
IU/ml)(ICN Flow Laboratories, Irvine, U.K.), streptomycin (50 |ig/ml)(ICN Flow
Laboratories, Irvine, U.K.) and 2 mM glutamine (ICN Flow Laboratories, Irvine,
U.K.) (complete medium) and either 5 % heat inactivated (56 °C: 30 min) fetal calf
serum (FCS)(ICN Flow Laboratories, Irvine, U.K.) or 5 % autologous serum (AS)
according to the experimental protocol to be followed. The cells were counted
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using a haemocytometer and resuspended at 2 x 106 cells/ml. Viability was
assessed by trypan blue exclusion and was 95-98 %.
2.3.2 PBMC culture
PBMCs were cultured in triplicate at 2 x 105 cells per well in 200 jllI of
complete medium containing 5 % FCS or 5 % AS in 96-well flat-bottomed tissue
culture plates (Costar, Cambridge, U.S.A.) and in the presence or absence of
endotoxin (LPS)(bacterial lipopolysaccharide - Escherichia coli 0127:B9, Sigma
Chemicals, Poole, U.K.) at a final concentration of 5 (Xg/ml. The cells were
incubated at 37 °C in 5 % carbon dioxide, 95 % humidified air for 24 hours. The
supernatants were then removed and stored in aliquots at -70 °C for subsequent
batch cytokine analysis.
2.4 PBMC lymphoproliferation assay
PBMCs were isolated as described above (Section 2.3.1) and cultured in
triplicate in the presence of phytohaemagglutinin (PHA)(Wellcome Diagnostics,
Dartford, U.K.) at final concentrations of 10 pg/ml and 100 |ig/ml. Control wells
were cultured in the absence of PHA. After culture for 72 hours, 1 |iCi [3H]-
methyl-thymidine (3HTdr)(Amersham, Aylesbury, U.K.) was added to each well.
After 4 hours the plates were removed and stored at -70 °C.
To determine 3HTdr uptake, the plate contents were thawed and the cells
harvested onto glass microfibre filter papers (Whatman, Maidstone, U,K,) using an
Automash cell harvester (Dynatech, Billinghurst, U.K.). The discs when dry were
counted in 4 ml of scintillation fluid (Toluene Scintillator, Packard, Groningen,
Netherlands) in an Isocap liquid scintillation counter (Searle, Uithoorn,
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Netherlands) for 10 minutes with the 3HTdr uptake expressed as counts per minute
(cpm).
2.5 Isolation and culture of human umbilical vein
endothelial cells
Unlike the other methods described in this chapter, the isolation and culture
of endothelial cells had not previously been undertaken in the laboratory, although
there was expertise in the laboratory with regard to the isolation and culture of other
primary cells, in particular, hepatocytes. A good deal of trial and error was required
to obtain endothelial cell cultures which are somewhat fastidious cells to isolate,
culture and passage successfully. The method described below was the outcome of
this preparatory work and in my hands became for the most part, a reliable method.
2.5.1 Isolation ofhuman umbilical vein endothelial cell cultures
Human umbilical vein endothelial cells (HUVECs) were obtained by a
modification of the method of Jaffe (Jaffe, 1973). Human umbilical cords were
obtained fresh and transported in ice cold Hanks balanced salt solution
(HBSS)(Sigma Chemicals, Poole, U.K.) containing penicillin (100 IU/ml) and
streptomycin (100 |Xg/ml)(HBSS). Both ends of the umbilical vein were cannulated
with a 14 G intra-venous cannula (Viggo-Spectramed, Helsingborg, Sweden),
secured with a nylon ligature (Ethicon, Edinburgh, U.K.) and the vein flushed with
HBSS to remove any retained blood. The vein was then infused with 15 ml of 0.05
% collagenase H (Boehringer Mannheim, Lewes, U.K.) in HBSS containing 180
mM CaCl2 and incubated for 15 minutes at 37 °C. Following this period the vein
was flushed with RPMI 1640, the perfusate collected in 50 ml polypropylene tubes
(Falcon, U.K.) and cells pelleted by centrifugation at 500 x g for 10 minutes. The
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cells were washed by centrifugation in endothelial-serum free (E-SFM) growth
medium (Gibco BRL, Paisley, U.K.) before being resuspended in E-SFM plating
media (Gibco BRL, Paisley, U.K.) supplemented with penicillin (50 IU/ml),
streptomycin (50 fig/ml), hydrocortisone (1 |ig/ml)(Sigma Chemicals, Poole, U.K.),
endothelial cell growth factor (50 |ig/ml)(ECGF)(Boehringer Mannheim, Lewes,
U.K.) and recombinant epidermal growth factor (10 ng/ml)(rEGF)(Gibco BRL,
Paisley, U.K.) (complete plating medium).
2.5.2 HUVEC culture
HUVECs were cultured in 75 cm3 plastic flasks (Costar, High Wycombe,
U.K.) in complete plating medium. Subsequent media change was with E-SFM
growth media supplemented with the same additives as the complete plating
medium (Section 2.5.1). Passage of HUVEC was as follows: primary cultures were
detached by incubation with trypsin-EDTA (0.25 % trypsin, 0.02 % EDTA in
phosphate buffered saline; pH 7.4), washed serially by centrifugation with RPMI
1640 supplemented with 10% FCS, then E-SFM growth media before being
resuspended in complete plating medium. For the purpose of experimentation,
HUVECs were cultured in triplicate and grown to confluence in 96-well flat-
bottomed tissue culture plates at 37 °C in 5 % carbon dioxide, 95 % humidified air.
All HUVEC cell lines were characterised by the expression of von Willebrand
factor (Section 2.5.3) and were used for experiments between the second and fourth
passage. Confluent HUVECs were incubated in the presence LPS at a final
concentration of 10 ng/ml with 5% human AB serum (Sigma Chemicals, Poole,
U.K.) for 5 hours. Following this period, the cells were washed with E-SFM growth
media and incubated in fresh E-SFM growth media for 12 hours . The supernatant
were then removed and stored in aliquots at -70 °C for subsequent batch cytokine
assay.
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2.5.3 vonWillebrand factor characterisation of HUVECs
Cytospin slide preparations of HUVECs were made and allowed to air dry
before being fixed in cold methanol for 5 minutes. The slides were washed in TBS
(20 mM Tris-HCl, 150 mM NaCl: pH 7.4) and then blocked with 20 % rabbit serum
(Scottish Antibody Production Unit, Carluke, U.K.) diluted in TBS for 20 minutes.
The slides were washed in TBS and the primary antibody, sheep anti-factor
VIII(vWF)(Scottish Antibody Production Unit, Carluke, U.K.) or the control
antibody, sheep serum (Scottish Antibody Production Unit, Carluke, U.K.) diluted
1/100, 1/1 000 or 1/5 000 in TBS added and incubated for 30 minutes. The slides
were washed in TBS and incubated with the secondary antibody, peroxidase
conjugated anti-goat IgG (Sigma Immunochemicals, Poole, U.K.) diluted 1:1 000
for 30 minutes. The slides were washed in TBS and the substrate, 3,3'-
diaminobenzidine tetrahydrochloride (Sigma Immunochemicals, Poole, U.K.)( 1
mg/ml in 0.2 M Tris-HCl, 0.01 M imidazole; pH 7.6 containing 0.15 (J.1 of 30 %
H2O2 per ml) added observing for a brown colour change. The slides were washed
in tap water, counterstained for 10 minutes in 25 % Harris haematoxylin and further
washed in tap water. The slides were dehydrated serially in 64 % ethanol, 74 %
ethanol, absolute ethanol and xylene at 1 minute per stage. The preparation was
mounted in DePex (BDH Ltd, Poole, U.K.) and examined by light microscopy.
2.6 Cytokine and C-reactive protein enzyme-linked
immunosorbant assays
2.6.1 Tumour necrosis factor-a ELISA
Ninety-six well ELISA plates (Costar, Cambridge, U.S.A.) were coated with
mouse monoclonal anti-human-TNFa clone 199 antibody (Boehringer Mannheim,
Lewes, U.K.) diluted in coating buffer (50 mM carbonate-bicarbonate; pH
9.6)(Sigma Chemicals, Poole, U.K.), according to the manufacturers instructions, at
100 jj.1 per well. After a 4 hour incubation at room temperature, the antibody was
removed and the wells blocked with coating buffer containing 1 % bovine serum
albumin (BSA)(Sigma Chemicals, Poole, U.K.) for 20 minutes at room temperature.
The plates were then washed five times in TBS containing 0.1 % Tween-20 (Sigma
Chemicals, Poole, U.K.). Sera diluted 1:5, or PBMC supernatants diluted 1:7 and
1:28 in TBS containing 10 mM EDTA (Sigma Chemicals, Poole, U.K.) and 1 %
BSA were added to wells in duplicate. Standards of recombinant human TNFa (R
& D Systems, Oxon, U.K.) in doubling dilution from 400 pg/ml to 3.12 pg/ml were
added to wells in duplicate. Additionally, two wells were filled with diluent only
and two with an international standard TNFa (National Institute for Biological
Standard and Control, Potters Bar, U.K.) at 50 pg/ml. After overnight incubation at
4 °C, the plates were washed again and 100 pi of peroxidase-conjugated mouse
monoclonal anti-human-TNFa, clone 196, Fab fragments (Boehringer Mannheim,
Lewes, U.K.) diluted according to the manufacturers instructions was added for 2 hr
at room temperature. The plates were washed as described before. The substrate
solution, 0.1 mg/ml tetramethylbenzidine (Boehringer Mannheim, Lewes, U.K.) in
lOOmM sodium citrate-acetate buffer; pH 4.9 (Sigma Chemicals, Poole, U.K.) was
added at 100 p,l per well. The reaction was stopped with 100 pi per well 1 M
H2SO4 (BDH Ltd, Poole, U.K.) and the plates read at 450 nm using a MR5000
ELISA plate reader (Dynatech, Billinghurst, U.K.). Concentrations in the samples
were calculated with "AssayZap" computer software (Biosoft, Cambridge, U.K.).
The intra-assay co-efficient of variation was 3.3 % and the inter-assay co-efficient




IL-6 was assayed in serum diluted 1:5 and 1:30, PBMC supernatants diluted
1:7 and 1:28 and HUVEC supernatants diluted 1:5 and 1:30. The method was
essentially as described for the TNFa ELISA (Section 2.6.1). The coating antibody
was mouse monoclonal anti-human-IL-6 antibody (Boehringer Mannheim, Lewes,
U.K.) diluted to 3 (ig/ml. The standard curve was recombinant human IL-6 (R&D
Systems, Oxon, U.K.) in doubling dilution from 4000 pg/ml to 7.8 pg/ml with an
international standard IL-6 (National Institute for Biological Standard and Control,
Potters Bar, U.K.) at 500 pg/ml. The second antibody was goat polyclonal (non-
enzyme-labelled) anti-IL-6 (R&D Systems, Oxon, U.K.) diluted to 3 (ig/ml. This
was detected by incubation with polyclonal sheep anti-goat-IgG conjugate with
horseradish peroxidase (Sigma Immunochemicals, Poole, U.K.) diluted 1:10 000 for
2 hours at room temperature. The substrate was added as described above (Section
2.6.1). The intra-assay co-efficient of variation was 3.6 % and the inter-assay co¬
efficient of variation was 4.4 %.
2.6.3 InterIeukin-8 ELISA
IL-8 was assayed in serum diluted 1:5 and 1:30, PBMC supernatants diluted
1:28 and 1:98 and HUVEC supernatants diluted 1:5 and 1:30. The method was
essentially as described for the TNFa ELISA (Section 2.6.1). The coating antibody
was rabbit polyclonal anti-human-IL-8, (AMS Biotechnology UK Ltd, Witney,
U.K.) diluted 1:2 000. The standard curve was recombinant human IL-8 (Genzyme,
West Mailing, U.K.) in doubling dilution from 10 000 pg/ml to 20 pg/ml with an
international standard IL-6 (National Institute for Biological Standard and Control,
Potters Bar, U.K.) at 500 pg/ml. The second antibody was goat polyclonal (non-
enzyme-labelled) anti-IL-8 (R&D Systems, Oxon, U.K.) diluted to 3 fig/ml. This
was detected by incubation with polyclonal sheep anti-goat-IgG conjugate with
horseradish peroxidase (Sigma Immunochemicals, Poole, U.K.) diluted 1:10 000 for
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2 hours at room temperature. The substrate was added as described above (Section
2.6.1). The intra-assay co-efficient of variation was 1.3 % and the inter-assay co¬
efficient of variation was 1.3 %.
2.6.4 Soluble TNFa receptor (55 and 75 kDa) ELISAs
Soluble TNFa receptors (STNFR55 and STNFR75) were assayed in serum
samples diluted 1:5 and 1:30. The antibodies were kindly donated by Dr.W.
Buurman, Maastricht, Netherlands. The method was essentially as described for the
TNFa ELISA (Section 2.6.1). The coating antibodies were mouse anti-sTNFR55 or
STNFR75 diluted 10 pg/ml and 5 |lg/ml respectively. Purified STNFR55 and
STNFR75 were used to construct standard curves from 2 500 pg/ml to 20 pg/ml.
The second antibody was biotinylated rabbit anti-sTNFRss or STNFR75, diluted 1:6
000 and 1:4 000 respectively, and detected by incubation with streptavidin ABC
complex/HRP (DAKO, High Wycome, U.K.) diluted 1:200 in TBS for 1 hour at
room temperature. The substrate was added as described above (Section 2.6.1).
The intra-assay co-efficient of variation for STNFR55 and STNFR75 was 2.4 and 1.9
% and the inter-assay co-efficient of variation was 2.4 and 1.9 % respectively.
2.6.5 C-Reactive protein ELISA
CRP was assayed in serum samples diluted 1:7 000 and 1:100 000. The
method was essentially as described for the TNFa ELISA (Section 2.6.1). The
coating antibodies was rabbit anti-human CRP (DAKO, High Wycombe, U.K.)
diluted 1:800. A human serum CRP calibrator (DAKO, High Wycombe, U.K.) was
used to construct standard curves from 100 |Ltg/mlto 0.39 (tg/ml. The second
antibody was peroxidase-conjugated rabbit anti-human CRP (DAKO, High
Wycombe, U.K.) diluted 1:3 000. The substrate was added as described above
(Section 2.6.1). The intra-assay co-efficient of variation was 3.3 % and the inter-
assay co-efficient of variation was 3.2 %.
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2.7 Preparation of PBMCs for fluorescence activated cell
sorter (FACS) analysis
PBMCs were isolated from whole blood by density centrifugation as
described in Section 2.3.1. Following counting using a haemocytometer, the cells
were pelleted and washed by centrifugation in PBS/1 % BSA with azide. The cells
were resuspended in 20 % rabbit serum (Scottish Antibody Production Unit,
Carluke, U.K.) in PBS/1 % BSA with azide at 1 x 105 to 106 cells per 50 pi and left
at room temperature for 20 minutes in order to block any non-specific Fc receptor
binding which might occur. 50 |il of individual antibody (neat supernatant) and 50
pi of the cell suspension were added to LP3 tubes, mixed by agitation and left at
room temperature for 30 minutes. The control antibody was anti-phycoerythin
antibody, an algal protein of mixed isotypes which should have no reactivity with
human tissues (obtained from Dr von Heynigen, MRC Human Genetics Unit,
Edinburgh, U.K.) The test antibodies were against the T cell CD3 antigen, the
helper T cell CD4 antigen, the cytotoxic/suppresser T cell CD8 antigen (obtained
from ECACC, Porton Down, U.K.) and the monocyte CD14 antigen (obtained from
Professor Zola, University of Melbourne, Australia). The cells were washed by
centrifugation in PBS/1 % BSA with 0.01 % azide before 50 pi of 1/100 sheep anti-
mouse FITC F(ab)2 added to the cell pellet, mixed by agitation and left at room
temperature for 30 minutes. The cells were washed by centrifugation in PBS/1%
BSA with azide and finally resuspended in 1 ml FACS fix (1 % formaldehyde in




Every attempt was made to ensure the use of laboratory grade standard
products throughout the study. However, variation in the standard concentration or
biological activity of reagents, particularly those obtained from animal origin such
as LPS, FCS, collagenase and cytokine standards, is well recognised. While
products with the same lot number were used for similar experiments, it is
inevitable that variation in final concentration or final biological activity did vary
throughout the experimental work. This is reflected in variation of baseline values
through out the thesis, making comparison or pooling of results performed several
months apart less reliable.
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Chapter 3
Pro-inflammatory cytokine release by peripheral
blood mononuclear cells from patients with acute
pancreatitis
3.1 Introduction
This chapter investigates pro-inflammatory cytokine release by peripheral
blood mononuclear cells (PBMCs). PBMCs are a mixed cell population comprising
monocytes and lymphocytes. Both cell populations are recognised to produce pro¬
inflammatory cytokines such as TNFa , IL-6 and IL-8. PBMCs are an important
cell population involved early in acute inflammation in the recognition of cellular
damage and the presence of foreign antigenic material such as endotoxin.
Monocytes arise from progenitor cells in the bone marrow. They
differentiate into blood monocytes and represent a circulating pool of phagocytes
that are able to migrate into various organs and tissues to become macrophages. It
is a relatively large cell (10-18 p,m in diameter) containing a well developed Golgi
complex and many intra-cytoplasmic lysosomes. These lysosomes contain a
number of acid hydrolases and peroxidase which is important in intracellular killing
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of micro-organisms. Monocytes will adhere strongly to glass and plastic surfaces.
Adherence and ingestion of cellular matter including micro-organisms is promoted
when the cells bind to the micro-organism through specialised cell surface receptors
for certain carbohydrates, immunoglobulin and complement. A number of these
receptors are found in intracytoplasmic vesicles and are rapidly expressed following
activation. Following activation, monocytes produce and release a number of
inflammatory active molecules termed cytokines. Class II major histocompatibility
antigens are expressed on some monocytes and are important in presentation of
antigens to T-cells. In return, the functions of monocytes can be enhanced or
inhibited by factors released from T-cells.
Lymphocytes are produced in the thymus and bone marrow. In peripheral
blood, they are heterogeneous in both size (6-10 |im in diameter) and morphology.
They are subdivided into T-cells and B-cells. B-cells are involved in the humoral
immune response, producing antibodies in response to exposure to specific antigens.
They have little role in acute pancreatitis and are not discussed further. In contrast,
T-cells are involved in the cellular immune response. When specific antigen is
encountered in the tissues, the T-cells programmed to recognise that particular
antigen transform into lymphoblasts. Lymphoblasts divide by mitosis to produce
activated T-cells. These activated T-cells produce a variety of substances,
collectively called lymphokines which attract and activate local and blood-borne
monocytes/macrophages. Activated macrophages possess greatly enhanced
phagocytic activity which is directed towards the destruction and elimination of
antigen. Other activated T-cells called cytotoxic T-cells promote direct destruction
of cells. The CD3 complex is a human leucocyte antigen that is specific for T-cells.
These cells can be further subdivided by cell surface expression of human leucocyte
antigens into CD4 positive (T-helper cells) and CD8 positive (T-
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cytotoxic/suppresser cells). It is the CD4 positive T-cells that appear to be most
important in the regulation ofmonocytes.
As alluded to already, monocytes and lymphocytes participate in
intercellular signalling which can significantly modify each others cell function
when incubated as co-cultures in comparison with cell function when incubated as
monocultures (Mattern, 1994; Oka, 1993). Thus co-culture of mononuclear cells is
important as this may more accurately reflect the net effect of their respective
actions in vivo. In order to examine aspects of intra-vascular leucocyte activation
directly, this chapter investigates the spontaneous and endotoxin-stimulated release
of pro-inflammatory cytokines from PBMCs isolated from patients with acute
pancreatitis. (Endotoxaemia, measured directly or indirectly by a depletion of
endogenous anti-endotoxin core antibody has been implicated in the development of
multiple organ failure in patients with acute pancreatitis (Windsor, 1993).
Secondly, endotoxin is a recognised standard stimulus for testing stimulated
cytokine release.) Measuring such stimulated cytokine release gives important
additional information compared with spontaneous release alone, indicating if
increased spontaneous release is actually maximal cytokine release or if further cell
stimulation can lead to further increases in cytokine release (Andersson, 1992). The
multitude of inflammatory molecules found in the serum of patients with acute
pancreatitis has been outlined in Chapter 1. In order to investigate the influence of
serum factors on cytokine release, PBMCs were incubated in both autologous serum
and fetal calf serum. Changes in cytokine release in vitro were related to the clinical
course of the patients and to the serum concentration of the corresponding cytokine.
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3.2 Patients and methods
Initial dose response curves were performed on PBMCs isolated from
healthy volunteers to identify the appropriate working concentrations of serum in
the culture medium and the dose of endotoxin for stimulation with respect to pro¬
inflammatory cytokine release. Time course experiments on pro-inflammatory
cytokine release from PBMCs were also performed. Furthermore, cytokine release
from PBMCs was compared with cytokine release from the adherent and non¬
adherent PBMC sub-populations (Bauer, 1988).
3.2.1 Patients
Sixteen consecutive patients with a diagnosis of acute pancreatitis (as
defined in Section 2.1.1) were admitted to the University Department of Surgery,
Royal Infirmary of Edinburgh. Peripheral blood was taken from the patients on the
first day of admission for the isolation of peripheral blood mononuclear cells,
acquisition of serum and white cell counting. The progress of the patient was
evaluated with regard to the development of pancreatic complications as defined by
the 1992 Atlanta Convention (Bradley, 1993) or the development ofmultiple organ
failure as defined by the Goris score (Goris, 1985). No patients were on steroid,
non-steroidal anti-inflammatory or any other immunosuppressive medication on
admission. Six control subjects were healthy volunteers, (Section 2.1.2). The
patients characteristics are given in Table 3.1.
3.2.2 PBMC study protocols
PBMCs were isolated and cultured as described in Sections 2.3.1 and 2.3.2.
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Table 3.1
Details of patients studied. Pancreatic complications defined by the Atlanta
criteria (Bradley, 1993) and organ failure by the modified Goris score (Goris, 1985).
The mononuclear cell count was measured by the Department of Haematology,
Royal Infirmary of Edinburgh on peripheral venous blood taken following
admission to hospital.
Patient Age Sex Aetiology Pancreatic Organ Mononuclear
(yrs) complication failure score cell count
(xlO9 cell/1)
Acute pancreatitis
1 23 F alcohol no 0 1.32
2 35 M alcohol no 0 1.91
3 51 M alcohol no 0 0.56
4 70 M gallstones no 0 1.99
5 47 M alcohol no 1 1.76
6 35 F alcohol no 0 1.81
7 75 M gallstones no 1 1.55
8 34 F gallstones necrosis/ 0 4.35
pseudocyst
9 82 M idiopathic no 1 3.54
10 43 F alcohol no 0 1.51
11 62 M gallstones no 0 1.34
12 53 F gallstones no 0 2.11
13 52 F gallstones necrosis 5 3.9
14 96 F idiopathic no 0 0.75
15 65 F gallstones no 0 1.53









3.2.2.1 Effect of fetal calf serum concentration on PBMC IL-6 and IL-8
release
PBMCs (isolated from 2 volunteers) were incubated at 2 x 105 cells per well
in complete media (Section 2.3.2) supplemented with FCS at 0, 1, 2.5, 5 and 10 %
final concentration in the presence or absence of LPS at 5 pg/ml final concentration.
Following 24 hr incubation, the supernatants were removed and stored in aliquots at
-70 °C for subsequent IL-6 and IL-8 assay.
3.2.2.2 Effect of lipopolysaccharide concentration on PBMC IL-6
release
PBMCs (isolated from 3 volunteers) were incubated at 2 x 105 cells per well
in complete media (Section 2.3.2) supplemented with 5 % FCS and LPS at a
concentration of 0, 0.02, 0.08, 0.31, 1.25, 5 and 20 fig/ml final concentration.
Following 24 hr incubation, the supernatants were removed and stored in aliquots at
-70 °C for subsequent IL-6 assay.
3.2.2.3 Effect of incubation period on PBMC TNFa , IL-6 and IL-8
release
PBMCs (isolated from 2 volunteers) were incubated at 2 x 105 cells per well
in complete media (Section 2.3.2) supplemented with 5 % FCS in the presence or
absence of LPS at 5 )Lig/ml final concentration. Following incubation for 3, 6, 9,12,
18 or 24 hr, the supernatants were removed and stored in aliquots at -70 °C for
subsequent TNFa , IL-6 and IL-8 assay.
3.2.2.4 PBMC IL-6 release from adherent cell, non-adherent cell and
adherent cell/non-adherent cell co-cultures
PBMCs (isolated from 2 volunteers) at 2 x 105 cells per well were incubated
in 200 (il of complete media (Section 2.3.2) supplemented with 5 % FCS for 2 hours
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to allow cell adherence. Following this time period, media in the adherent cell/non-
adherent cell co-culture wells was carefully changed to fresh complete media with 5
% FCS. The wells designated for adherent cell were washed 3 times with fresh
media to remove the non-adherent cells, the washings collected and the wells
refilled with 200 |il of complete media with 5 % FCS. The washing were
centrifuged at 500 x g for 10 minutes and the cell pellet resuspended in 200 |il of
complete media per well washed and replated into clean wells. Following 24 hr
incubation, the supernatants were removed and stored in aliquots at -70 °C for
subsequent IL-6 assay.
3.2.2.5 FACS analysis of PBMC subsets in whole blood and following
purification by density centrifugation
PBMCs were isolated from two volunteers by density centrifugation as
described in Section 2.3.1 and prepared for flow cytometry as described in Section
2.7. Cells were also prepared for whole blood FACS analysis. 2 ml of peripheral
blood was mixed with 45 ml of lysis buffer (8.29 g NH4CI, 1 g KHCO3, 3.7 mg
EDTA in 11 distilled water at pH 7.2). Following 10 minutes at room temperature,
the cells were washed by centrifugation at 4 °C and then resuspended in PBS/0.1 %
BSA at a cell concentration around 5 x 106/ml. The cell suspension was then
prepared for flow cytometry as described in Section 2.7. The antibodies used were
antiphycoerythrin (APE) as the control along with CD3, CD4, CD8 and CD14.
3.2.2.6 PBMC TNFa , IL-6 and IL-8 release from patients and
volunteers
PBMCs (isolated from 16 patients and 6 volunteers) were incubated at 2 x
105 cells per well in complete media (as described in Section 2.3.2) supplemented
with 5 % FCS or AS in the presence or absence of LPS at 5 ftg/ml final
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concentration. Following incubation for 24 hr, the supernatants were removed and
stored in aliquots at -70 °C for subsequent TNFa , IL-6 and IL-8 assay.
3.2.3 TNFa IL-6 and IL-8 ELISAs
Supernatants and serum were assayed for TNFa, IL-6 and IL-8 by ELISAs
as described in Sections 2.6.1, 2.6.2 and 2.6.3 respectively.
3.2.4 White cell counting
The total white cell count and the neutrophil, monocyte and lymphocyte
population count in patients with acute pancreatitis was performed by the
Department of Haematology, Royal Infirmary of Edinburgh.
3.2.5 Statistical analysis
Comparison between patient and control groups or between patients with
mild and severe disease was made with the Mann-Whitney U test while comparison
within patient or control groups was made with the paired Student's t test with
significance taken at a p value < 0.05.
3.3 Results
There was no significant difference in the mean age (55.8 years, range 23-96
v 47.5 years, range 26-73, p = 0.41) between the acute pancreatitis group and the
control groups with a 1:1 sex ratio in both groups (Table 3.1). Five of the 16
patients were considered to have severe disease in that they developed
complications related to their disease. Two patients had pancreatic necrosis
demonstrated by contrast-enhanced CT scanning during the first week of admission
and one of these patients later developed a pancreatic pseudocyst requiring surgical
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drainage. Three patients had renal impairment on admission, scoring 1 on the Goris
score for the renal system (serum creatinine greater than 170 (imol/1). Renal
function in these three patients returned to normal limits with conservative therapy.
3.3.1 Effect of fetal calf serum concentration on PBMC EL-6 and IL-8
release
The concentration of FCS in the culture medium produces a dose-dependent
increase on both spontaneous and LPS-stimulated IL-6 and IL-8 release from
PBMCs. The results of a representative experiment are shown in Figure 3.1. A
concentration of 5 % FCS was chosen for further PBMC culture.
3.3.2 Effect of lipopolysaccharide concentration on PBMC IL-6 release
LPS stimulation resulted in an increased release of IL-6 from PBMCs which
did not appear to be dose-dependent over the dose range studied. The results of a
representative experiment are shown in Figure 3.2. The final concentration of LPS
chosen was 5 pg/ml. While the results would suggest that a lower concentration of
LPS could have been used without reducing the degree of PBMC IL-6 release,
previous PBMC experimentation in the same laboratory had employed LPS at a
final concentration of 5 |ig/ml and this concentration was continued to allow more
direct comparison of results.
3.3.3 Effect of incubation period on PBMC TNFa , IL-6 and IL-8
release
Both spontaneous and LPS-stimulated release of TNFa, IL-6 and IL-8 from
PBMCs into the culture supernatant increased with time, reaching a maximum for
TNFa at 12 hr, IL-6 at 18 hr and IL-8 at 24 hr. The results of a representative
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Figure 3.1
Spontaneous (—) and lipopolysaccharide-stimulated (final concentration 5
|ig/ml)(- -) IL-6 (O) and IL-8 (□) concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from healthy volunteers as a function of
fetal calf serum concentration in the culture medium. 2 x 105 cells per well were
incubated in triplicate under standard conditions in the presence of fetal calf serum





IL-6 concentration in the culture supernatant from peripheral blood
mononuclear cells isolated from healthy volunteers as a function of
lipopolysaccharide concentration in the culture medium. 2 x 105 cells per well were
incubated in triplicate under standard conditions in the presence of
lipopolysaccharide (0-20 (ig/ml) for 24 hr. IL-6 was measured by ELISA. Results




















Spontaneous (—) and lipopolysaccharide-stimulated (final concentration 5
[ig/ml)(- -) TNFa (A), IL-6 (O) and IL-8 (□) concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from healthy
volunteers as a function of the period of incubation. 2 x 105 cells per well were
incubated in triplicate under standard conditions for a period of time up to 24 hr.
TNFa, IL-6 and IL-8 were measured by ELISA. Results of a representative
experiment.
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3.3.4 PBMC IL-6 release from adherent cell, non-adherent cell and
adherent cell/non-adherent cell CO-culture
Spontaneous release of IL-6 from either adherent or non-adherent PBMC
cultures was undetectable. In contrast, IL-6 was detectable in both adherent and
non-adherent LPS-stimulated PBMC cultures. Spontaneous and LPS-stimulated
release of IL-8 was detectable from either adherent or non-adherent PBMC cultures.
However, both spontaneous and LPS-stimulated IL-6 and IL-8 release from
adherent and non-adherent PBMC co-cultures was greater than the sum of cytokine
released from the separate culture of either adherent or non-adherent PBMCs under
similar culture conditions. The results of a representative experiment are shown in
Table 3.2. These findings support the concept of studying cytokine release from
PBMC rather than the cytokine release from isolated monocytes and lymphocyte
monocultures.
3.3.5 FACS analysis of PBMC subsets in whole blood and following
purification by density centrifugation
The percentage recovery of T lymphocytes including their subsets and of
monocytes by density centrifugation is similar to the relative proportions found on
whole blood analysis (Table 3.3). This finding alleviates the concern that density
centrifugation alters the relative proportion of T-cells and monocytes making
extrapolation of the in vitro results back to the in vivo situation less valid.
3.3.6 PBMC TNFoc, IL-6 and IL-8 release from patients and volunteers
The mean spontaneous TNFoc release from PBMCs of patients with acute
pancreatitis, whether incubated in FCS or AS, was similar to that of the control
group (Table 3.4). Similarly, the mean release of TNFoc from LPS-stimulated
PBMCs was not significantly different between the patient and the control group
(Table 3.4). In contrast, the mean 24 hour, spontaneous IL-6 release from PBMCs
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Table 3.2
Spontaneous and LPS-stimulated (final LPS concentration 5 |ig/ml) IL-6 and
IL-8 concentration in the supernatant from adherent PBMCs, non-adherent PBMCs
and adherent/non-adherent PBMC co-culture (2 x 105 cells per well in triplicate)
following 24 hour incubation. Results of a representative experiment in a healthy
volunteer.
Spontaneous LPS-stimulated
IL-6 IL-8 IL-6 IL-8
(pg/ml) (ng/ml) (pg/ml) (ng/ml)
Adherent <200 0.67 290 4.57
Non-adherent <200 6.34 1820 32.47
Co-culture 1560 8.78 5260 52.52
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Table 3.3
FACS analysis of PBMC subsets in whole blood and following purification
by density centrifugation (Histopaque® 1077). Cell surface antigens examined
were CD3 (T lymphocyte), CD4 and CD8 (T lymphocyte sub-populations ) and
CD 14 (monocyte). A minimum of 5000 cells were evaluated for each antigen.
Results of a representative experiment in a healthy volunteer.
Density Separation Whole blood
% CD3 positive 71.7 29.3
% CD4 positive 36.2 15.4
% CD8 positive 31.7 12.9
% CD14 positive 24.6 8.2
Ratio CD3/CD14 2.91 3.57
Ratio CD4/CD8 1.14 1.19
% CD3 and CD14 positive 96.3 37.5
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Table 3.4
Spontaneous and lipopolysaccharide-stimulated (final LPS concentration 5
|0,g/ml) TNFa, IL-6 and IL-8 concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from 6 healthy volunteers and during
the first day of admission from 16 patients with acute pancreatitis. 2 x 105 cells per
well were incubated in triplicate in the presence of 5 % fetal calf (FCS) or 5 %
autologous serum (AS) for 24 hr under standard conditions. * 0.81 > p > 0.18 (not
significant), f 0.037 > p > 0.001. Mann-Whitney U test comparing the acute


















































was significantly increased in the pancreatitis group compared with the control
group when cultured in AS but this effect was not seen when the cells were cultured
in FCS (Table 3.4). The mean 24 hour, LPS-stimulated IL-6 release from PBMCs
was significantly increased in the patient group compared with the control group
when cultured with either FCS or AS (Table 3.4). The mean 24 hour, spontaneous
and LPS-stimulated release of IL-8 from PBMCs was significantly increased in the
pancreatitis group compared with the control group, with the effect seen when the
cells were incubated with either FCS or AS (Table 3.4).
Release of TNFa , IL-6 and IL-8 from PBMCs isolated from patients with
acute pancreatitis and healthy volunteers was significantly increased when the cells
were incubated in the presence of LPS in comparison with spontaneous cytokine
release (Table 3.4). Although the mean ratio of LPS-stimulated TNFa and IL-6
release over spontaneous cytokine release appeared greater in the pancreatitis group
compared with the control group, 3.5 (2.4-4.9) mean (95 % confidence limit) v 2.3
(1.4-3.3) for TNFa and 2.8 (1.7-4.0) v 1.7 (1.2-2.5) for IL-6 respectively, this did
not achieve statistical significance (p > 0.24).
Incubation of PBMCs with AS in comparison with FCS resulted in a greater
spontaneous TNFa and IL-6 release in both the pancreatitis and control groups.
The spontaneous release of TNFa and IL-6 was significantly increased in the
pancreatitis group compared with the control group 3.4 (2.1-5.0) mean (95 %
confidence limit) v 1.7 (1.6-1.9);p = 0.01 and 2.0 (1.6-2.8) v 1.6 (1.4-1.9); p = 0.04
respectively. IL-8 release was not significantly enhanced in either the pancreatitis
or the control group from PBMCs cultured in media supplemented with AS when
compared with PBMCs cultured in media supplemented with FCS 1.4 (0.9-1.8) v
1.2 (0.8-1.7); p = 0.36.
Page 73
TNFa and IL-6 were detectable on the first day of admission in the serum
of 7 patients, 5 of whom developed severe disease as described above (Figure 3.4).
However, there was no correlation between the serum TNFa and IL-6
concentration and the spontaneous PBMC cytokine release (r = 0.10; p = 0.71 and r
= 0.22; p = 0.42 for TNFa and IL-6 respectively). IL-8 was detected in the sera of
only 2 patients. TNFa , IL-6 and IL-8 were undetectable in the sera of the
volunteers.
The spontaneous release of TNFa , IL-6 and IL-8 from PBMCs isolated
from patients with acute pancreatitis on the first day of admission, and cultured at a
standard cell concentration of 106/ml are depicted in Figure 3.5, Figure 3.6 and
Figure 3.7 respectively. There was no significant difference between the 11 patients
with mild and 5 patients with severe pancreatitis in PBMC release of TNFa , IL-6
or IL-8. To allow an estimation of cytokine production per unit volume of blood in
order to take into account the variation in white cell count between patients,
cytokine production from the standard cell concentration was multiplied by the
mononuclear cell count (Table 3.1)(monocyte count plus lymphocyte count)
measured on the first day of admission. The results for TNFa , IL-6 and IL-8 are
depicted in Figure 3.5, Figure 3.6 and Figure 3.7 respectively. PBMC IL-6 and IL-8
release per unit volume of blood in patients with severe disease was significantly
increased compared with mild disease (Figure 3.6 and Figure 3.7). However, there


























Serum TNFa and IL-6 concentration in 16 patients with acute pancreatitis
measured on the first day of admission. Patients with severe disease (n=5; •) and
mild disease (n=ll; 0)(Atlanta classification (Bradley, 1993)). TNFa and IL-6
were measured by ELISA with the minimum level of detection 15 pg/ml and 40





























Mild Severe Mild Severe
Figure 3.5
Spontaneous TNFa concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 16 patients with acute pancreatitis on the first
day of admission (O), stratified for mild (n=ll) and severe (n=5) disease (Atlanta
classification (Bradley, 1993)). 2 x 105 cells per well incubated in triplicate under
standard conditions for 24 hr. Spontaneous TNFa concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from the same 16
patients multiplied by the peripheral blood mononuclear cell count (•) and
stratified for disease severity as before. TNFa was measured by ELISA. * p > 0.13
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Spontaneous IL-6 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 16 patients with acute pancreatitis on the first
day of admission (O), stratified for mild (n=ll) and severe (n=5) disease (Atlanta
classification (Bradley, 1993)). 2 x 105 cells per well incubated in triplicate under
standard conditions for 24 hr. Spontaneous IL-6 concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from the same patients
multiplied by the peripheral blood mononuclear cell count (•) and stratified for
disease severity as before. IL-6 was measured by ELISA. * p = 0.31 (N.S). f p =































Mild Severe Mild Severe
Figure 3.7
Spontaneous IL-8 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 16 patients with acute pancreatitis on the first
day of admission (O), stratified for mild (n=ll) and severe (n=5) disease (Atlanta
classification (Bradley, 1993)). 2 x 105 cells per well incubated in triplicate under
standard conditions for 24 hr. Spontaneous IL-8 concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from the same patients
multiplied by the peripheral blood mononuclear cell count (•) and stratified for
disease severity as before. IL-8 was measured by ELISA. * p = 0.16 (N.S.). t P =
0.02. MannWhitney-U test comparing patients with mild and severe disease.
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3.4 Discussion
The findings that both adherent and non-adherent PBMC sub-populations
release the pro-inflammatory cytokines measured and the synergistic effect on such
cytokine release when both sub-populations are co-cultured re-inforce the value of
studying mixed cell cultures when seeking to understand events that may be
occurring in vivo (Table 3.2). Furthermore, the procedure of density centrifugation
appears to be an appropriate method of isolation of PBMCs, achieving similar
mononuclear cell populations in vitro to that in vivo as per the manufacturers
instructions (Table 3.3). Clearly, the cell numbers are preserved but what is less
certain is the effect of density centrifugation on cell function.
The studies described in this chapter demonstrate an increased release of IL-
6 and IL-8 from PBMCs in the blood of patients with acute pancreatitis compared
with healthy volunteers, (Table 3.4). While there was no significant difference in
pro-inflammatory cytokine release per cell when comparing patients with mild or
severe disease (Figure 3.5, Figure 3.6 and Figure 3.7), making allowance for the
white cell count revealed that IL-6 and IL-8 release per unit volume of blood was
significantly greater in patients with severe disease (Figure 3.6 and Figure 3.7).
This effect was not observed for PBMC TNFa release (Figure 3.5) despite the
observation that TNFa plays an important early role in the cascade of inflammatory
events (Lowry, 1993). Although blood was withdrawn from patients as soon after
admission as feasible, it was evident that the disease process, as manifest by patient
symptoms, had been present for many hours and in some cases, a day or two prior to
admission. It is thus likely that significant release of TNFa from PBMCs had
already occurred, as indicated by elevated serum TNFa levels in a number of
patients (Figure 3.4). It is perhaps of greater significance, with regard to the
pathogenesis of acute pancreatitis and its complications, that PBMCs in patients
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were still able to mount a similar TNFa response to healthy volunteers despite the
elevated serum TNFa concentration without the appearance of tolerance to the
initial stimulus (Mathieson, 1990).
Monocyte activation generally follows exposure to bacterial LPS. While
monocytes are able to recognise LPS directly (Dentener, 1993), activation is
potentiated when LPS forms a complex with serum proteins such as LPS-binding
protein which then interact with the CD 14 receptor on the surface of the monocyte
(Wright, 1990). LPS-binding protein is present in human serum but being an acute
phase protein, its serum concentration is elevated in patients with inflammatory
conditions such as acute pancreatitis. The concentration of LPS-binding protein in
fetal calf serum is not known. However, the presence of a LPS-binding protein
appears to be a consistent finding in other animals (Schumann, 1990) and its
presence in fetal calf serum is likely. In the present study, incubation with
endotoxin led to an increased release of TNFa , IL-6 and IL-8 from PBMCs in both
the patient and control groups, although the mean stimulation index (comparing
LPS-stimulated cytokine release with spontaneous cytokine release) was not
significantly different between the patient and control groups. While endotoxaemia
is unlikely to be the primary event in the pathogenesis of acute pancreatitis, its
presence could contribute to the state of monocyte activation and the subsequent
development of the systemic inflammatory response syndrome associated with the
disease.
Culture of isolated PBMCs in either autologous or fetal calf serum allows
comparison between the behaviour of cells under the same conditions (FCS) or in
the conditions prevailing in vivo (AS). Incubation with AS increased both
spontaneous and LPS-stimulated TNFa and IL-6 release in both patients and
controls, but this effect was not seen with regard to IL-8 release (Table 3.4).
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Furthermore, spontaneous TNFa and IL-6 PBMC release in patients with acute
pancreatitis in comparison with the control group, showed a greater cytokine release
in response to incubation with AS compared with FCS. This finding suggests that
circulating factors in the sera of patients with acute pancreatitis contribute to the
state of PBMC activation with regard to TNFa and IL-6 secretion. Damaged acinar
cells and the leucocyte infiltrate associated with the pancreatitis are known to
secrete a wide variety of pro-inflammatory agents, including complement factors
(Lasson, 1984a), oxygen derived free radicals (Sanfey, 1985), cytokines, platelet
activating factor (Fujimura, 1992) and products of the lipo-oxygenase pathway such
as leukotriene B4 (Rinderknecht, 1988). All these agents are known to affect
endothelial cells and promote circulating leucocyte activation. Differences in
endotoxin concentration between FCS and AS are unlikely to account for this
observation as the lipopolysaccharide stimulation concentration used in this study
protocol had been shown to induce maximal cytokine release (Figure 3.2) with no
evidence of cell cytotoxicity at higher LPS stimulation doses.
Elevation of serum IL-6 levels early in the course of acute pancreatitis is
well documented (Heath, 1993; Leser, 1991; Viedma, 1992). While a number of
immunocompetent cells secrete IL-6 in vivo, the increased secretion of IL-6 by
PBMCs observed in patients in the present study suggests that this source may
contribute significantly to elevated serum IL-6 concentrations. Studies have
reported that both the concentration on admission and the peak concentration of
serum IL-6 correlate with disease severity (Leser, 1991; Viedma, 1992). This
correlation is also described in other conditions where inflammation plays a key
role. For example, the risk of sepsis correlates with serum IL-6 concentration in
patients following major burns (Drost, 1993) and in post-operative patients in an
intensive care unit (Damas, 1992). Furthermore, Faist and co-workers (Faist, 1992)
have shown that monocyte IL-6 secretion is increased two-fold in patients by sepsis.
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In an intervention study using a mouse burns-sepsis model, IL-16 and indomethacin
administration reduced the production of TNFa , IL-16 and IL-6 by cultured
splenocytes towards normal control levels with a corresponding improvement in
survival (O'Riordain, 1992). These results suggest that in inflammatory conditions,
such as acute pancreatitis, excessive production of IL-6 from PBMCs may be
altered by therapeutic intervention and could conceivably influence outcome.
Alternatively, IL-6 may simply be a marker of more important pro-inflammatory
mediators.
Although there is evidence that serum IL-8 levels are elevated in acute
pancreatitis (Gross, 1992), IL-8 was detected in the serum on the first day of
admission in only two patients in the present study. However, the IL-8 ELISA did
not allow accurate measurement of serum IL-8 concentrations below 200 pg/ml.
Furthermore, blood has a large capacity for inactivating IL-8, principally through
irreversible binding with red blood cells (Horuk, 1994; Tilg, 1993), and thus serum
IL-8 measurement early in the course of an acute inflammatory disease might not
reflect cellular or PBMC IL-8 production. Nevertheless, the increase in PBMC IL-8
release in vitro observed in the present study may help explain the elevation of
serum IL-8 in acute pancreatitis. Similar up-regulation of IL-8 release from
monocytes has been observed in a study simulating ischaemia-reperfusion
(Metinko, 1992). However, Faist (Faist, 1992), who observed up-regulation of IL-6
release from monocytes in patients with sepsis or multiple trauma, found that
monocyte IL-8 release was suppressed in the same patients.
The results of the present study reveal increased LPS-stimulated IL-6 and
IL-8 release and spontaneous IL-8 release from PBMCs in patients with acute
pancreatitis early in the course of their disease. Increased de novo synthesis of these
cytokines could possibly account for these findings although this can not be
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determined from the present study. Increased synthesis is likely as it is recognised
that messenger RNA can be detected for these cytokines within minutes of
stimulation (Zhong, 1993). However, the link between disease progression and
resolution and such pro-inflammatory cytokine release is not known. Furthermore,
whether this up-regulation results from an imbalance in the production of




Changes in peripheral blood mononuclear cell pro¬
inflammatory cytokine release from patients with
acute pancreatitis and correlation with disease
progression
4.1 Introduction
The previous chapter demonstrated that IL-6 and IL-8 release from PBMCs
isolated on the first day of admission from patients with acute pancreatitis was
increased compared with healthy volunteers. However, the intensity of the pro¬
inflammatory cytokine release under standard conditions did not appear to be
associated with subsequent disease severity. Only when allowance was made for the
white cell count prevailing at the same time in patients with the disease, total IL-6
and IL-8 release (per unit volume of blood) from PBMCs appeared to be greater in
those who subsequently developed severe disease. However, the changes in such
PBMC cytokine release with time during the course of the illness is not known.
The aim of this study was to compare PBMC IL-6 and IL-8 release on the
first and fifth day of admission in patients confirmed to have mild or severe disease.
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Day 5 was chosen for several reasons. On clinical grounds, the differentiation as to
the severity category of the patient is usually clear and the study of patients with
mild disease beyond this time point can be difficult as the patient is fit for discharge
from hospital. Furthermore, studies looking at indirect evidence of leucocyte
activation such as neutrophil elastase or IL-6 in the serum report a difference in the
median between the two groups of patients up to this time (Banks, 1991a; Heath,
1993). As in chapter 3, both spontaneous and LPS-stimulated cytokine release was
examined.
4.2 Patients and methods
4.2.1 Patients
The study group comprised 14 patients with acute pancreatitis as defined in
Section 2.1.1. Peripheral blood was taken from patients on the first and fifth day of
admission for the isolation and culture of PBMCs (as described in Section 2.3). The
progress of the patient was evaluated with regard to the development of pancreatic
complications as defined by the 1992 Atlanta Convention (Bradley, 1993) or the
development of multiple organ failure as defined by the Goris score (Goris, 1985).
The patient characteristics are given in Table 4.1. Six healthy volunteers were also
studied to provide an indication of 'normal' cytokine release.
4.2.2 PBMC study protocol
PBMCs were incubated at 2 x 105 cells per well in the presence or absence
of LPS (final concentration 5 fig/ml). Following 24 hr incubation, the supernatants
were removed and stored in aliquots at -70 °C for subsequent batch cytokine assay.
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Table 4.1
Details of patients studied. Pancreatic complications defined by the Atlanta
criteria (Bradley, 1993) and organ failure by the modified Goris score (Goris, 1985).
Patient Age Sex Aetiology Pancreatic Organ failure
(years) complication score
Acute pancreatitis
1 90 F gallstones no 0
2 86 F gallstones no 0
3 68 F gallstones no 0
4 61 F gallstones no 0
5 79 M idiopathic no 1
6 69 M gallstones necrosis 0
7 47 F alcohol necrosis 5 (Died)
8 54 F gallstones no 0
9 31 M alcohol no 1
10 42 M alcohol no 0
11 77 F idiopathic no 0
12 84 F gallstones no 2
13 42 F alcohol no 0









4.2.3 IL-6 and IL-8 ELISAs
Supernatants and serum were assayed for IL-6 and IL-8 by ELISAs as
described in Sections 2.6.2 and 2.6.3 respectively.
4.2.4 Statistical analysis
Initial comparison between patients with mild disease, severe disease and
volunteers was performed using the Kruskal-Wallis test. Thereafter, Mann-Whitney
U tests were applied to compare differences between any two groups while
comparison within the acute pancreatitis group was made with the paired Student's t
test with significance taken at a p value < 0.05.
4.3 Results
While the volunteer group were younger than the patient group (40 years,
range 28-49 v 63 years, range 31-90 respectively, p = 0.70), there was no significant
difference in the mean age between patients classified as mild or severe disease (65
years, range 42-90 v 61 years, range 31-84 respectively, p = 0.70). Six of the 14
patients were considered to have severe disease in that they developed complications
related to their disease. Three of these patients had pancreatic necrosis
demonstrated by contrast-enhanced CT scanning during the first week of admission.
Five of the six patients with severe disease scored 1 or more on the modified Goris
score, one of whom died ofmultiple organ failure.
The mean spontaneous release of IL-6 in patients with either mild or severe
acute pancreatitis on the first day of admission was significantly increased compared
with the volunteer group (mild 2855 pg/ml or severe 3488 pg/ml v volunteer 791
pg/ml; p<0.02, Table 4.2). There was no significant difference in the mean
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Table 4.2
Mean (standard error of the mean) spontaneous IL-6 and IL-8 concentration
in the culture supernatant from peripheral blood mononuclear cells isolated from 6
healthy volunteers and from 14 patients with acute pancreatitis on day 1 and day 5
of admission, stratified for mild (n=8) and severe (n=6) disease (Atlanta
classification (Bradley, 1993)). 2 x 105 cells per well incubated in triplicate under
standard conditions for 24 hr. IL-6 and IL-8 were measured by ELISA.
Day 1 Day 5
Cytokine Volunteer Mild Severe Mild Severe
IL-6 (pg/ml) 791 2855 3488 1538 6724
(168) (615) (980) (418) (3093)
IL-8 (ng/ml) 35.0 146 174 50.1 131
(16.5) (45.9) (49.7) (24.8) (28.7)
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spontaneous release of IL-6 in patients with mild disease compared with severe
disease on the first day of admission (2855 and 3488 pg/ml respectively; p=0.15,
Table 4.2). In contrast, on the fifth day of admission in patients with acute
pancreatitis, mean spontaneous release of IL-6 remained significantly elevated
compared with the volunteer group (6724 pg/ml; p=0.01, Table 4.2) while the mean
spontaneous release of IL-6 in the mild pancreatitis group was not significantly
different compared with the volunteer group (1538 pg/ml; p=0.30, Table 4.2). The
individual data points for PBMC IL-6 release for the 14 patients with acute
pancreatitis are shown in Figure 4.1. All the patients with severe disease
demonstrated on day 5 an IL-6 release increased or within 90 % of the day 1 value.
In contrast, PBMC IL-6 release in the mild disease group on day 5 fell by more than
10 % in all patients except one.
The mean spontaneous release of IL-8 in patients with either mild or severe
acute pancreatitis on the first day of admission was significantly increased compared
with the volunteer group (mild 85.5 ng/ml or severe 174 ng/ml v volunteer 35.0
ng/ml; p<0.03, Table 4.2). There was no significant difference in the mean
spontaneous release of IL-8 in patients with mild disease compared with severe
disease on the first day of admission (146 and 174 ng/ml respectively; p=0.07, Table
4.2). In contrast, on the fifth day of admission in patients with acute pancreatitis,
mean spontaneous release of IL-8 remained significantly elevated compared with
the volunteer group (131 ng/ml; p=0.02, Table 4.2) while the mean spontaneous
release of IL-8 in the mild pancreatitis group was not significantly different
compared with the volunteer group (53.8 pg/ml; p=l, Table 4.2). Furthermore, on
day 5 IL-8 release in the severe group was elevated compared with the mild group
(p=0.04). The individual data points for PBMC IL-8 release for the 14 patients with




Spontaneous IL-6 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 6 healthy volunteers and from 14 patients
with acute pancreatitis on day 1 and day 5 of admission, stratified for mild (n=8) and
severe (n=6) disease (Atlanta classification (Bradley, 1993)). 2 x 105 cells per well





Spontaneous IL-8 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 6 healthy volunteers and from 14 patients
with acute pancreatitis on day 1 and day 5 of admission, stratified for mild (n=8) and
severe (n=6) disease (Atlanta classification (Bradley, 1993)). 2 x 105 cells per well
incubated in triplicate under standard conditions for 24 hr. IL-8 was measured by
ELISA.
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disease demonstrated on day 5 a fall in IL-8 release of greater than 10 % of the day
1 value.
LPS-stimulation resulted in an increase in both IL-6 and IL-8 in all the study
groups compared with spontaneous release. The mean stimulation index for each
study group is shown in Table 4.3. While the mean stimulation index was higher in
the pancreatitis groups compared with the volunteer group, this was not significant
on statistical analysis for either IL-6 (p=0.66) or IL-8 (p=0.43).
4.4 Discussion
The present study again demonstrates (in keeping with the findings of
Chapter 3) an increased release of IL-6 and IL-8 from PBMCs isolated from the
blood of patients with acute pancreatitis compared with those isolated from healthy
volunteers, (Table 4.2, Figures 4.1 and 4.2). Again, there was no significant
difference in pro-inflammatory cytokine release per cell when comparing patients
with mild or severe disease on the day of admission. However, by day 5 of
admission, PBMC IL-6 and IL-8 release from patients subsequently shown to have
mild disease have returned to levels approaching that for healthy volunteers. In
contrast, patients with severe disease had persisting significantly increased IL-6 and
IL-8 release from PBMCs. Thus severe disease is characterised more by the
duration of increased pro-inflammatory cytokine release rather than the intensity of
the release when measured on admission to hospital. What is not clear from this
study, is whether this prolonged duration of increased IL-6 and IL-8 release is the
cause or the result of developing complications of severe disease.
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Table 4.3
Mean (standard error of the mean) lipopolysaccharide-stimulation index for
IL-6 and IL-8 concentration in the culture supernatant from peripheral blood
mononuclear cells isolated from 6 healthy volunteers and from 14 patients with
acute pancreatitis on day 1 and day 5 of admission, stratified for mild (n=8) and
severe (n=6) disease (Atlanta classification (Bradley, 1993)). 2 x 105 cells per well
incubated in triplicate under standard conditions for 24 hr. IL-6 and IL-8 were
measured by ELISA. There was no significant difference in the mean stimulation
index in any of the acute pancreatitis groups compared with the mean volunteer









IL-8 3.46 6.70 8.05 9.51 5.15
(0.65) (1.71) (4.40) (2.37) (1.61)
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The two patients in the severe group who demonstrated a further marked
increase in IL-6 release between day 1 and day 5 represent patients 7 and 14 detailed
in Table 4.1, both of whom developed multiple organ failure, one of whom
succumbed on day 9 from the disease. In accordance with the findings of the
present study, Faist and co-workers reported that monocyte IL-6 secretion is
increased two-fold in patients with sepsis compared with controls but no data on the
time course of this increase is described (Faist, 1992). In the same report, patients
undergoing major elective surgery also demonstrated increased monocyte IL-6
release in the week following surgery. However, PBMC IL-6 release in this group
was also greater pre-operatively compared with the control group and it is of note
that the surgery group was composed of patients predominately with malignancy.
Chronically increased TNFa and IL-6 release has been reported from PBMCs
isolated from patients with pancreatic cancer (Falconer, 1994). It is interesting to
note that PBMC IL-6 release in patients following major trauma (thought to have a
similar common pathogenesis as acute pancreatitis with the development of a
systemic inflammatory response and the potential for multiple organ failure) is
suppressed on day 1 of the injury compared with controls and returns to levels
comparable with the controls by day 7. The explanation for this conflicting finding
is not clear. Major trauma is associated with a marked monocytosis (Faist, 1988)
and it is possible that this rapid monocyte recruitment is of a population of
functionally immature cells which behave quite differently from monocytes released
from a pool of marginating cells under less severe conditions.
The pattern of IL-8 release from PBMCs in patient with acute pancreatitis
was similar to that of IL-6. A variation to this pattern is noted on day 5, where IL-8
release even in the severe group is generally returning towards levels found in
healthy volunteers. Two patients in the severe group did manifest a further increase
in IL-8 release between day 1 and day 5 but only one of these (compared with both
Page 94
patients with rising IL-6 release) progressed to multiple organ failure. It is
interesting to note that in a study where PBMCs were exposed in vitro to anoxia
followed by normal conditions of incubation induced less of an IL-8 response
compared with a similar anoxic stress followed by a period of hyperoxia (Metinko,
1992). These experimental conditions may well be mimicked in vivo following
therapeutic intervention in patients with ischaemia-reperfusion type injury,
including those with acute pancreatitis. In contrast, Faist and co-workers (Faist,
1992) who observed up-regulation of IL-6 release from monocytes in patients with
sepsis, found that monocyte IL-8 release was suppressed in the same patients. This
suppression of IL-8 release had reverted to normal by the seventh day of admission.
The trigger for enhanced IL-6 and IL-8 release is not clear from this study.
The current understanding of the role of endotoxin in acute pancreatitis has already
been discussed in Chapter 1, Section 1.11 and in Chapter 3, Section 3.4. The
present study again demonstrates (in keeping with the findings of Chapter 3) that
incubation with lipopolysaccharide results in an increased release of IL-6 and IL-8
from PBMCs in both the patient and volunteer groups (Table 4.3), although the
mean stimulation index (comparing LPS-stimulated cytokine release with
spontaneous cytokine release) was not significantly different between the patient
and control groups. The stimulation indices in the experimental findings reported in
this chapter are several fold higher than those found in Chapter 3. The reason for
this is not clear but is likely to be related to variation in culture reagents, and in
particular, the use of a new batch of stock lipopolysaccharide. Variations in the
lipopolysaccharide-stimulation index have also been noted in the laboratory with
changes in the batch of fetal calf serum and may relate to the concentration of LPS-
binding protein present in different batches. Nevertheless, the further increase in IL-
6 and IL-8 release by LPS-stimulation is important as it implies that PBMCs that
already appear to have been activated in patients with acute pancreatitis are able to
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respond to further stimulation. Thus, while endotoxaemia (Exley, 1992; Windsor,
1993) is unlikely to be the primary event in the pathogenesis of acute pancreatitis,
its presence could exacerbate mononuclear cell activation and the subsequent
development of the systemic inflammatory response syndrome associated with the
disease. Furthermore, it implies that mononuclear cells possess the ability to
produce a graded response to a stimulus, suggesting that control mechanisms exist
to regulate the response such as the degree of pro-inflammatory cytokine release.
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Chapter 5
Regulatory control by indomethacin and Type II
cytokines of pro-inflammatory cytokine release by
peripheral blood mononuclear cells isolated from
patients with acute pancreatitis
5.1 Introduction
A number of control mechanisms exist for the regulation of pro¬
inflammatory cytokines (Type I cytokines) from PBMCs. Intracellular control
mechanisms are recognised, principally through products of the cyclo-oxygenase
pathway such as prostaglandins and intercellular control mechanisms such as the
Type II cytokines (that include interleukin-4 and interleukin-10), secreted
principally from subsets of CD4 positive T-helper cells.
Among the prostaglandin series of compounds, attention has focused on the
role of prostaglandin E2 as a modulator of monocyte, lymphocyte and
monocyte/lymphocyte interaction functions (Goldyne, 1980; Goodwin, 1983).
PGE2 is produced endogenously by a number of immune competent cells including
monocytes (Ellner, 1979; Miller-Graziano, 1988) and macrophages (Molloy, 1993;
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Roland, 1994). In addition to the effects on lymphocyte function including
impaired blastogenesis, lymphokine production and cytotoxicity (Ellner, 1979;
Goodwin, 1983), endogenous PGE2 appears to exert an autocrine feedback loop on
monocytes themselves (Callery, 1991). The plateau of TNFa release from LPS-
stimulated murine peritoneal macrophages was concomitant with an accelerated
increase in PGE2 production (Kunkel, 1988). Furthermore, the addition of PGE2
demonstrated a dose-dependent effect in LPS-induced activity as well as a
significant reduction in TNFa messenger RNA accumulation. A number of groups
have confirmed the co-production of TNFa and PGE2 and the regulatory feedback
by PGE2 on monocyte and macrophage TNFa production (Callery, 1991; Molloy,
1993; Spengler, 1989). In accordance with this, the administration in vitro and in
vivo of indomethacin (a cyclo-oxygenase inhibitor) appears to suppress endogenous
PGE2 production (Callery, 1990; Roland, 1994). while increasing the release and
synthesis of a number of cytokines including TNFa, IL-1G, IL-2, IL-6 and IL-8
(Callery, 1990; Chouaib, 1984; Endres, 1989; Faist, 1987; Roland, 1994; Spengler,
1989; Standiford, 1992). This is not a universal finding, as lipopolysaccharide and
PGE2 synergistically induced IL-6 release from intestinal epithelial cells (Meyer,
1994). Nevertheless, increased production of PGE2 can be detected in the sera of
patients following major burns (Ninnemann, 1984).
The human immune response to inflammation is thought to be regulated in
part by the balance between so called Type I and Type II cytokines (Modlin, 1993;
Sher, 1992). These latter cytokines are generally considered to be inhibitory or anti¬
inflammatory (Colquhoun, 1993; Howard, 1992). Not only can they regulate the
number of monocytes and neutrophils released from bone marrow progenitor cells
(Snoeck, 1993), but IL-4 and IL-10 are known to down-regulate pro-inflammatory
cytokine production from a wide-variety of immune cells including mononuclear
(de Wall Malefyt, 1993; Donnelly, 1990; Essner, 1989; Fiorentino, 1991; Lee,
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1990) and polymorphonuclear (Cassatella, 1993) cells isolated from normal
subjects. These regulatory cytokines are produced mainly by specific sub-
populations of CD4-positive T helper cells but also, in the case of EL-10, by cells of
the monocyte lineage (Howard, 1992). Curley and co-workers (Curley, 1993) have
demonstrated a depletion of CD4-positive T helper lymphocytes in patients with
acute pancreatitis with the greatest depletion occurring in those with severe disease
who had significantly higher serum IL-6 levels. Following resolution of the
pancreatitis and recovery of the patient, the CD4-helper population returned towards
normal values. Similar findings have been reported for CD4-positive T helper cell
depletion following thermal injury (O-Mahony, 1985) and trauma (Faist, 1987). It
has been proposed that this depletion of CD4-positive T helper cells causes an
imbalance in the regulatory control of the immune response early in acute
pancreatitis, diminishing the down-regulatory control on leucocyte activation and
allowing up-regulation of pro-inflammatory cytokine release with subsequent
progression to multiple organ failure (Casey, 1993).
The aims of this chapter were to examine the effects of indomethacin, PGE2,
IL-4 and IL-10 on the spontaneous release of IL-6 and IL-8 from PBMCs isolated
from patients with acute pancreatitis compared with healthy volunteers.
5.2 Patients and methods
5.2.1 Patients
The study group comprised a total of 20 patients with acute pancreatitis as
defined in Section 2.1.1. For the IL-4/10 experiments, peripheral blood was taken
from patients on the first day of admission for the isolation and culture of PBMCs
(as described in Section 2.3). For the indomethacin/PGE2 experiments, peripheral
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blood was taken from patients on the first and fifth day of admission for the
isolation and culture of PBMCs (as described in Section 2.3). The progress of the
patient was evaluated with regard to the development of pancreatic complications as
defined by the 1992 Atlanta Convention (Bradley, 1993) or the development of
multiple organ failure as defined by the Goris score (Goris, 1985). The patient
characteristics are given in Table 3.1, Chapter 3 (page 61) and represent patients
numbered 6 to 11 for the IL-4/10 experiments and Table 4.1, Chapter 4 (Page 86)
for the indomethacin/PGE2 experiments. Six healthy volunteers were also studied
to provide an indication of 'normal' cytokine release; the volunteers detailed in
Table 3.1, Chapter 3 (page 61) and Table 4.1, Chapter 4 (Page 86) were used for the
IL-4/10 and indomethacin/PGE2 experiments respectively.
5.2.2 PBMC study protocol
5.2.2.1 EL-4/10 protocol
PBMCs from both patients and volunteers were incubated at 2 x 105 cells
per well in the presence or absence of LPS (final concentration 5 |ig/ml) and in the
presence of IL-4 or IL-10 (final concentration 0-50 ng/ml)(Genzyme, West
Mailing, U.K.) for 24 hours. PBMCs from 4 volunteers were incubated at 2 x 105
cells per well in the presence or absence of LPS (final concentration 5 |ig/ml) for 24
hours and in the presence of IL-4 or IL-10 (final concentration 5 ng/ml) with the
addition of IL-4 and IL-10 to the culture medium taking place at fixed time points
between 0 and 24 hours incubation. Supernatants were removed and stored in
aliquots at -70 °C for subsequent batch cytokine assay.
5.2.2.2 Indomethacin/PGE2 protocol
PBMCs from both patients and volunteers were incubated at 2 x 105 cells
per well in the presence or absence of indomethacin (final concentration 10 "6
M)(Sigma Chemicals, Poole, U.K.) and in the presence of indomethacin and PGE2
(final concentration 10 "6 M and 10 "6 to 10_9 M to respectively) (Sigma Chemicals,
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Poole, U.K.). Supernatants were removed and stored in aliquots at -70 °C for
subsequent batch cytokine assay.
5.2.3 IL-6 and IL-8 ELISAs
Supernatants and serum were assayed for IL-6 and IL-8 by ELISAs as
described in Sections 2.6.2 and 2.6.3 respectively.
5.2.4 Statistical analysis
5.2.4.1 DL-4/10 protocol
Comparison of patient and control groups was made with the Mann-Whitney
U test while comparison of the dose response to IL-4 or IL-10 was made with
analysis of covariance of the logio transformed data with significance taken at a P
value < 0.05 (Altman, 1991; Altman, 1989).
5.2.4.2 Indomethacin/PGE2 protocol
Comparison of patient and control groups was made with the Mann-Whitney
U test while comparison within each acute pancreatitis group was made with the
paired Student's t test with significance taken at a P value < 0.05.
5.3 Results
5.3.1 IL-4/10 protocol
There was no significant difference in the mean age between the patient and
control groups (55.4 years, range 34-82 v 47.5 years, range 26-73, respectively,
p=0.40) with an equal sex ratio in both groups. Three of the 6 patients were
considered to have severe disease.
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The mean spontaneous 24 hr PBMC IL-6 release was not significantly
different in the pancreatitis group compared with the control group (13.7±3.0 v
9.1+2.1 ng/ml; Mean±SEM, p=0.61). However, mean 24 hr LPS-stimulated IL-6
PBMC release was significantly increased in the patient group compared with the
control group (31.5±5.2 v 14.1±2.1 ng/ml, p=0.02). Mean 24 hr spontaneous and
LPS-stimulated IL-8 PBMC release was significantly increased in the pancreatitis
group compared with the control group (337±48 v 106±10 ng/ml, p=0.002 and
553±49 v 112±13 ng/ml, p=0.002 respectively).
Both IL-4 and IL-10 inhibited spontaneous and LPS-stimulated PBMC IL-6
release in a dose dependent manner, and there was no significant difference in the
percentage inhibition between the patient and control groups, p>0.1 (Figures 5.1 and
5.2). In a similar manner, both IL-4 and IL-10 inhibited spontaneous and LPS-
stimulated PBMC IL-8 release in a dose dependent manner, and there was no
significant difference in the percentage inhibition between the patient and control
groups, p>0.1 (Figures 5.3 and 5.4).
The degree of inhibition of both spontaneous and LPS-stimulated PBMC IL-
6 release by IL-4 or IL-10 was preserved even if the addition of IL-4 or IL-10 was
delayed up to 2 hours after plating the cells, (Figure 5.5). However, delaying the
addition of IL-4 or IL-10 by 4 hours after the plating of PBMCs, reduced the degree
of inhibition, (Figure 5.5) in PBMCs isolated from healthy volunteers.
5.3.2 Indomethacin/PGE2 protocol
While the volunteer group were younger than the patient group (40
years, range 28-49 v 63 years, range 31-90 respectively, p=0.70), there was no
significant difference in the mean age (65.0 years, range 42-90 v 60.5 years, range
31-84, p=0.70) between patients classified as mild or severe disease. Six of the 14
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Figure 5.1
Inhibition of the mean spontaneous IL-6 concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from 6 healthy
volunteers (- -) and from 6 patients with acute pancreatitis on the first day of
admission (—) by IL-4 (□) or IL-10 (O)(dose range 0-50 ng/ml). Error bars
represent the standard error of the mean. 2 x 105 cells per well incubated in
triplicate under standard conditions for 24 hr. IL-6 was measured by ELISA. P >
0.1 comparing the patient with the corresponding volunteer group (analysis of
covariance, logio transformed data).
Pa§e 103
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Figure 5.2
Inhibition of the mean lipopolysaccharide-stimulated (final concentration 5
|ig/ml) IL-6 concentration in the culture supernatant from peripheral blood
mononuclear cells isolated from 6 healthy volunteers (- -) and from 6 patients with
acute pancreatitis on the first day of admission (—) by IL-4 (□) or IL-10 (O)(dose
range 0-50 ng/ml). Error bars represent the standard error of the mean. 2 x 105
cells per well incubated in triplicate under standard conditions for 24 hr. IL-6 was
measured by ELISA. P > 0.1 comparing the patient with the corresponding
volunteer group (analysis of covariance, logio transformed data).
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IL-4 or 10 (ng/ml)
Figure 5.3
Inhibition of the mean spontaneous IL-8 concentration in the culture
supernatant from peripheral blood mononuclear cells isolated from 6 healthy
volunteers (- -) and from 6 patients with acute pancreatitis on the first day of
admission (—) by IL-4 (□) or IL-10 (O)(dose range 0-50 ng/ml). Error bars
represent the standard error of the mean. 2 x 105 cells per well incubated in
triplicate under standard conditions for 24 hr. IL-8 was measured by ELISA. P >
0.1 comparing the patient with the corresponding volunteer group (analysis of
covariance, logio transformed data).
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IL-4 or 10 (ng/ml)
Figure 5.4
Inhibition of the mean lipopolysaccharide-stimulated (final concentration 5
pg/ml) IL-8 concentration in the culture supernatant from peripheral blood
mononuclear cells isolated from 6 healthy volunteers (- -) and from 6 patients with
acute pancreatitis on the first day of admission (—) by IL-4 (□) or IL-10 (O)(dose
range 0-50 ng/ml). Error bars represent the standard error of the mean. 2 x 105
cells per well incubated in triplicate under standard conditions for 24 hr. IL-8 was
measured by ELISA. P > 0.1 comparing the patient with the corresponding
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Figure 5.5
Mean spontaneous (- -) and lipopolysaccharide-stimulated (—)(final
concentration 5 (lg/ml) IL-6 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 4 healthy volunteers. IL-4 (□) or IL-10
(O)(both 5 ng/ml final concentration) were added at time points from the start of
cell incubation. Results are expressed as the mean percentage of IL-6 released when
IL-4 or IL-10 was added at the end of the 24 hour incubation period and the error
bars represent the standard error of the mean. 2 x 105 cells per well incubated in
triplicate under standard conditions for 24 hr. IL-6 was measured by ELISA.
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patients were considered to have severe disease in that they developed
complications related to their disease. Three of these patients had pancreatic
necrosis demonstrated by contrast-enhanced CT scanning during the first week of
admission. Five of the six patients with severe disease scored 1 or more on the
modified Goris score, one of whom died ofmultiple organ failure.
Indomethacin in the culture medium had no significant effect on
spontaneous IL-6 or IL-8 release from PBMCs isolated from volunteers, as shown
in Table 5.1. In contrast, indomcthacin increased IL-6 release from PBMCs isolated
from patients with acute pancreatitis with both mild and severe disease on day 1 and
also on day 5 of admission (Table 5.1). Furthermore, indomethacin increased IL-8
release from PBMCs isolated from patients with acute pancreatitis with both mild
and severe disease on day 1 and also on day 5 of admission, (Table 5.1). (The mean
PBMC IL-6 and IL-8 release from both the patient group and the healthy volunteer
group varied between the IL-4 or IL-10 and the indomethacin experiments. This
was most marked for IL-6 release with a 10 fold variation observed in the mean IL-
6 release for the IL-4 or IL-10 and the indomethacin experiments. The reason for
this is not clear. The two sets of experiments were performed a number of months
apart during which time, many of the reagents had changed including the IL-6
standard for the ELISA. It is likely that I made a dilution error in the stock IL-6
standard)
While indomethacin had no significant effect on PBMC IL-6 release in the
volunteer group, indomethacin in combination with PGE2 (both at 10~6 M) resulted
in a significant increase in IL-6 release as shown in Figure 5.6. Reducing the
concentration of PGE2 led to a reduced response and indeed there appeared to be an
inhibition of IL-6 release at lower PGE2 concentrations compared with
indomethacin alone (Figure 5.6). Similar findings were observed for patients with
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Table 5.1
Effect of indomethacin (final concentration 10"6 M) on the mean
spontaneous IL-6 and IL-8 concentration in the culture supernatant from peripheral
blood mononuclear cells isolated from 6 healthy volunteers and from 14 patients
with acute pancreatitis on day 1 and day 5 of admission, stratified for mild (n=8)
and severe (n=6) disease (Atlanta classification (Bradley, 1993)). 2 x 105 cells per
well incubated in triplicate under standard conditions for 24 hr. IL-6 and IL-8 were
measured by ELISA. Results are expressed as the mean (SEM). The paired t test
compares cytokine release in the presence or absence of indomethacin for each
group.
Day 1 Day 5
Volunteer Mild Severe Mild Severe
IL-6 (pg/ml)
No indomethacin 791 2855 3488 1538 6724
(168) (615) (980) (418) (3093)
Indomethacin 941 7669 8082 1744 12539
(10 6 M) (212) (1438) (2164) (462) (4666)
paired t test p>0.29 p<0.01 p<0.02 p<0.01 p<0.03
IL-8 (ng/ml)
No indomethacin 35.0 146 174 50.1 131
(16.5) (45.9) (49.7) (24.8) (28.7)
Indomethacin 37.6 246 277 93.9 233
(10 "6 M) (20.0) (53.7) (71.9) (44.3) (57.8)
paired t test p>0.59 p<0.02 p<0.02 p<0.05 p<0.04
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PGE2 concentration (M)
Figure 5.6
Mean spontaneous IL-6 concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from 6 healthy volunteers (A) and from
14 patients with acute pancreatitis on day 1 (#,■) and day 5 (0,D) of admission,
stratified for mild (n=8; O) and severe (n=6; □) disease (Atlanta classification
(Bradley, 1993)). Results are expressed as the ratio of IL-6 release when co-
cultured in indomethacin (10"6 M) and PGE2 (dose range 10"6 M to 10~9 M) over
IL-6 release when cultured in indomethacin alone (10~6 M) against the PGE2
concentration. 2 x 105 cells per well incubated in triplicate under standard
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Figure 5.7
Mean spontaneous IL-8 concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from 6 healthy volunteers (A) and from
14 patients with acute pancreatitis on day 1 (#,■) and day 5 (0,D) of admission,
stratified for mild (n=8; O) and severe (n=6; □) disease (Atlanta classification
(Bradley, 1993)). Results are expressed as the ratio of IL-8 release when co-
cultured in indomethacin (10-6 M) and PGE2 (dose range 10~6 M to 10-9 M) over
IL-8 release when cultured in indomethacin alone (10~6 M) against the PGE2
concentration. 2 x 105 cells per well incubated in triplicate under standard
conditions for 24 hr. IL-8 was measured by ELISA.
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both mild and severe acute pancreatitis on days 1 and 5 of admission (Figure 5.6).
The findings for PBMC IL-8 release in the presence of indomethacin alone and
indomethacin with PGE2 are similar as shown in Figure 5.7.
5.4 Discussion
The findings of this chapter demonstrate that indomethacin increases IL-6
and IL-8 release from PBMCs isolated from patients with acute pancreatitis but not
healthy volunteers while PGE2 produces a dose-dependent increase or decrease in
such cytokine release in both healthy volunteers and patients with acute pancreatitis.
The dose dependent inhibition of IL-6 and IL-8 release from PBMCs by IL-4 or IL-
10 seen in healthy volunteers is preserved in patients with acute pancreatitis .
Under normal conditions, spontaneous cytokine release does not appear to
be under the control of products of the cyclo-oxygenase pathway (Callery, 1990;
Goodwin, 1983) and the findings of the present study are in agreement with this.
However, LPS-stimulated PBMCs from healthy volunteers appear to be under such
control (Endres, 1989). In contrast, in patients with both mild and severe acute
pancreatitis on admission, a product of the cyclo-oxygenase pathway appears to be
active in an attempt to minimise the increased release of IL-6 and IL-8 from
PBMCs. Furthermore, this control mechanism appears to still be active on day 5 of
admission in such patients. Of note, while IL-6 and IL-8 release on day 5 in
patients with mild disease have returned to levels comparable with healthy
volunteers, the presence of indomethacin in the culture medium significantly
increases such cytokine release to levels comparable with patients with severe
disease (Table 5.1). It is postulated that the use of indomethacin and perhaps other
cyclo-oxygenase inhibitors may adversely influence pro-inflammatory cytokine
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release in patients with acute pancreatitis. Whereas Lankisch and co-workers (in
Hollender, 1983) noted a life-prolonging effect of indomethacin in a rat model of
acute pancreatitis, another group observed an aggravation of the disease following
the administration of indomethacin or aspirin in a rat model (Olazabal, 1980).
There are no reports in the literature to my knowledge that indicate that patients
taking aspirin or cyclo-oxygenase inhibitors do better or worse on such medication.
However, an association between the use of such agents and complicated
diverticular disease has been demonstrated (Campbell, 1991); the postulated
mechanism being an impairment in the immune response to the diverticulitis to limit
the inflammatory/infective process.
The dose response of PGE2 on IL-6 and IL-8 release from indomethacin
treated PBMCs isolated from both healthy volunteers and patients with acute
pancreatitis was the reverse of that expected (Molloy, 1993). If the effect of
indomethacin was to inhibit endogenous PGE2 production and thus block the
regulatory effect of PGE2, then the administration of exogenous PGE2 would
conceivably restore the control mechanism. But despite healthy volunteers showing
no significant change in cytokine release in the presence of indomethacin, PGE2
increased IL-6 and IL-8 release in a dose-dependent manner. In patients with acute
pancreatitis, PGE2 appeared to increase IL-6 and IL-8 release at 10~6 M
concentration while being inhibitory at 10'9 M concentration. Furthermore, the
dose response curve for both IL-6 and IL-8 release tended to regress towards the
curve for healthy volunteers with improvement in the patients condition (Figures 5.6
and 5.7). A possible explanation for this finding is that it is not the PGE2
concentration alone but the ratio of PGE2 to other prostaglandins or products of the
cyclo-oxygenase pathway that is the important in the control of cytokine release
(Goodwin, 1983). Indeed, PGE2 and lipopolysaccharide synergistically induced IL-
6 release from intestinal epithelial cells (Meyer, 1994) and treatment with
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indomethacin in a murine burn-sepsis model reduced the overproduction of TNFa
and IL-6 from splenocytes normally observed in this model (O'Riordain, 1992).
Another possible explanation is that indomethacin exerts effects through pathways
in addition to cyclo-oxygenase inhibition (Mathieu, 1994). It has been reported that
indomethacin can act directly on normal purified T lymphocytes to increase IL-2
production independent of arachidonic metabolism but related to a rise in calcium
influx and to an increase in T cell membrane fluidity (Flescher, 1991). In
retrospect, an important 'control' arm to these experiments was omitted, namely the
dose response of PGE2 on PBMCs in the absence of indomethacin. However, the
use of PGE2 in experimental acute pancreatitis has not been of significant benefit
(Lankisch, 1983b; Martin, 1981).
The dose dependent inhibition of IL-6 and IL-8 release from PBMCs by IL-
4 or IL-10 is preserved in patients with acute pancreatitis in a similar manner to
healthy volunteers despite the increased release of IL-6 and IL-8 in patients with
acute pancreatitis compared with healthy volunteers. It is evident that IL-4 and IL-
10 have a potent immunoregulatory function and this is reflected in their ability to
suppress cellular responses in vitro (Cassatella, 1993; Fiorentino, 1991; Lee, 1990).
IL-4 and IL-10 have also been used as immunotherapy in a variety of situations. In
both experimental arthritis (Allen, 1993) and in cancer patients receiving
immunotherapy (Wong, 1993), the production of the pro-inflammatory cytokine IL-
1 is reduced by the administration of IL-4 although there is a related toxicity at
higher dosages (Gilleece, 1992). In addition, IL-10 protects mice against
Staphylococcus enterotoxin B-induced lethal shock (Bean, 1993) and IL-4 and IL-
10 exhibit synergy in the inhibition of cell-mediated immunity in a mouse model of
leishmaniasis (Powrie, 1993). However, it is evident that not all cell types respond
uniformly to the regulatory effect of the Type II cytokines. IL-4 induced a selective
production of IL-6 from normal human B lymphocytes (Smeland, 1989). IL-4 also
Page 114
appears to up-regulate IL-6 release from endothelial cells (Howells, 1991) and work
in the present thesis shows that both IL-4 and IL-10 increase IL-6 and IL-8 release
from LPS-stimulated endothelial cells (see Chapter 7). These regulatory events on




Studies on PBMC proliferation and cell sub-types in
patients with acute pancreatitis
6.1 Introduction
The findings of Chapter 5 demonstrated the dose dependent inhibition of IL-
6 and IL-8 release from PBMCs by exogenous IL-4 or IL-10 is preserved in patients
with acute pancreatitis in a similar manner to healthy volunteers despite the
increased release of IL-6 and IL-8 in patients with acute pancreatitis compared with
healthy volunteers. While sensitivity to the signal is retained, perhaps the
production of the signal is reduced in patients with acute pancreatitis to allow
increased pro-inflammatory cytokine release. These regulatory cytokines are
produced mainly by specific sub-populations of CD4-positive T helper cells. The
findings of Curley and co-workers (Curley, 1993) have already been discussed but
%
to recap, they demonstrated a depletion of CD4-positive T helper lymphocytes in
patients with acute pancreatitis with the greatest depletion occurring in those with
severe disease who had significantly higher serum IL-6 levels. Following resolution
of the pancreatitis and recovery of the patient, the CD4-helper population returned
towards normal values. One flaw in this study was that CD8-positive suppresser
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lymphocytes numbers were not also measured to allow determination of the
CD4/CD8 ratio which may be the more useful index of lymphocyte imbalance.
Nevertheless, similar findings have been reported for CD4-positive T helper cell
depletion following thermal injury (O-Mahony, 1985), trauma (Faist, 1987) and
septic patients with multiple organ failure (Nishijima, 1986) although the CD4/CD8
ratio was only significantly altered compared with controls in the trauma study.
In addition to the changes in the phenotype of PBMC sub-populations,
lymphocyte function may also be deranged. T cell DNA synthesis as determined by
thymidine incorporation in vitro has been shown to correlate well with host
resistance to infection in vivo (Moss, 1988). PBMCs isolated from patients
following trauma demonstrated significant impairment in both phytohaemagglutinin
(Faist, 1987) and pokeweed mitogen (McRitchie, 1990) induced blastogenesis
compared with controls. A similar result was observed in septic patients with
multiple organ failure (Nishijima, 1986).
The aims of this chapter were to determine the phenotype of PBMC
populations and to assess lymphocyte function by the incorporation of thymidine
into unstimulated and phytohaemagglutinin-stimulated PBMCs isolated from
patients with acute pancreatitis compared with those isolated from healthy
volunteers.
6.2 Patients and methods
6.2.1 Patients
The study group comprised 14 patients with acute pancreatitis as defined in
Section 2.1.1. These patients have been described in Table 4.1, Chapter 4, (Page
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86). Peripheral blood was taken from patients on the first and fifth day of admission
for the isolation and culture of PBMCs (as described in Section 2.3). The progress
of the patient was evaluated with regard to the development of pancreatic
complications as defined by the 1992 Atlanta Convention (Bradley, 1993) or the
development of multiple organ failure as defined by the Goris score (Goris, 1985).
Six healthy volunteers were also studied and these are similarly described in
Chapter 4, Table 4.1, (Page 86).
6.2.2 PBMC phenotype
PBMCs were obtained by density centrifugation from 10 patients with acute
pancreatitis and 6 healthy volunteers and were prepared for flow cytometry as
described in Section 2.7, Chapter 2. The surface markers examined were CD3,
CD4, CD8 and C14.
6.2.3 Phytohaemagglutinin-stimulated PBMC protocol
PBMCs from 14 patients with acute pancreatitis and 6 healthy volunteers
were incubated at 2 x 105 cells per well in the presence or absence of
phytohaemagglutinin (final concentration 0, 10 or 100 |ig/ml). Subsequent
incubation, pulse with tritiated thymidine, storage and cell harvest are described in
Section 2.4, Chapter 2.
4.2.4 Statistical analysis
Initial comparison in tritiated thymidine uptake between patients with mild
disease, severe disease and volunteers was performed using the Kruskal-Wallis test.




While the volunteer group were younger than the patient group (40 years,
range 28-49 v 63 years, range 31-90 respectively, p = 0.70), there was no significant
difference in the mean age between patients classified as mild or severe disease (65
years, range 42-90 v 61 years, range 31-84 respectively, p = 0.70). Six of the 14
patients were considered to have severe disease in that they developed
complications related to their disease. Three of these patients had pancreatic
necrosis demonstrated by contrast-enhanced CT scanning during the first week of
admission. Five of the six patients with severe disease scored 1 or more on the
modified Goris score, one of whom died ofmultiple organ failure.
6.3.1 PBMC phenotype
The percentage of cells expressing the cell surface antigens, CD3, CD4,
CD8 and CD14 for each volunteer and patient are shown in Table 6.1. The mean
percentage of cells expressing CD3 fell in the patient groups compared with the
volunteer group, but this was only significant in the severe groups on day 1 and day
5: volunteer, 58.5 % (2.8) Mean (SEM); mild pancreatitis day 1, 44.4 % (7.2); mild
pancreatitis day 5, 52.3 % (6.4); severe pancreatitis day 1, 22.4 % (6.9) p<0.01 and
severe pancreatitis day 5, 24.3 % (6.8) p<0.01. Similarly, the mean percentage of
cells expressing CD4 fell in the patient groups compared with the volunteer group,
but this was only significant in the severe groups on day 1 and day 5: volunteer,
39.8 % (2.2) Mean (SEM); mild pancreatitis day 1, 33.1 % (5.1); mild pancreatitis
day 5, 38.1 % (3.9); severe pancreatitis day 1, 17.8 % (4.4) p<0.01 and severe
pancreatitis day 5, 17.0 % (6.8) p=0.04. There was no significant difference in the
mean percentage of cells expressing CD8 in the patient groups compared with the
volunteer group, (p>0.31): volunteer, 28.7 % (2.1) Mean (SEM); mild pancreatitis
day 1, 20.0 % (4.6); mild pancreatitis day 5, 22.8 % (3.1); severe pancreatitis day 1,
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Table 6.1
Percentage of PBMCs isolated from 6 healthy volunteers and 10 patients
with acute pancreatitis on day 1 and day 5 of admission (stratified for mild (n=5)
and severe (n=5) disease (Atlanta classification (Bradley, 1993)) expressing the cell
surface antigens examined by flow cytometry. Minimum of 5 000 cells examined
per episode for each subject.
CD3+ CD4+ CD8+ CD14+
(%) (%) (%) (%)
Volunteers
1 63.2 39.8 28.2 10.8
2 67.1 39.7 38.4 12.8
3 48.0 29.7 27.7 14.6
4 58.1 47.6 24.5 14.8
5 64.1 42.9 31.3 9.1
6 52.0 39.2 21.9 15.2
Mild pancreatitis
1 Day 1 34.8
Day 5 38.7
2 Day 1 28.8
Day 5 40.5
3 Day 1 55.7
Day 5 61.8
4 Day 1 66.9
Day 5 72.2













1 Day 1 29.5
Day 5 26.4
2 Day 1 44.0
Day 5 27.7
3 Day 1 23.4
Day 5 46.8
4 Day 1 8.6
Day 5 7.1













22.5 % (7.5) and severe pancreatitis day 5, 15.0 % (4.7). However, the ratio of CD4
positive cells to CD8 positive cells in the study groups was found to be similar as
depicted in Figure 6.1. The increase in the mean percentage of cells expressing
CD 14 in the patient groups compared with the volunteer group just failed to reach
statistical significance, (p=0.0528): volunteer, 12.8 % (0.9) Mean (SEM); mild
pancreatitis day 1, 28.5 % (3.6); mild pancreatitis day 5, 25.8 % (7.0); severe
pancreatitis day 1, 25.1 % (3.8) and severe pancreatitis day 5, 21.7 % (6.1).
However, the ratio of the sum of the percentage of CD4 positive cells and CD 8
positive cells over the percentage of CD14 positive cells fell significantly in the
patient groups compared with the volunteer group as depicted in Figure 6.2.
During FACS analysis, the forward light scatter gives an assessment of cell
size. In PBMC isolates, the relative size difference ofmonocytes from lymphocytes
enables them to appear as two distinct cell populations on the FACS scattergram.
However, in a number of patients with acute pancreatitis, particularly those with
severe disease, a third population of cells, larger again in cell size than monocytes,
and which did not express the surface antigens for lymphocytes or monocytes being
tested, were observed (Figure 6.3). In one patient with severe disease who died on
the ninth day following admission from multiple organ failure, this large cell
population constituted 29.9 % of the PBMC isolate.
6.3.2 PHA-stimulated PBMC ^HTdr uptake
Results were available from only 5 volunteers because of an operator error
with the cell harvester. In patients with both mild and severe acute pancreatitis on
admission demonstrate a fall in mean DNA synthesis although this is only
statistically significant in the severe group compared with volunteers as shown in
Figure 6.3. By day 5 of admission, DNA synthesis is returned towards volunteer

































Ratio of CD4 positive to CD8 positive cells in PBMC populations isolated
from 6 volunteers and 10 patients with acute pancreatitis on day 1 and day 5 of
admission (stratified for mild (n=5) and severe (n=5) disease (Atlanta classification
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Day 1 Day 5
Figure 6.2
Ratio of CD4 positive plus CD8 positive cells over CD 14 positive cells in
PBMC populations isolated from 6 volunteers and 10 patients with acute
pancreatitis on day 1 and day 5 of admission (stratified for mild (n=5) and severe
(n=5) disease (Atlanta classification (Bradley, 1993)). Minimum of 5 000 cells
examined per episode for each subject by flow cytometry. * P<0.01 and ** P=0.03
comparing the volunteer group with the patient group (Mann-Whitney U test).
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Figure 6.3
Flow cytometry scattergrams of PBMCs isolated from a patient with (a) mild
disease and (b) severe disease (Atlanta classification (Bradley, 1993)). The cell sub-
populations labelled A, B and C represent predominately CD3 positive
(lymphocytes), CD 14 positive (monocytes) and CD3 and CD14 negative (non
lymphocyte/monocyte) cells respectively. Minimum of 5 000 cells examined. Note
the prominent CD3 and CD 14 negative cell population in (b) severe disease



































Mean uptake of tritiated thymidine (3HTdr) phytohaemagglutinin-stimulated
PBMCs isolated from 5 volunteers and 14 patients with acute pancreatitis on day 1
and day 5 of admission (stratified for mild (n=6) and severe (n=8) disease (Atlanta
classification (Bradley, 1993)). Final phytohaemagglutinin concentration, O 0
(ig/ml, □ 10 |ig/ml and ■ 100 |ig/ml. 2 x 105 cells per well incubated in triplicate
under standard conditions for 72 hr before being pulsed with 1 |iCi of tritiated
thymidine for 4 hr. Error bars represent the standard error of the mean. * P=0.03
comparing the volunteer group with the severe group on day 1
(phytohaemagglutinin concentration, 100 (ig/ml)(Mann-Whitney U test).
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6.4 Discussion
The findings of the present study demonstrate a shift in the phenotype of
PBMCs in patients with acute pancreatitis compared with volunteers represented by
an increase in the percentage of monocytes (CD 14 positive cells) and a fall in the
percentage of T lymphocytes although the CD4 to CD8 ratio was maintained
(Figure 6.1). PBMC DNA synthesis as assessed by PHA-stimulated uptake of
thymidine is reduced in patients with acute pancreatitis on admission although this
only achieved statistical significance in those subsequently shown to have severe
disease (Figure 6.4).
A monocytosis in the days following major injury is well recognised (Faist,
1987; Faist, 1988; Miller-Graziano, 1988). A similar pattern of monocytosis is
demonstrated in the present study in patients with acute pancreatitis. As monocytes
produce the greatest amount of pro-inflammatory cytokines per cell compared with
lymphocytes and neutrophils, the finding of the monocytosis may explain in part the
increase in IL-6 and IL-8 release observed from PBMCs cultured in standard cell
I
numbers in patients with acute pancreatitis compared with healthy volunteers (as
reported in Chapters 3 and 4). However, this is clearly not the whole picture, as on
day 5 of admission, the mean percentage of monocytes in patients with mild or
severe disease were similar but yet there was a significant difference in both PBMC
IL-6 and IL-8 release between these two groups.
The depletion of T lymphocytes is also well reported in patients with major
trauma (Faist, 1988), burns (O-Mahony, 1985) and sepsis (Nishijima, 1986;
Williams, 1983). The findings of the present study suggest that this phenomenon is
also observed in patients with acute pancreatitis and is in agreement with the
findings of Widdison and co-workers (Widdison, 1994d). As already mentioned,
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Curley and co-workers (Curley, 1993) observed a fall in CD4 positive cells, most
marked in those with severe disease although the total lymphocyte count in this
study is not reported. In the present study, the ratio of CD4 positive to CD8 positive
cells is not significantly different in patients with acute pancreatitis compared with
volunteers and again this finding is in accordance with the findings of Widdison and
co-workers (Widdison, 1994c). The mechanism for this lymphocyte depletion is not
fully known, but exposure to endotoxin is a recognised precipitating factor
(Richardson, 1989), a feature observed in acute pancreatitis (Exley, 1992; Windsor,
1993). Furthermore, exogenous steroids (Haynes, 1978) and adrenaline (Crary,
1983) will redistribute circulating T cells and cause them to leave the peripheral
blood and enter the spleen and other lymphoid tissue and it is possible that high
circulating levels of endogenous hormones in patients with acute pancreatitis could
mediate these effects. It is also evident that in a variety of inflammatory conditions,
an imbalance occurs in the distribution of T cells between the peripheral blood and
the tissues (O-Mahony, 1985). Thus the distribution of lymphocytes within the
peripheral blood may not reflect the distribution of lymphocytes in other parts of the
body and in particular, at sites of inflammation. Furthermore, the significance of
the present results depends on the extent to which the phenotypic markers detected
by the monoclonal antibodies used reflect the functional capacity or activity of the T
cells they identify. This correlation between phenotype and function may not be
exact. For example, a small subset of CD4 helper cells have been shown to be of
importance in the generation of suppresser cells (Thomas, 1982) and it is now clear
that the two main T cell subsets are both phenotypically and functionally
heterogeneous (Takada, 1983). However, the data of the present study do not
support the theory that there is an unopposed decrease in the number of CD4
positive helper T lymphocytes.
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While the balance of T suppresser to T helper cells appears to be preserved
in patients with acute pancreatitis (Figure 6.1), T lymphocyte control of monocyte
activity may be impaired as the ratio of such cells to monocytes is altered, (Figure
6.2). Of note, this imbalance is significantly different compared with volunteers in
the groups of patients with acute pancreatitis except for those with mild disease on
day 5. It is in these groups of patients that PBMC IL-6 and IL-8 release is
significantly increased compared with volunteers, while such cytokine release has
returned to within 'normal' levels in patients with mild acute pancreatitis on day 5.
A possible explanation for these findings could be the reduced production of Type II
cytokines from the reduced number of lymphocytes as there was not an apparent
alteration in the response of PBMCs in vitro to IL-4 or IL-10 in patients with acute
pancreatitis compared with volunteers as reported in Chapter 5. Attempts to
quantify IL-4 and IL-10 concentrations in the culture supernatants of PBMCs were
unsuccessful. ELISAs for these cytokines are under development but the limit of
detection of commercially available kits do not appear to be sensitive enough for
such a study (de Wall Malefyt, 1993).
An additional finding of importance to that of the redistribution of
lymphocytes and monocytes observed in the present study, is that a greater
proportion of the isolated PBMCs from patients with acute pancreatitis (particularly
those with severe disease) compared with the healthy volunteer group do not appear
to express any the surface antigens being tested (Figure 6.3). An increase in
immature lymphocytes and monocytes is likely (Wood, 1987) but in addition, the
appearance of immature granulocytes in so called PBMCs obtained by Ficoll-
fractionation is also described in patients with burns (Volenac, 1979). This
phenomenon would tend to dilute the number of IL-6 and IL-8 producing cells in
the standard cell number of plated PBMCs. Thus the real increase in IL-6 and IL-8
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from mononuclear cells isolated from patients with acute pancreatitis may be under¬
estimated in the present study.
The interpretation of changes in DNA synthesis as indicated by the PHA-
stimulated uptake of thymidine is difficult in the light of the lymphocyte
redistribution described above. Furthermore, there is marked inter-individual
variation in both the volunteer and patient groups. Reduced DNA synthesis may
simply reflect reduced lymphocyte number in the standard PBMC population.
However, this may not be the full picture and impaired histogenesis may also be
present. For example, the mean percentage depletion of CD3 positive cells in
patients with severe acute pancreatitis on the first day of admission was 38 % of the
mean volunteer value, while the mean PHA-stimulated (100 |ag/ml) uptake of 3HTdr
was only 29 % of the mean volunteer value. Nevertheless, it is conceivable that
lymphocyte function is impaired in patients with acute pancreatitis.
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Chapter 7
Effect of interleukin-4 and interleukin-10 on human
umbilical vein endothelial cell interleukin-6 and
interleukin-8 release
7.1 Introduction
Endothelial cells form a physical but interactive barrier between the blood
and the tissues and are important in the pathophysiology of conditions such as
multiple organ failure and septic shock (Glauser, 1991; McMillen, 1993). A variety
of circulating factors present in major inflammatory conditions including acute
pancreatitis such as bacterial lipopolysaccharide, IL-ip and TNFa have been shown
to induce functional alterations in endothelial cells in culture including the synthesis
and release of pro-inflammatory cytokines such as IL-6 and IL-8 (Gimbrone, 1989;
Jirik, 1989; Shalaby, 1989) and alterations in the expression of cell surface
structures involved in neutrophil and monocyte adhesion to endothelial cells
(Baggiolini, 1989; Bevilacqua, 1993; Zimmerman, 1992). The role of the IL-6 and
IL-8 produced by endothelial cells is not clear, but they appear to influence the
inflammatory response by interacting with circulating immune cells in order to
mediate local cell activation and chemoattraction (Kuijpers, 1992; Mantovani, 1992;
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Tanaka, 1993). Clearly, if such pro-inflammatory events occur unchecked then this
might contribute to micro-circulatory failure and the tissue destruction seen in
severe sepsis.
It seems reasonable that there should be mechanisms that down-regulate IL-
6 and IL-8 release by endothelial cells. Of considerable interest in this regard are
the actions of IL-4 and IL-10, which have been shown to attenuate pro¬
inflammatory cytokine production from a variety of immune-competent cells
including polymorphonuclear cells, monocytes and macrophages (Cassatella, 1993;
Essner, 1989; Fiorentino, 1991; Lee, 1990). The data presented in Chapter 5
demonstrates that PBMCs isolated from patients with acute pancreatitis on the first
day of admission manifest a similar percentage down-regulation in pro¬
inflammatory cytokine release in response to IL-4 or IL-10 compared with healthy
volunteers. The presence of such regulatory cytokines may favour a balance of
cytokine production which diminishes the inflammatory response in vivo, for
example, IL-4 promotes IL-lra production from alveolar macrophages while
simultaneously reducing the production of IL-la or IL-1G (Galve-de Rochemonteix,
1993). However, there is also evidence to suggest that IL-4 and IL-10, (like many
other members of the cytokine family) may not act uniformly on all cell types
(Smeland, 1989). Indeed, IL-4 has been shown to induce rather than suppress IL-6
production from unstimulated and endotoxin-stimulated human endothelial cells
(Colotta, 1992; Howells, 1991), but IL-10 had no effect on lipopolysaccharide
stimulated IL-6 production in a murine endothelioma cell line(Sironi, 1993).
The purpose of this study was to examine the potential regulatory role of IL-
4 and IL-10 on endotoxin (LPS)-stimulated human umbilical vein endothelial cell
(HUVEC) release of IL-6 and IL-8.
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7.2 Materials and Methods
7.2.1 Human umbilical vein endothelial cell cultures
HUVECs were obtained and cultured as described in Sections 2.5.1 and
2.5.2 respectively. Initial dose response curves were performed to identify the
appropriate working conditions of human AB serum concentration (0-10 %), time of
LPS pulse (1-5 hours), LPS-stimulation concentration (0.1-100 ng/ml), and the time
of incubation following the LPS pulse (0-48 hours) to optimise IL-6 and IL-8
release.
Confluent HUVECs were then cultured in the presence or absence of LPS at
a final concentration of 10 ng/ml with 5% human AB serum for 5 hours.
Recombinant human IL-4 or IL-10 were added at the same time at a final
concentration ranging from 50 fg/ml to 50 ng/ml. After 5 hours, the cells were
washed with E-SFM growth media and further incubated for 12 hours in E-SFM
growth media. Supernatants from the cultures were removed after 12 hours and
stored at -70 °C for subsequent batch cytokine assay. All cultures were performed
at 37 °C in the presence of 5 % CO2, 95% humidified air.
7.2.2 InterIeukin-6 and InterIeukin-8 ELISA
IL-6 and IL-8 were assayed using sandwich ELISAs as described in Sections
2.6.2 and 2.6.3 respectively.
7.2.3 Statistical analysis
One-factor analysis of variance was used to compare the effect of IL-4 or IL-
10 on LPS-stimulated HUVEC cytokine release with that of LPS-stimulated
HUVEC in the absence of IL-4 or IL-10.
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7.3 Results
Initial dose response curves were obtained on HUVEC lines to identify the
appropriate working conditions of human AB serum concentration (Figure 7.1),
time of LPS pulse (Figure 7.2), LPS-stimulation concentration (Figure 7.3), and the
time of incubation following the LPS pulse (Figure 7.4). For subsequent
experimentation on HUVEC, the human AB serum concentration chosen was 5 %,
the time of LPS pulse was 5 hours, the LPS-stimulation concentration was 10 ng/ml,
and the time of incubation following the LPS pulse was 12 hours.
Results are expressed as the mean of experiments performed on four
HUVEC lines. Spontaneous HUVEC IL-6 and IL-8 release in the presence or
absence of 5 % AB serum was undetectable over the study period. IL-4 and IL-10
had no measurable effect on spontaneous IL-6 and IL-8 release from HUVECs
following the 12 hour incubation period. In the presence of LPS and human AB
serum, the addition of IL-4 to the culture medium led to a dose-dependent increase
in the mean IL-6 release by HUVEC, rising from 428 ± 44 pg/ml (no IL-4) to 1337
±168 pg/ml (IL-4: 50 ng/ml; p=0.023, one-factor analysis of variance) (Figure 7.5).
IL-10 had no effect on mean IL-6 production from HUVEC in the presence of LPS
(Figure 7.6). In the presence of LPS and human AB serum, the addition of IL-4 to
the culture medium led to an initial dose-dependent increase in the mean IL-8
release by HUVEC rising from 2594 ± 493 pg/ml (no IL-4) to 7892 ± 320 pg/ml
(IL-4; 5 pg/ml; p=0.001, one-factor analysis of variance) (Figure 7.7). Similarly, in
the presence of LPS and human AB serum, the addition of IL-10 to the culture
medium led to a dose-dependent increase in the mean IL-8 release by HUVEC
rising from 2594 ± 493 pg/ml (no IL-4) to 8359 ±712 pg/ml (IL-4; 50 pg/ml;






















Lipopolysaccharide-stimulated (final concentration 100 ng/ml) IL-6 (O) and
IL-8 (□) concentration in the culture supernatant from human umbilical vein
endothelial cell monolayers as a function of human AB serum concentration in the
culture medium. Wells were pulsed in triplicate with LPS for 3 hrs in the presence
of human AB serum (0-10 %) with subsequent incubation under standard conditions




Lipopolysaccharide-stimulated (final concentration 100 ng/ml) IL-6 (O) and
IL-8 (□) concentration in the culture supernatant from human umbilical vein
endothelial cell monolayers as a function of length of LPS pulse. Wells were pulsed
in triplicate with LPS for 1, 3 or 5 hr in the presence of 5 % human AB serum with
subsequent incubation under standard conditions for 24 hr. IL-6 and IL-8 were
























Lipopolysaccharide-stimulated IL-6 (O) and IL-8 (□) concentration in the
culture supernatant from human umbilical vein endothelial cell monolayers as a
function of LPS concentration. Wells were pulsed in triplicate with LPS (final
concentration 0.1 to 100 ng/ml) for 3 hr in the presence of 5 % human AB serum
with subsequent incubation under standard conditions for 24 hr. IL-6 and IL-8 were
measured by ELISA. Results of a representative experiment.
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Figure 7.4
Lipopolysaccharide-stimulated IL-6 (O) and IL-8 (□) concentration in the
culture supernatant from human umbilical vein endothelial cell monolayers as a
function of period of incubation. Wells were pulsed in triplicate with LPS (final
concentration 10 ng/ml) for 5 hr in the presence of 5 % human AB serum with
subsequent incubation under standard conditions for 0-48 hr. IL-6 and IL-8 were




















Lipopolysaccharide-stimulated IL-6 (O) concentration in the culture
supernatant from human umbilical vein endothelial cell monolayers as a function of
IL-4 concentration. Wells were pulsed in triplicate with LPS (final concentration 10
ng/ml) for 5 hrs in the presence of 5 % human AB serum and IL-4 (final
concentration 0-50 ng/ml) with subsequent incubation under standard conditions for
12 hr. IL-6 was measured by ELISA. Results are the mean of four HUVEC lines
with the standard error of the mean represented by the error bars. * P < 0.03
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Figure 7.6
Lipopolysaccharide-stimulated IL-6 (O) concentration in the culture
supernatant from human umbilical vein endothelial cell monolayers as a function of
IL-10 concentration. Wells were pulsed in triplicate with LPS (final concentration
10 ng/ml) for 5 hrs in the presence of 5 % human AB serum and IL-10 (final
concentration 0-50 ng/ml) with subsequent incubation under standard conditions for
12 hr. IL-6 was measured by ELISA. Results are the mean of four HUVEC lines





Lipopolysaccharide-stimulated IL-8 (□) concentration in the culture
supernatant from human umbilical vein endothelial cell monolayers as a function of
IL-4 concentration. Wells were pulsed in triplicate with LPS (final concentration 10
ng/ml) for 5 hrs in the presence of 5 % human AB serum and IL-4 (final
concentration 0-50 ng/ml) with subsequent incubation under standard conditions for
12 hr. IL-8 was measured by ELISA. Results are the mean of four HUVEC lines
with the standard error of the mean represented by the error bars. * P < 0.03





Lipopolysaccharide-stimulated IL-8 (□) concentration in the culture
supernatant from human umbilical vein endothelial cell monolayers as a function of
IL-10 concentration. Wells were pulsed in triplicate with LPS (final concentration
10 ng/ml) for 5 hrs in the presence of 5 % human AB serum and IL-10 (final
concentration 0-50 ng/ml) with subsequent incubation under standard conditions for
12 hr. IL-8 was measured by ELISA. Results are the mean of four HUVEC lines
with the standard error of the mean represented by the error bars. * P < 0.02
compared with 0 ng/ml of IL-10 (one-factor analysis of variance).
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The addition of IL-4 and IL-10 after the 5 hr pulse of LPS (at the start of the
12 hour incubation period had little effect on IL-6 or IL-8 release. In these
experiments results are the mean ± standard error of the mean of two HUVEC lines.
LPS-stimulated HUVEC release of IL-6 was 470 ± 90 pg/ml, and IL-4 at 50 ng/ml
following the LPS pulse enhanced the release of IL-6 to 540 ±120 pg/ml, and IL-10
at 50 ng/ml following an LPS pulse increased the release of IL-6 to 500 ± 90 pg/ml.
LPS-stimulated HUVEC release of IL-8 was 2490 ± 100 pg/ml, and IL-4 at 50
ng/ml following the LPS pulse enhanced the release of IL-8 to 3130 ± 480 pg/ml,
and IL-10 at 50 ng/ml following an LPS pulse increased the release of IL-8 to 3065
± 95 pg/ml. None of these increases were statistically significant.
7.4 Discussion
The anti-inflammatory actions of IL-4 and IL-10 are well recognised
(Cassatella, 1993; Essner, 1989; Fiorentino, 1991; Lee, 1990). For example, both in
experimental arthritis (Allen, 1993) and in cancer patients receiving immunotherapy
(Wong, 1993), the production of the pro-inflammatory cytokine IL-1 is reduced by
IL-4 coupled with the selective up-regulation of IL-lra by resting or activated
monocytes. IL-10 protects mice against Staphylococcus enterotoxin B-induced
lethal shock (Bean, 1993) and IL-4 and IL-10 exhibit synergy to inhibit cell-
mediated immunity in a mouse model of leishmaniasis (Powrie, 1993). IL-6 and IL-
8 can be regarded as pro-inflammatory cytokines. Thus, in the present study, the
enhancement by IL-4 and IL-10 of the release of the pro-inflammatory cytokines IL-
6 and IL-8 by endothelial cells in the presence of endotoxin appears somewhat
paradoxical. Both IL-4 and IL-10 up-regulated IL-8 release in the presence of
endotoxin. In contrast, IL-4 but not IL-10 up-regulated IL-6 release in the presence
of endotoxin. HUVEC pro-inflammatory cytokine production is generally
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detectable within hours of an LPS-stimulus in the presence of serum factors (von
Asmuth, 1993). The results of the present study agree with those of Sironi and co¬
workers (Sironi, 1993) who showed that IL-10 does not alter LPS-stimulated IL-6
production in a murine endothelioma cell line. IL-4 had no effect on pro¬
inflammatory cytokine production in the absence of an LPS stimulus in the present
study and this differs from the findings of Howells and co-workers (Howells, 1991)
who observed increased IL-6 release in HUVECs not exposed to endotoxin. These
differences may, however, be due to different time courses since the incubation
period in the present study was just 12 hours compared with 3 days in the study by
Howells and co-workers.
The role of pro-inflammatory cytokines in both acute and chronic
inflammatory diseases is now well recognised and successful therapeutic strategies
have been developed to reduce the influence of such cytokines, for example, the
administration of anti-TNFa (Exley, 1990) or anti-IL-6 (Starnes, 1990) in certain
models of septic shock. The established role of IL-4 and IL-10 in the down-
regulation of leukocyte pro-inflammatory cytokine release has led to the suggestion
that IL-4 and IL-10 could be used to treat conditions such as septic shock. The
results of the present study indicate that IL-4 and IL-10 augment LPS-mediated IL-6
and IL-8 release from endothelial cells and may indeed provide a means of altering
pro-inflammatory cytokine concentration gradients within the local micro
environment. Further studies are required to determine the outcome of treatment
with IL-4 or IL-10 under various conditions in vivo. Nevertheless, the findings
presented here indicate that IL-4 and IL-10 may be involved in a complex regulation
of endothelial cell activation following exposure to endotoxin. An acute
inflammatory response requires the sequestration of circulating monocytes,
lymphocytes and neutrophils into sites of inflammation. Clearly, the attraction and
migration of circulating cells into such sites must be regulated with some precision
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and specificity. The fine-tuning of the cytokines produced by endothelial cells and
the cell-surface molecules expressed by these cells in the local micro-environment
may lend this precision and specificity.
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Chapter 8
Serum concentrations of inflammatory mediators in
patients with acute pancreatitis and their
relationship to organ failure
8.1 Introduction
The central role of TNFa in orchestrating aspects of the early inflammatory
response in sepsis is well established (Dinarello, 1993a). Elevated levels of TNFa
have been documented in the serum of some groups of patients with sepsis (Damas,
1989) and following exposure to endotoxin (Michie, 1988b). However, TNFa is
often undetectable in the sera of patients with acute pancreatitis, even those with
severe disease (Banks, 1991a; Exley, 1992)- This may be due to the short half life
of TNFa, binding of TNFa to other proteins, or difficulties with the various
methods of measuring TNFa in serum. Alternatively, it may be that TNFa is not
produced in patients with acute pancreatitis or is mainly produced in the tissues and
only occasionally spills over into the circulation. TNFa release from PBMCs
isolated from patients with acute pancreatitis on admission was found not to be
different from healthy volunteers (as discussed in Chapter 3). However, this may
actually be an important finding as in a number of patients, 'normal' PBMC TNFa
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release may be inappropriate in the presence of an elevated serum TNFa
concentration.
The paracrine and endocrine actions of TNFa are exerted by interaction with
membrane-bound TNFa receptors on the surface of target cells (Sherry, 1988). It
appears that following exposure to substances such as bacterial endotoxin (and
indeed TNFa itself) and during adherence, such target cells down-regulate their
responsiveness to TNFa by shedding the receptor into the circulation (Lantz, 1994;
Leeuwenberg, 1994; Shapiro, 1993). Two such soluble receptors have been
identified, a 55 kDa (sTNFR.55) and a 75 kDA (sTNFR/75) fragment (Tartaglia,
1992). The release of these soluble receptors (which have a longer half life in serum
than TNFa itself) appears to reflect the degree of TNFa-induced inflammation
(Spinas, 1992). Thus, although TNFa may be undetectable in blood, the presence
of such soluble TNFa receptors may be a useful index of TNFa activity. The role
of the shed TNFa receptors is not fully understood. On the one hand, they could
exert an anti-inflammatory effect; the shedding of surface receptors down-regulating
the target cell's responsiveness and the soluble TNFR may bind TNFa in the
circulation thereby reducing its bioavailability (Olsson, 1991). On the other hand, it
is not inconceivable that the TNFa-sTNFR complex could be recognised by a
different cell surface receptor allowing the induction of a secondary inflammatory
response (analogous to the soluble CD 14 receptor-LPS-LPS binding protein
complex that allows endothelium and other target cells that do not possess the CD14
receptor to respond to the presence of endotoxaemia (Arditi, 1993; Frey, 1992;
Haziot, 1993)). However, sTNFR appear to be protective against TNFa mediated
cell injury in vitro (Engelmann, 1989; Olsson, 1991; Van Zee, 1992). They also
appear to be effective in vivo; the administration of sTNFR to baboons following
LPS challenge reduced the typical release of TNFa and also the TNFa inducible
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cytokines, IL-1B and IL-6 (Van Zee, 1992). STNFR also improved survival in a
lethal endotoxaemia model in mice (Mohler, 1993).
Other cytokines involved in the inflammatory cascade, such as IL-6 are
more often detected in the sera of patients with acute pancreatitis (Heath, 1993;
Leser, 1991; Viedma, 1992). Both the serum concentration of IL-6 on admission
and the peak level of IL-6 have some correlation with the severity of the disease
(Heath, 1993; Leser, 1991; Viedma, 1992). One of the many actions of IL-6 is to
induce the production of hepatic acute phase proteins, such as C-reactive protein
(CRP). Serum CRP concentration is also elevated in patients with acute pancreatitis
and correlates with the severity of the disease (Mayer, 1984; Puolakkainen, 1987;
Wilson, 1989). The rise in serum CRP concentration lags behind the peak in serum
IL-6 concentration by some 24 to 48 hours (Windsor, 1993) and this has been
interpreted by some investigators to indicate a cause and effect relationship.
It has been proposed that a prolonged or excessive inflammatory response
may be one of the mechanisms whereby patients develop multiple organ failure
(Cerra, 1987; Deitch, 1992). The major causes of death in acute pancreatitis stem
from either local peripancreatic complications or from multiple organ failure, or a
combination of the two (de Beaux, 1995; Mann, 1994). In the present study, the
systemic inflammatory response as measured by markers of inflammation (TNFoc,
STNFR55, STNFR75, IL-6 and CRP) in the serum of patients with acute pancreatitis
and the relationship of these to the development of local complications and organ
failure has been investigated.
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8.2 Patients and Methods
8.2.1 Patients
The study population comprised patients with acute pancreatitis (section
2.1.1) admitted to the Royal Infirmary of Edinburgh. The clinical course of the
patients was followed prospectively, allowing retrospective categorisation of
patients into those with mild or severe disease based on the Atlanta classification
(Bradley, 1993). Twenty eight patients with severe disease represent a consecutive
series over a 16 month period. Patients with mild disease for comparison (n=30)
represent a random selection from 78 patients with mild disease admitted over the
same time period. Patients with severe disease were further sub-categorised into
those with local pancreatic complications alone (n=18) and those with organ failure
(a score of 1 or more; Goris score (Goris, 1985)) (n=10). Six patients with organ
failure died during the index admission. The patient characteristics are given in
Table 8.1. Venous blood was sampled on the first and second day of admission and
the serum stored at -70 °C until subsequent batch analysis for TNFa, STNFR55,
STNFR75, IL-6 and CRP concentration by indirect enzyme-linked immunosorbant
assays (ELISAs).
8.2.2 Cytokine and CRP ELISAs
TNFa and the soluble TNFa receptors were measured by ELISA as
described in sections 2.6.1 and 2.6.4 respectively. IL-6 and CRP were also
measured by ELISA as described in sections 2.6.2 and 2.6.5 respectively.
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Table 8.1
Details of patients with acute pancreatitis studied. Pancreatic complications
defined by the Atlanta criteria (Bradley, 1993) and organ failure by the modified
Goris score (Goris, 1985).
Patient Age Sex Aetiology Pancreatic Organ
(years) complication failure score
1 40 M Alcohol no 0
2 69 F Idiopathic no 0
3 88 F Gallstone no 0
4 34 F Idiopathic no 0
5 60 F Alcohol no 0
6 88 F Gallstone no 0
7 57 M Alcohol necrosis 0
8 62 F Gallstone no 0
9 42 F Gallstone no 0
10 65 F Alcohol pseudocyst 0
11 48 M Alcohol no 0
12 57 M Idiopathic no 0
13 31 F Gallstone no 0
14 31 F Alcohol no 0
15 53 F Idiopathic no 0
16 35 M Post ERCP no 0
17 61 F Gallstone no 0
18 74 F Gallstone necrosis 0
19 75 F Gallstone necrosis 0
20 71 M Gallstone necrosis 0
21 41 M Alcohol pseudocyst 0
22 33 M Alcohol no 0
23 20 F Gallstone no 0
24 25 F Gallstone no 0
25 59 M Gallstone necrosis 0
26 60 M Idiopathic no 0
27 68 M Gallstone no 0
28 31 M Alcohol necrosis 0
29 39 M Alcohol no 0
30 56 F Gallstone no 0
continued over the page
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Table 8.1 continued
Patient Age Sex Aetiology Pancreatic Organ
(years) complication failure score
31 65 F Post ERCP no 0
32 75 F Gallstone no 2 (Died)
33 49 M Alcohol no 0
34 82 F Gallstone necrosis 0
35 34 F Alcohol no 0
36 56 M Alcohol no 0
37 53 M Pancreatic necrosis 0
cancer
38 32 F Gallstone no 0
39 76 F Gallstone necrosis 0
40 53 M Gallstone necrosis 0
41 60 F Alcohol no 0
42 71 M Gallstone necrosis 0
43 69 F Idiopathic necrosis 6 (Died)
44 58 F Idiopathic necrosis 0
45 37 M Alcohol no 0
46 53 M Alcohol no 2
47 49 M Alcohol no 1
48 34 F Idiopathic necrosis/ 0
pseudocyst
49 66 M Idiopathic necrosis 2
50 52 F Gallstone necrosis 5
51 54 M Idiopathic necrosis 6 (Died)
52 73 M Gallstone no 4 (Died)
53 82 F Gallstone necrosis 3 (Died)
54 89 F Gallstone necrosis 0
55 77 M Idiopathic necrosis 0
56 69 M Gallstone no 0
57 47 F Alcohol necrosis 5 (Died)
58 57 M Gallstone necrosis 0
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8.2.3 Statistical analysis
Results are presented as the median (interquartile range). Initial comparison
between patients with mild disease, a local pancreatic complication alone and organ
failure was performed using the Kruskal-Wallis test. Thereafter, Mann-Whitney U
tests were applied to compare differences between any two groups with significance
taken at a p value < 0.05. Where levels of the cytokine being measured were below
the limit of detection of the assay, the minimum detection concentration was
assigned to the sample and statistical analysis performed using this convention.
8.3 Results
None of the 30 patients with mild disease developed significant
complications. In contrast, 18 of the 28 (64 %) with severe pancreatitis developed
local complications alone while the remaining 10 (36 %) developed failure of one or
more organ systems, with or without an accompanying local pancreatic
complication. There was no significant difference in the age (p=0.29) or sex ratio
(p=0.57) between those with mild pancreatitis and those with severe pancreatitis.
Serum TNFa concentrations were below the level of detection in 41 of the
58 patients on the first day of admission (29/30 who had mild disease, 8/18 who
developed a local pancreatic complication and 4/10 who developed organ failure)
and 50 of the 58 patients on the second day of admission (30/30 who had mild
disease, 16/18 who developed a local pancreatic complication and 4/10 who
developed organ failure). On the first day of admission, median serum TNFa
concentration was greater in the group who developed organ failure (p<0.001) and
in those who developed a local pancreatic complication (p<0.001) compared with
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the group who had mild disease (Figure 8.1). There was no significant difference
between the group who developed organ failure and the group who developed a
local pancreatic complication alone (p=0.34) (Figure 8.1). On the second day of
admission, median serum TNFa concentration was greater in the group who
developed organ failure compared with both the group who developed a local
pancreatic complication (p<0.006) and the group who had mild disease (p<0.006)
(Figure 8.1). There was no significant difference between the group who developed
a local pancreatic complication alone and those who had mild disease (p=0.07)
(Figure 8.1).
Serum STNFR55 and STNFR75 were detectable in all 58 patients. On both
day 1 and 2 of admission, median serum STNFR55 concentration was greater in the
group who developed organ failure compared with the group who developed a local
pancreatic complication (p<0.003). In both groups with severe disease, median
serum STNFR55 concentration was greater than in the group who had mild disease
(pcO.OOl in both cases) (Figure 8.2). STNFR75 concentrations showed a similar
distribution between the 3 groups to that found for the STNFR55 receptor (Figure
8.3).
Serum IL-6 concentrations were below the level of detection in 24 of the 58
patients on the first day of admission (20/30 who had mild disease, 3/18 who
developed a local pancreatic complication and 1/10 who developed organ failure)
and 23 of the 58 patients on the second day of admission (19/30 who had mild
disease, 4/18 who developed a local pancreatic complication and 0/10 who
developed organ failure). On both day 1 and 2 of admission, median serum IL-6
concentration was greater in the group who developed organ failure compared with













Day 1 Day 2
Figure 8.1
Median serum TNFa concentration in the peripheral venous blood on the
first and second day of admission in patients with acute pancreatitis categorised by
eventual disease outcome: mild disease (On=30), local pancreatic complication
alone (□ n=18)(Atlanta criteria (Bradley, 1993)); and organ failure (■
n=10)(modified Goris score (Goris, 1985)). Interquartile range represented by the
error bars. TNFa measured by ELISA. The dotted line represents the limit of
detection of the assay (15 pg/ml).
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Figure 8.2
Median serum soluble TNFa receptor (55 kDa fragment) concentration in
the peripheral venous blood on the first and second day of admission in patients
with acute pancreatitis categorised by eventual disease outcome: mild disease (O
n=30); local pancreatic complication alone (□ n=18)(Atlanta criteria (Bradley,
1993)); and organ failure (■ n=10)(modified Goris score (Goris, 1985)).




















Day 1 Day 2
Figure 8.3
Median serum soluble TNFa receptor (75 kDa fragment) concentration in
the peripheral venous blood on the first and second day of admission in patients
with acute pancreatitis categorised by eventual disease outcome: mild disease (O
n=30); local pancreatic complication alone (□ n=18)(Atlanta criteria (Bradley,
1993)); and organ failure (■ n=10)(modified Goris score (Goris, 1985)).
Interquartile range represented by the error bars. STNFR75 measured by ELISA.
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8.4), which in turn was greater than in the group who had mild disease (pcO.OOl)
(Figure 8.4).
CRP was detectable in the serum of all patients. On the first day of
admission, there was no significant difference in median serum CRP levels between
patients who developed organ failure, a local pancreatic complication or had mild
disease (p=0.15) (Figure 8.5). By the second day of admission, median serum CRP
concentration was greater in the group who went on to develop organ failure
compared with those who developed a local pancreatic complication (p=0.02) or
those who had mild disease alone (p=0.003) (Figure 8.5). However, median serum
CRP level was not significantly different in the group who developed a local
pancreatic complication compared with the group who had mild disease (p=0.80)
(Figure 8.5).
8.4 Discussion
The present study demonstrates that during the first two days of admission,
concentrations of markers of inflammation in the sera of patients with acute
pancreatitis are highest in those who subsequently develop organ failure.
TNFa has been implicated as a key mediator in the development of multiple
organ failure (Casey, 1993; Deitch, 1992). However in the present study, (in
keeping with previous reports (Banks, 1991a; Exley, 1992)) TNF was detected in
only a minority of patients on the first day of admission (41 of 58) and in only 8
patients by the second day of admission. This finding may be accounted for by the
short half life of serum TNFa and the fact that in the present study, blood for TNFa
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Figure 8.4
Median serum IL-6 concentration in the peripheral venous blood on the first
and second day of admission in patients with acute pancreatitis categorised by
eventual disease outcome: mild disease (On=30), local pancreatic complication
alone (□ n=18)(Atlanta criteria (Bradley, 1993)); and organ failure (■
n=10)(modified Goris score (Goris, 1985)). Interquartile range represented by the
error bars. IL-6 measured by ELISA. The dotted line represents the limit of
detection of the assay (40 pg/ml).
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Figure 8.5
Median serum C-reactive protein concentration in the peripheral venous
blood on the first and second day of admission in patients with acute pancreatitis
categorised by eventual disease outcome: mild disease (On=30), local pancreatic
complication alone (□n=18)(Atlanta criteria (Bradley, 1993)); and organ failure (■
n= 10)(modified Goris score (Goris, 1985)). Interquartile range represented by the
error bars. C-reactive protein measured by ELISA.
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TNFa appears transiently and repetitively in the circulation and thus the peak
concentration of TNFa could easily be missed by infrequent blood sampling
(Dofferhoff, 1992). In contrast, sTNF receptors were detected in all patients, with a
stepwise increase in the median concentration of both sTNFR.55 and STNFR75 being
observed between patients who had mild disease, those who developed a local
pancreatic complication alone, and those who developed organ failure (Figures 8.2
and 8.3). Spinas and coworkers (Spinas, 1992) demonstrated a significant
correlation between peak serum TNFa and sTNFR.55 in human volunteers after
intravenous administration of Escherichia coli endotoxin suggesting that sTNFR.55
may reflect the degree of TNFa-induced inflammation. If this assumption is
correct, the finding in the present study of elevated sTNF receptors on admission in
patients who subsequently develop severe acute pancreatitis would support the
contention that TNFa is an important central mediator of a systemic inflammatory
response with progression to multiple organ failure early in the course of the
disease.
In the present study, the serum levels of sTNFR on admission in patients
with acute pancreatitis was most elevated in those who subsequently developed
organ failure. Increased serum levels of sTNFR are reported in patients with sepsis
and correlated with the simultaneously obtained APACHE II and multiple organ
failure score as well as with mortality (Ertel, 1994; Froon, 1994). This correlation is
perhaps not surprising in patients with established organ failure as the serum
concentration of sTNFR correlates with the serum creatinine concentration,
reflecting the degree of existing renal failure complicating the sepsis (Froon, 1994).
However, in the present study, the serum levels of sTNFR were measured in
patients with acute pancreatitis shortly following admission and the vast majority of
these patients had no overt renal failure as manifest by a rise in serum creatinine at
the time of venous sampling. While the administration of sTNFR was demonstrated
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to be protective against TNFa mediated cell injury in vitro (Engelmann, 1989;
Olsson, 1991; Van Zee, 1992), and also in vivo in a baboon model (Van Zee, 1992)
and a mouse model of intravenous endotoxin challenge, the potential role of such
therapy in patients with acute pancreatitis is less promising as in many patients, the
major TNFa challenge would appear from the present study to have occurred prior
to admission. Nevertheless, sTNFR therapy may have a part to play in the
minimisation of secondary inflammatory responses.
IL-6 has also been implicated in the pathogenesis of multiple organ failure
(Hoch, 1993). In the present study IL-6 was detectable more often than TNFa,
being present in the serum of 34 patients on day 1 and 35 on day 2 of admission,
with a stepwise increase in the median concentration of IL-6 between patients
progressing to mild disease, a local pancreatic complication alone or organ failure
(Figure 8.4). Furthermore, by day 2 of admission, IL-6 was detectable in all 10
patients who later developed organ failure. Patel and co-workers (Patel, 1994)
found that serum IL-6 levels in patients with sepsis syndrome from an intra¬
abdominal septic focus, were greater on enrolment in those patients who
subsequently died when compared with survivors. Furthermore, the non-survivors
had a greater incidence of organ failure relative to survivors. I have demonstrated
prolonged up-regulation of IL-6 release from peripheral blood mononuclear cells
isolated from patients with acute pancreatitis who develop severe disease compared
with patients with mild disease (Chapter 4), which demonstrates the possible
contribution of leucocyte activation to the increase in serum IL-6 concentration.
In the present study, serum CRP concentrations were unhelpful on the first
day of admission in predicting disease outcome (Figure 8.5). However, by the
second day following admission, median serum CRP concentration was
significantly elevated in the group of patients developing organ failure compared
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with patients with mild disease or a local pancreatic complication alone. This
finding concurs with other authors who report an elevation of serum CRP
concentration in patients with acute pancreatitis who subsequently develop severe
disease (Mayer, 1985; Puolakkainen, 1987; Wilson, 1989). This is consistent with
the concept of a systemic inflammatory response contributing to the development of
organ failure in critical illness (Cerra, 1987).
Patients dying from acute pancreatitis, appear to do so as a consequence of
multiple organ failure (de Beaux, 1995; Tran, 1992). While such organ failure is
usually associated with pancreatic inflammation and necrosis, development of a
local pancreatic complication alone in the absence of organ failure is rarely fatal (de
Beaux, 1995). The present study has shown that severe acute pancreatitis is
associated with increased levels of serum markers of a systemic inflammatory
response and that within this group of patients, those who develop organ failure
show a greater concentration of these markers compared with those who develop
local pancreatic complications alone. The serum markers of inflammation which
were measured may have derived from the tissues, endothelial cells or leukocytes
but the source of these mediators cannot be identified from the present study.
Nevertheless, the findings reflect the host systemic response to pancreatic
inflammation and the level of the response in the present study did relate to the
development of organ failure. While there is evidence to suggest that the host
response to pancreatic inflammation may have a significant genetic pre¬
determination (Rinderknecht, 1994), further study of the mechanisms leading to a
systemic inflammatory response may allow early identification of patients at risk
and thereby aid the development of therapeutic intervention to modify the biological
response in patients with acute pancreatitis.
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Chapter 9
A randomised double-blind study of glutamine
supplementation of total parenteral nutrition in
patients with severe acute pancreatitis: effect on
peripheral blood mononuclear cell pro¬
inflammatory cytokine release and proliferative
response
9.1 Introduction
Glutamine is the most abundant amino acid both in the plasma and in the
intracellular free amino acid pool (Wallace, 1992). The glutamine molecule has a 5
carbon chain with 2 amino moieties and accounts for some 30 % of all of the amino
acid nitrogen that is transported in the plasma. Despite an intense traffic of
glutamine between organs, the circulating concentration of glutamine (500-900 (iM)
is usually maintained at a fairly constant level. In the postabsorptive state,
glutamine is synthesised de novo by a number of cells, principally skeletal muscle,
the lungs and the liver and is therefore not an essential amino acid. Glutamine
accounts for more than 50 % of the intracellular free amino acid pool in skeletal
muscle and this serves as a major source of this amino acid during periods of
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metabolic stress (Herskowitz, 1990). Furthermore, branched chain amino acids
(isoleucine, leucine, valine) can be metabolised to glutamine in skeletal muscle.
The lungs also release glutamine in the post absorptive state by the uptake of
precursor nitrogen from the circulation in the form of ammonia and glutamate. The
liver plays an important role in glutamine homeostasis because it can either generate
or consume glutamine.
Glutamine is essential for a wide variety of physiological processes. It is the
principal fuel source for the intestinal mucosa and other rapidly dividing cells, in
particular, the growth and function of immune cells including lymphocytes and
macrophages (Alexander, 1993; Sarantos, 1993) as well as pneumatocytes and
vascular endothelial cells. In conditions of excess glutamine utilisation, such as
sepsis, trauma, major surgery or severe acute pancreatitis, endogenous glutamine
production may not be adequate and glutamine depletion occurs (Lacey, 1990;
Steininger, 1989). Intracellular glutamine stores may be depleted by more than 50
% while plasma levels fall by up to 30 %. Exogenous glutamine may be required to
satisfy the body's glutamine requirements, but the glutamine depletion is
compounded by the fact that many of these patients are being fed parenterally rather
than enterally, and traditional parenteral feeding does not contain glutamine. This is
because of its relative insolubility as well as its long term instability in solution
where it may degrade to ammonia and pyroglutamic acid.
Patients with severe acute pancreatitis can develop local pancreatic
complications related to pancreatic necrosis and develop distant organ dysfunction
(Bradley, 1993). Infection of the necrotic pancreas is thought to be a key step in the
progression to a persistent systemic inflammatory response and multiple organ
dysfunction (Beger, 1986; Widdison, 1993). An intact T-cell response and gut
mucosal barrier play a important roles in the defence of the host against bacterial
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invasion, and T-cell DNA synthesis (as determined by thymidine incorporation in
vitro) correlates well with host resistance to sepsis in vivo (Moss, 1988). T-cells
are dependent on glutamine for optimal growth and function (Ardawi, 1988) and
glutamine depletion may be partly responsible for T-cell suppression seen in these
severely stressed patients (Curley, 1993; Widdison, 1996). T-cells also exert an
important regulatory role on monocyte pro-inflammatory cytokine release
(Fiorentino, 1991; Lee, 1990), and T-cell suppression may contribute to the
prolonged increase in pro-inflammatory cytokine release (IL-6 and IL-8) observed
in patients with severe acute pancreatitis as described in Chapter 4. Clinical
susceptibility to sepsis may also be enhanced by abnormal production of pro¬
inflammatory cytokines (O'Riordain, 1992).
Recently, the development of glutamine dipeptides has allowed glutamine to
be introduced into total parenteral nutrition regimens which are stored prior to
administration to patients. These dipeptides, are very stable in solution but are
rapidly broken down in vivo to allow immediate bio-availability of the constituent
amino-acids. The clinical administration of these compounds is well tolerated, even
in patients with severe sepsis (Karner, 1989). Van der Hulst and coworkers (van der
Hulst, 1993) demonstrated that glutamine given via the parenteral route can prevent
the deterioration of gut integrity and preserve mucosal structure in patients with
inflammatory bowel disease or intestinal malignancy. O'Riordain and coworkers
(O'Riordain, 1994) demonstrated that glutamine given via the parenteral route can
restore T cell blastogenesis in patients undergoing colorectal resection. While
glutamine may improve gut barrier function and T cell blastogenesis, it is not clear
whether glutamine would increase or decrease pro-inflammatory drive in patients
with acute pancreatitis. The aims of this study then, were to perform a double blind
randomised controlled study comparing the effect of glutamine supplemented total
parenteral nutrition versus conventional total parenteral nutrition on T-cell
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proliferative response and pro-inflammatory cytokine release (TNFa, IL-6 and IL-
8) by peripheral blood mononuclear cells in patients with severe acute pancreatitis.
9.2 Patients and Methods
9.2.1 Patients
Patients over the age of 18 years with severe acute pancreatitis were
included in the study. Severe acute pancreatitis for the purpose of this study was
defined as a modified Glasgow score (Blarney, 1984) of 3 or more in a patient
requiring total parenteral nutrition because of persisting failure of the
gastrointestinal tract 7 days after the onset of illness. Patients with respiratory
failure (requiring ventilatory support), renal failure (creatinine >200 (imol/1) or
hepatic failure (bilirubin >100 |imol/l in the absence of choledocholithiasis) were
excluded until resolution of organ failure. In addition, patients receiving systemic
steroids were excluded. The study protocol was approved by the Ethical Committee
(Subcommittee for Surgery and Orthopaedic Surgery) of the Lothian Health Board.
Full written informed consent was obtained from all patients before inclusion to the
study.
9.2.2 Study protocol
The 14 study patients were commenced on conventional total parenteral
nutrition for a minimum of 3 days prior to randomisation to receive either
conventional or glutamine supplemented total parenteral nutrition which ran
continuously for 7 subsequent days. Following the study period, total parenteral
nutrition was stopped or continued with a conventional regimen depending on the
clinical condition of the patient. Peripheral blood was taken on day 0 (before the
commencement of the study total parenteral nutrition), on day 4 and on day 7 (at the
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end of the study total parenteral nutrition) for the isolation of blood mononuclear
cells. In vitro peripheral blood mononuclear cell cultures were performed to
determine unstimulated and phytohaemagglutinin-stimulated T-cell DNA synthesis
and the spontaneous release of TNFa, IL-6 and IL-8 into the supernatant. The
clinicians responsible for patient management and the laboratory investigator were
blinded to which total parenteral nutrition was used.
9.2.3 Total parenteral nutrition formulae
Conventional total parenteral nutrition was based on an amino acid solution
(Vamin 18 EF, Pharmacia & Upjohn GmbH, Erlangen, Germany) providing 0.25 g
nitrogen per kg body weight per day with lipid emulsion (Intralipid 20 %,
Pharmacia & Upjohn) and glucose (Baxter, Newbury, U.K.). Electrolytes, trace
elements and vitamins were added to maintain requirements. The calorie to
nitrogen ratio was 2060 kcal to 17.5 g nitrogen and the glucose to lipid calories was
57% to 43 % respectively. The total parenteral nutrition supplemented with
glutamine consisted of an isocaloric, isonitrogenous and isovolumetric solution, but
Vamin 18 EF in the conventional regime was replaced with glutamine-
supplemented amino-acid solution (Glamin, Pharmacia & Upjohn). This regimen,
based on the amino-acid profile of Vamin 18 EF additionally provided 0.22 g
glutamine per kg body weight per day in the form of dipeptide glycyl-glutamine,
and glutamine in this regimen represented 17 % of the total administered nitrogen.
9.2.4 PBMC proliferation protocol
PBMCs were incubated in triplicate at 2 x 105 cells per well in the presence
or absence of phytohaemagglutinin (final concentration 100 fig/ml). Subsequent
incubation, pulse with tritiated thymidine, storage and cell harvest are described in
Section 2.4, Chapter 2.
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9.2.5 PBMC pro-inflammatory cytokine release protocol
PBMCs were incubated in triplicate at 2 x 105 cells per well. Following 24
hr incubation, the supernatants were removed and stored in aliquots at -70 °C for
subsequent batch cytokine assay.
9.2.6 TNFa, IL-6 and IL-8 ELISAs
Supernatants and serum were assayed for TNFa, IL-6 and IL-8 by ELISAs
as described in Sections 2.6.1, 2.6.2 and 2.6.3, Chapter 2 respectively.
9.2.7 Statistical analysis
The Mann-Whitney U tests was used to compare patients characteristics and
the change in DNA synthesis and cytokine release over the study period between
groups. Two-tailed tests were used on all occasions. P values of less than 0.05
were considered statistically significant.
9.3 Results
Fourteen patients with severe acute pancreatitis were recruited to the study, 7
in each group. One patient in the glutamine supplemented total parenteral nutrition
group was withdrawn as a result of central line sepsis on day 3 of the study protocol
and was excluded from further analysis or comparison. The patients characteristics
at entry to the study are shown in Table 9.1. The aetiology of the acute pancreatitis
in the glutamine total parenteral nutrition group was gallstones in 2 patients, alcohol
in 1 patient, idiopathic in 2 patients and post endoscopic retrograde
cholangiopancreatography in 1 patient and in the conventional total parenteral
nutrition group, gallstones in 2 patients, alcohol in 3 patients and idiopathic in 2
patients. Local pancreatic complications (pancreatic necrosis, pseudocyst or abscess
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Table 9.1
Characteristics of patients with severe acute pancreatitis at entry to the study.
Values are median (interquartile range) P values were calculated using the Mann-












Sex (male:female) 4:2 4:3 0.74



















































as defined by the Atlanta classification (Bradley, 1993)) were present in 4 patients
in the glutamine total parenteral nutrition group and 5 patients in the conventional
total parenteral nutrition group. No patient died from the disease during the index
admission.
9.3.2 PBMC proliferation
While median unstimulated T-cell DNA synthesis increased by 472 counts
per min in the glutamine total parenteral nutrition group over the study period
compared with a decrease of 416 cpm in the conventional total parenteral nutrition
group, this change was not significantly different between the two groups (Figure
9.1). The median phytohaemagglutinin stimulated T-cell DNA synthesis increased
in both the glutamine and conventional total parenteral nutrition groups (3099 and
216 cpm respectively) but this change was not significantly different between the
two groups (Figure 9.2).
9.3.2. PBMC pro-inflammatory cytokine release
There was no significant change in median peripheral blood mononuclear
cell TNFa release or IL-6 release over the study period in the glutamine total
parenteral nutrition group compared with the conventional total parenteral nutrition
group (Figure 9.3 and 9.4 respectively). In contrast, the median peripheral blood
mononuclear cell IL-8 release decreased by 17.7 ng/ml in the glutamine total
parenteral nutrition group over the study period compared with an increase of 43.3
ng/ml in the conventional total parenteral nutrition group and this change was
significantly different between the two groups; p=0.045 (Figure 9.5).
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Figure 9.1
Median change in unstimulated T-cell DNA synthesis on day 4 and day 7 of
the study period compared with baseline (day 0) in patients with severe acute
pancreatitis randomised to receive either glutamine supplemented total parenteral
nutrition (■) or isonitrogenous, isocaloric conventional total parenteral nutrition
(□). Box and whisker plots represent the interquartile range and the range
respectively. 2 x 105 cells per well incubated in triplicate under standard conditions

























Day 4 Day 7
Figure 9.2
Median change in phytohaemagglutinin stimulated (final concentration 100
|lg/ml) T-cell DNA synthesis on day 4 and day 7 of the study period compared with
baseline (day 0) in patients with severe acute pancreatitis randomised to receive
either glutamine supplemented total parenteral nutrition (■) or isonitrogenous,
isocaloric conventional total parenteral nutrition (□). Box and whisker plots
represent the interquartile range and the range respectively. 2 x 105 cells per well
incubated in triplicate under standard conditions for 72 hr before being pulsed with
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Figure 9.3
Median change on day 4 and day 7 of the study period compared with
baseline (day 0) in spontaneous tumour necrosis factor-a concentration in the
culture supernatant from peripheral blood mononuclear cells isolated from patients
with severe acute pancreatitis randomised to receive either glutamine supplemented
total parenteral nutrition (■) or isonitrogenous, isocaloric conventional total
parenteral nutrition (□). Box and whisker plots represent the interquartile range
and the range respectively. 2 x 105 cells per well incubated in triplicate under
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Figure 9.4
Median change on day 4 and day 7 of the study period compared with
baseline (day 0) in spontaneous IL-6 concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from patients with severe acute
pancreatitis randomised to receive either glutamine supplemented total parenteral
nutrition (■) or isonitrogenous, isocaloric conventional total parenteral nutrition
(□). Box and whisker plots represent the interquartile range and the range
respectively. 2 x 105 cells per well incubated in triplicate under standard conditions
for 24 hr. IL-6 was measured by ELISA.
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Figure 9.5
Median change on day 4 and day 7 of the study period compared with
baseline (day 0) in spontaneous IL-8 concentration in the culture supernatant from
peripheral blood mononuclear cells isolated from patients with severe acute
pancreatitis randomised to receive either glutamine supplemented total parenteral
nutrition (■) or isonitrogenous, isocaloric conventional total parenteral nutrition
(□). Box and whisker plots represent the interquartile range and the range
respectively. 2 x 105 cells per well incubated in triplicate under standard conditions
for 24 hr. IL-8 was measured by ELISA. * P=0.045 comparing the glutamine
group with the conventional group; Mann-Whitney U test.
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9.4 Discussion
Patients with severe acute pancreatitis are recognised to suffer glutamine
depletion and the development of sepsis both within the necrotic pancreas and at
distant sites may adversely affect survival of the patient. Glutamine depletion has
been implicated in the development of T-cell suppression seen in such patients.
This study has shown that the administration of total parenteral nutrition
supplemented with glutamine (as the glycyl-glutamine dipeptide) tends to improve
T-cell DNA synthesis in patients with severe acute pancreatitis. However, this
difference failed to reach statistical significance compared with a conventional total
parenteral nutrition (Figure 9.1 and 9.2). In a previous study (O'Riordain, 1994), it
was demonstrated that total parenteral nutrition supplemented with glutamine
significantly improves T-cell DNA synthesis in patients with colorectal surgery
undergoing elective resection compared with both preoperative values and a group
receiving conventional total parenteral nutrition. In the present study, small patient
numbers associated with substantial inter-individual variation may partly explain the
lack of statistical significance. The ability of T cells to respond to a mitogenic
stimulus correlates well with host resistance to sepsis, (Moss, 1988) and
experimental in vivo enhancement of T-cell response is associated with reduced
susceptibility to infection (Horgan, 1990). Glutamine supplementation reduces
mortality in septic rats (Ardawi, 1991) and Ziegler et al (Ziegler, 1992) have shown
a reduction in the rate of clinical infection in patients undergoing bone marrow
transplantation who received glutamine supplemented total parenteral nutrition.
These papers suggested that glutamine supplementation may reduce the incidence of
clinical infection by enhancing immune function, but specific immunologic
parameters were not examined in either of these studies. In the present study, there
was no mortality and few clinical infections to allow meaningful comparison
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between the glutamine supplemented and conventional total parenteral nutrition
groups and these were not the stated aims of the study.
Glutamine can play an important role in lymphocyte metabolism for the
generation of energy and as a precursor of protein and nucleotide synthesis within
the rapidly dividing cell (Brand, 1989). Lymphocyte activation in vivo results in a
large increase in protein synthesis which corresponds with a significant increase in
thymidine uptake in vitro. Although glutamine may be synthesised in the body, it
becomes "conditionally essential" when demand outstrips supply within conditions
of increased use. It has been speculated that one of the reasons why intracellular
free glutamine in skeletal muscle becomes depleted under these conditions is to
provide glutamine for the cells of the immune system (O'Riordain, 1994). In
addition to the direct effects on the T-cell, it is also possible that glutamine may
mediate beneficial effects indirectly. Glutamine may help reduce T-cell suppression
by reversing pathophysiological processes which lead to such suppression. Loss of
gut barrier function has been implicated as a major cause of sepsis (Deitch, 1991;
Wilmore, 1988). By maintaining gut barrier function (van der Hulst, 1993),
glutamine may well prevent the translocation of endotoxin and other mediators of
sepsis, thus preventing the T-cell suppression. Another possible mechanism by
which glutamine may prevent the T-cell suppression associated with disease is via
glutathione. Glutathione is an important anti-oxidant, and tissue glutathione levels
are known to be reduced in acute pancreatitis (Braganza, 1995). A decrease in
glutathione levels is associated with a decreased phytohaemagglutinin response in
an animal model (Robinson, 1993) and glutamine has been shown to restore
glutathione levels in these situations (Hong, 1992).
In addition to its role in lymphocyte function, glutamine also plays an
important role in macrophage/monocyte metabolism. The present study
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demonstrated that there was no significant change in peripheral blood monocyte
TNFa and IL-6 release in either group over the study period (Figure 9.3 and 9.4
respectively). In contrast, IL-8 release was reduced in the glutamine supplemented
total parenteral nutrition group while it was increased in the conventional total
parenteral nutrition group (Figure 9.5). Monocytes are terminally differentiated
cells with a low rate of DNA synthesis. Although glutamine may be required for
nucleic acid synthesis in the lymphocyte, Souba and coworkers (Souba, 1990) have
suggested that in times of stress, glutamine also may support monocyte production
of the cytokine mediators of the catabolic response. Indeed glutamine is required
for the production of interleukin-1 by cultured macrophages (Wallace, 1992) and it
seems likely that it is required for the production of other pro-inflammatory
cytokines as well. However, glutamine may have an indirect effect to mediate a
reduction in pro-inflammatory cytokine release. Restoration of T-cell function will
improve the lymphocyte mediated regulation of monocyte pro-inflammatory
cytokine release. Furthermore, glutamine improves gut barrier function and if this
is associated with an attenuation of portal endotoxaemia, this might reduce the
stimulus to monocyte pro-inflammatory cytokine release. TNFa is recognised as an
important central mediator of the systemic inflammatory response seen in sepsis.
However, its role in acute pancreatitis is less clear. The detection of tumour
necrosis factor in the serum of patients with acute pancreatitis, even in those with
severe disease, is not a consistent finding as discussed more fully in Chapter 8. IL-6
is a key cytokine as a signal to the hepatocyte to induce an acute phase protein
response and serum levels of IL-6 are typically elevated in patients with acute
pancreatitis. However, in the present study, glutamine supplemented total
parenteral nutrition had no significant effect on TNFa or IL-6 release from
peripheral blood mononuclear cells. Perhaps a more important cytokine as far as
damage to distant organs and the production of distant organ failure is IL-8. IL-8
has a multiplicity of actions, but it is an important cytokine in the context of acute
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pancreatitis as it can prime circulating neutrophils as well as stimulate endothelial
cells, thereby promoting neutrophil sequestration in uninjured end-organs, setting
the stage for neutrophil-mediated end-organ injury (Biffl, 1995; Botha, 1996).
Indeed, IL-8 has been implicated in the acute lung injury seen in acute pancreatitis
(Donnelly, 1993). Thus, the reduction in interleukin-8 release from peripheral
blood mononuclear cells observed in the present study may be of benefit to patients
with severe acute pancreatitis. In this context, we have observed that resolution of
IL-8 release from peripheral blood mononuclear cells back towards levels found
from healthy volunteers is associated with the patients clinical recovery (Chapter 4).
The present study has demonstrated potential benefits of glutamine
supplemented total parenteral nutrition over conventional regimens in patients with
established severe acute pancreatitis. The administration of glutamine (either via
the enteral route where possible, or the parenteral route) earlier in the course of the
disease in patients with predicted severe disease may have more marked




Acute pancreatitis remains a common and potentially lethal disease. The
greater the magnitude of the systemic inflammatory response (as part of the disease
pathophysiology) the greater is the likely severity of the illness with progression to
multiple organ dysfunction. The hypothesis of this thesis is that pro-inflammatory
cytokine release from peripheral blood mononuclear cells is increased in patients
with acute pancreatitis early in the course of the disease (as part of the systemic
inflammatory response), and this increased cytokine release contributes to the
severity of the illness. I have examined aspects of the immune system relating to
this hypothesis in patients with acute pancreatitis with a view to the possibility of
modulating the systemic inflammatory response and thus the outcome for the
patient.
IL-6 and IL-8 release from peripheral blood mononuclear cells isolated from
patients with acute pancreatitis at the time of admission is increased compared with
healthy volunteers (Chapter 3). Severe disease (as defined by the Atlanta
classification (Bradley, 1993)) is characterised by prolonged increased release of
such cytokines at least until day five of admission (Chapter 4). Products of the
Page 179
cyclo-oxygenase pathway are recruited to minimise such increased release of IL-6
and IL-8 (Chapter 5). Moreover, peripheral blood mononuclear cells from patients
with acute pancreatitis appear to remain sensitive in vitro to the down-regulatory
effect of IL-4 and IL-10, (cytokines produced mainly from T lymphocytes)(Chapter
5). However, both the number of circulating T lymphocytes and the in vitro
phytohaemagglutinin-stimulated proliferative response appears to be diminished in
patients with acute pancreatitis (especially in those with severe disease) compared
with healthy volunteers (Chapter 6). These findings would suggest a potential
therapeutic benefit for the administration of regulatory cytokines, such as IL-4 and
IL-10, to patients with acute pancreatitis in an attempt to control the systemic
inflammatory response. The timing of such intervention is likely to be as soon as
possible after the diagnosis of the illness, perhaps targeting the group of patients at
risk of severe disease to minimise potential adverse effects of therapy in those who
will have mild disease anyway. However, the administration of IL-4 or IL-10
themselves may have an adverse effect on the overall release of IL-6 and IL-8 as
demonstrated in Chapter 7 where in vitro IL-6 and IL-8 release from endothelial
cells is significantly increased by IL-4 and IL-10. Furthermore, TNFoc induced
inflammation, as suggested by elevated serum levels of soluble TNFot receptors in
patients with acute pancreatitis on admission, (especially in those who subsequently
developed organ failure) would imply that significant inflammatory events have
occurred in patients prior to presentation to hospital and thus before therapeutic
intervention could be implemented (Chapter 8). Nevertheless, in patients with
established severe acute pancreatitis, glutamine supplementation of total parenteral
nutrition led to a significant reduction in IL-8 release from peripheral blood
mononuclear cells and a trend towards improved un-stimulated and
phytohaemagglutinin-stimulated proliferative responses compared with a
conventional total parenteral nutrition regimen (Chapter 9).
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Measurement of cytokine release by peripheral blood mononuclear cells in
disease states and extrapolation of such release to the pathophysiology of disease is
complicated by intra- and inter-subject variation. Gene polymorphism in the control
mechanisms of cytokine production of human monocytes is recognised (Danis,
1995). Furthermore, the change in cytokine production rather than the absolute
level of cytokine production may be more important for the individual in
determining outcome, but in most human studies, the individual's resting or normal
cytokine production is usually not known. An alternative approach, (as employed in
this thesis) is to study groups with similar severity of disease and use the mean
values obtained from each group for comparison. In a recent study, peripheral
blood mononuclear cells were isolated from 10 patients (including one with acute
pancreatitis) who were critically ill with sepsis over a three day study period (Rogy,
1996). Five of the subjects died. While LPS-stimulated TNFa, IL-1 (3 and IL-6
release were generally higher in the non-survivors than survivors, there was no
significant difference between the two study groups. McKay and co-workers
(McKay, 1996) studied LPS-stimulated monocytes isolated from patients with acute
pancreatitis, stratified for 'uncomplicated course' (n=10) and 'systemic
complications' (n=16) of whom five died during the index admission. Monocyte
TNFa release was significantly greater one day following admission but not by day
3 or day 5 in the systemic complication group compared with the uncomplicated
group. Monocyte IL-1(3 release, in contrast, only became significantly greater in the
systemic complication group by day 5. Monocyte IL-6 release was significantly
greater on day 1 and day 3 but not day 5 while IL-8 release was only significantly
greater on day 3 in the systemic complication group compared with the
uncomplicated group. These findings vary from the findings of this thesis. In the
present work, pro-inflammatory cytokine release was increased in patients with
acute pancreatitis compared with controls. However, there was no significant
difference in peripheral blood mononuclear cell IL-6 and IL-8 release on day 1
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between those patients with mild or severe disease. In contrast, IL-6 and IL-8
release remained significantly elevated by day 5 in the severe group whereas levels
of release returned to 'normal' values in the mild group. A number of factors may
explain these different findings. Firstly, McKay and co-workers studied isolated
monocytes rather than blood mononuclear cells. Secondly, the uncomplicated
group in the McKay study had evidence of potential severe disease, all study
patients having an APACHE II score greater than 5 and thus representing a sicker
population than the mild group of the present study. While monocyte pro¬
inflammatory cytokine release may be increased in patients with acute pancreatitis,
monocyte phagocytic activity is significantly impaired in those patients with
predicted severe disease compared with mild disease (Liras, 1996). Although
monocyte phagocytic activity had improved by day 5 in both the mild and severe
groups, the activity in the severe group was reported to be still below the level
observed in healthy volunteers. Neutrophil phagocytic activity mirrored these
results. In contrast, granulocyte elastase activity and fluorescence with acridine
orange were greater in patients with predicted severe disease, indicative of excessive
neutrophil activation, which persisted by day 5 of admission (Liras, 1996).
The role of TNFa in patients with acute pancreatitis remains unclear. TNFa
is often undetectable in the sera of such patients although soluble TNFa receptors
are usually detected and relate on admission to subsequent disease activity. Similar
findings were reported in a study which recruited 146 patients with sepsis syndrome
admitted to an intensive care unit (Goldie, 1995). The median APACHE II score on
admission in this study was 23 and the 30 day mortality in the study was 49 %.
TNFa was detectable in the serum on admission to the intensive care unit in only 14
%. However, soluble TNFa receptors were detectable in all patients and were
significantly higher in non-survivors compared with survivors. Nevertheless,
studies in experimental models of acute pancreatitis have suggested a primary role
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for TNFa. In one study (Hughes, 1995), severe acute pancreatitis was induced in
germ-free rats, (which have no source of endogenous endotoxin), by ductal infusion
of artificial bile. Serum TNFa levels remained low in the sham group but were
significantly elevated in both normal rats and germ-free rats with acute pancreatitis
and there was with no significant difference in TNFa concentration between the
latter two groups. These findings would suggest that the rise in serum TNFa was
related to the onset of acute pancreatitis rather than due to subsequent endotoxaemia
related to the disease. In another study (Fink, 1995), acute pancreatitis was induced
in two strains of mice by two different methods (caerulein hyper-stimulation or
feeding a choline deficient, ethionine enriched diet) and total pancreatic mRNA for
TNFa and the 55 kDa and 75 kDa TNFa receptors measured. There was no
constitutive expression of TNFa mRNA within pancreatic tissue, but it was induced
rapidly in the pancreata of all animals during the progression of acute pancreatitis.
All normal pancreata demonstrated a 55 kDa to 75 kDa receptor mRNA ratio of 5:1.
During the progression of both forms of acute pancreatitis, mRNA for the 55 kDa
receptor was down-regulated to zero while the 75 kDa receptor mRNA was up-
regulated five fold. The precise role of such mRNA expression for TNFa and its
receptors in the pathophysiology of acute pancreatitis in these models is not clear.
However, in a human model of inflammation, local production of TNFa enhanced
neutrophil function at the site of inflammation, with increased cytotoxicity and
enhanced ability to respond to weak environmental signals (Yee, 1994).
The increased IL-6 and IL-8 release from peripheral blood mononuclear
cells isolated from patients with acute pancreatitis compared with healthy volunteers
is believed to contribute to the elevation in serum levels of these pro-inflammatory
cytokines in patients with acute pancreatitis and also other conditions associated
with sepsis syndrome (Goldie, 1995) including major trauma (Botha, 1996). The
role of these cytokines when they appear in the circulation has not been fully
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elucidated but their propagation of a state of systemic leucocyte activation has been
proposed by Rot (Rot, 1992). In a study of 33 patients at risk of multiple organ
failure following major trauma, plasma from these patients was tested for the
priming effect on normal neutrophils and for the presence of platelet-activating
factor (PAF) and IL-8 (Botha, 1996). Plasma sampled at 3, 6, 12 and 24 hr after
injury significantly primed normal neutrophils to release increased amounts of
superoxide. The priming effect of the plasma taken at 3 hours could be inhibited by
a PAF antagonist, but not thereafter suggesting other mediators such as complement
fragments, IL-6 or IL-8 was responsible for subsequent neutrophil priming. Indeed,
plasma IL-8 levels were raised at 6 and 12 hours after injury and were significantly
higher in the 6 patients who developed multiple organ failure. Other studies have
demonstrated that IL-8 can stimulate normal endothelial cells to an activated
phenotype (Biffl, 1995). Thus, pro-inflammatory molecules such as IL-8 can prime
circulating neutrophils as well as endothelial cells, thereby promoting neutrophils
sequestration in uninjured end organs and setting the stage for distant organ damage
(Wang, 1995).
While increased pro-inflammatory cytokine release has been demonstrated
in patients with acute pancreatitis, the biological effect of such cytokines is
tempered by the balance between pro-inflammatory and anti-inflammatory
mediators (Kubes, 1993). IL-4 and IL-10 are cytokines thought to exert
predominately anti-inflammatory effects. For example, in a mouse model, the role
of TNFa in T-cell-mediated inflammation depended on the prevailing pro-
inflammatory/anti-inflammatory cytokine balance (Hernandez-Pando, 1994). Joyce
and co-workers (Joyce, 1994) demonstrated that IL-10 reduced the pro¬
inflammatory potential of TNFa by down-regulation of monocyte TNFa receptor
expression, increasing soluble TNFa receptor levels and inhibiting the release of
TNFa itself. In a recent abstract, IL-10 levels in the sera of patients with acute
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pancreatitis appear to inversely reflect the severity of the disease (Galloway, 1996a).
IL-10 concentration was elevated in patients with mild disease while levels recorded
in the severe group were similar to those seen in healthy human volunteers. These
relatively low values in severe acute pancreatitis would support the concept of
reduced anti-inflammatory cytokine production allowing unbalanced pro¬
inflammatory activity. In contrast, another study, demonstrated that
phytohaemagglutinin-stimulated peripheral blood mononuclear cells isolated from
patients following major trauma (n=8) or burns (n=16) produced greater amounts of
IL-4 and IL-10 compared with healthy volunteers (O'Sullivan, 1995). However,
pro-inflammatory cytokines such as TNFa, IL-6 and IL-8 were not measured, and it
may be that the final ratio of cytokine production are more important with regard to
biological action. IL-4 plasma levels have also been reported in major trauma
victims (DiPiro, 1995). IL-4 plasma levels were significantly greater in those
patients (both on admission and maximal values) who developed sepsis. However,
two observations in this paper (DiPiro, 1995), may have relevance to acute
pancreatitis. A low admission IL-4 level was associated with a greater incidence of
nosocomial infection, and patients over the age of 30 years had significantly lower
IL-4 levels in response to sepsis (risk of infection and increasing age are risk factors
in acute pancreatitis). Another study reported that the intra-peritoneal
administration of IL-10 reduced the severity of acute pancreatitis in a rat model
(Rongione, 1995).
The severity of acute pancreatitis is related to the magnitude of the systemic
inflammatory response associated with the disease. The sequential release of
TNFa, IL-1|3, IL-6, IL-8 and other inflammatory molecules such as PAF are
incriminated in the pathogenesis of this response. It thus follows that strategies to
inhibit either the production or the function of such pro-inflammatory mediators
could abrogate the response. A variety of antibodies to cytokines, soluble cytokine
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receptors and receptor antagonists have been identified or developed and their use in
both animal models and patients with sepsis syndrome have been described
(Christman, 1995; Debets, 1994). An alternative approach is to reduce the serum
levels of inflammatory molecules by continuous haemofiltration (Wakabayashi,
1996). An anti-TNFa polyclonal antibody attenuated the physiological and
biochemical changes associated with acute pancreatitis in a rat model (Grewal,
1994). The calcium channel blocker, diltiazem, improved survival from 40 % to 80
% in a rat model of bile-induced pancreatitis (Hughes, 1996). Calcium has been
suggested as a signal for TNFa release and also for TNFa action at distant sites.
Calcium channel blockade reduced serum TNFa levels although whether this was a
direct effect on TNFa production or mediated indirectly through alteration in
pancreatic blood flow or anti-protease activity is not clear from this study (Hughes,
1996).
IL-1 receptor antagonism (IL-lra) has been investigated in rat and mice
models of acute pancreatitis. IL-lra given before or shortly after the induction of
acute pancreatitis by intra-peritoneal injection reduced the pancreatic inflammation
and necrosis as well as significantly diminishing the expected rise in serum TNFa
and IL-6 in a dose-response effect (Norman, 1995a). The administration of IL-lra
also reduced the multiple organ failure and mortality in these animal models
(Norman, 1995b; Tanaka, 1995).
The beneficial effects of PAF antagonists on experimental acute pancreatitis
have been discussed in the Introduction (Section 1.10). A further report
demonstrated that an intra-peritoneal injection of a PAF antagonist 30 minutes after
the induction of acute pancreatitis in a microembolic rat model of acute pancreatitis
ameliorated the acute lung injury typical of this model (Galloway, 1996b). A phase
II trial of the same PAF antagonist as referred to above in patients with acute
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pancreatitis has demonstrated the agent to be safe and well tolerated (Kingsnorth,
1995). Furthermore, there was a significant reduction in the incidence of organ
failure and in total organ failure score at the end of the 72 hour medication period
compared with placebo. PAF antagonist treatment also reduced serum IL-8
although the changes in serum IL-6 were not significant.
These studies discussed above point to the potential of bio-modulation of the
systemic inflammatory response (in conditions such as acute pancreatitis) by
blocking, through a variety of mechanisms, key steps in the initiation and
propagation of inflammation. However, a number of difficulties are evident that
currently limit such intervention in current clinical acute pancreatitis. The timing of
intervention is important. In the majority of studies using animal models of the
disease, the immuno-modulatory compounds were given at the time of, or shortly
after, the induction of acute pancreatitis. In the clinical situation, several hours if
not days go by prior to the patient seeking medical attention and the diagnosis being
confirmed. In this respect, the finding of significant TNFa induced inflammation as
indicated by raised levels of soluble TNFa receptors in the sera of patients with
acute pancreatitis who subsequently developed severe disease and organ failure
(Chapter 8), suggest that the window of opportunity for such immuno-therapy may
have been missed. However, one small group of patients that afford rapid diagnosis
are those patients who develop acute pancreatitis following endoscopic retrograde
cholangiopancreatography. Nevertheless, strategies of immuno-modulation may
also be applicable to minimise the effect of secondary events that would add to the
state of systemic inflammation. A further limitation of immuno-therapy,
particularly with regard to the use of monotherapy, is the level of redundancy within
the human immune system. It is recognised that the triggering signals and the
subsequent actions of cytokines and other inflammatory mediators overlap to a large
extent so that a number of inflammatory events would require to be abrogated.
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Furthermore, the immune system is primarily present to aid with healing and repair
following injury or infection and tampering with the system could alter the balance
of inflammation in a deleterious manner to the host. This was the recent view of a
drug company seeking to embark on clinical trials of an IL-1 receptor antagonist in
acute pancreatitis. Despite the encouraging results in animal studies, (Norman,
1995a; Norman, 1995b; Tanaka, 1995) the company were dissuaded from mounting
such a clinical trial (Pancreatitis Experts Meeting, Amsterdam, March 1996).
Immuno-therapy is not without its adverse effects. It would therefore seem
logical to target those patients at risk of severe disease. However, current methods
of disease prediction are inaccurate and require 24 if not 48 hours of physical and
biochemical measurements to make the assessment; the time period over which
immuno-therapy is likely to be most effective.
An alternative approach is the use of nutritional agents that have an
influence on the immune system. For example, glutamine, along with other amino-
acids such as arginine are under study in this respect. In the present study, I was
able to demonstrate reduced IL-8 release from peripheral blood mononuclear cells
in patients with established severe disease with the use of glutamine supplemented
total parenteral nutrition compared with a conventional regimen (Chapter 9). The
median time to randomisation in this study was approximately two weeks following
admission (Table 9.1, Page 168). There is a case for considering the administration
of glutamine (along with other nutritional substances) earlier in the course of the
disease, and for employing the more physiological enteral route where possible. A
preliminary report has demonstrated encouraging findings with early enteral
nutrition on markers of the systemic inflammatory response, organ failure and time
in the intensive care unit in patients with acute pancreatitis (Kanwar, 1997). Another
abstract has reported the benefits of glutamine supplementation of both enteral and
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parenteral nutrition in 156 critically ill adult patients including patients with acute
pancreatitis (Griffiths, 1996). Glutamine supplementation reduced both the post-
intervention intensive care unit and total hospital costs per survivor, and in the case
of parenteral feeding, also improved survival compared with conventional regimens.
Clearly, further research in nutritional pharmacy is required but the findings to date
are encouraging.
While the systemic inflammatory response of acute pancreatitis can occur
solely in the presence of pancreatic necrosis, endotoxaemia from the intestines and
infection of the pancreas or distant organs can significantly contribute to the
response. A number of factors predispose to endotoxin or bacterial translocation
across the gut. Reduced intestinal transit time and bacterial overgrowth (Leveau,
1996), along with reduced blood flow and increased intestinal permeability (Wang,
1996) are described in experimental acute pancreatitis. Serum LPS binding protein
(which binds LPS and facilitates its presentation to monocytes and macrophages) is
increased in patients with acute pancreatitis (Erwin, 1996). Furthermore, LPS
binding protein correlated with the severity of the disease, higher levels found in
those patients with severe disease, becoming significant by 72 hours following
admission compared with mild disease. A number of strategies to reduce infection
in acute pancreatitis have been tried including selective decontamination of the gut
and systemic anti-microbial agents. In one study (Luiten, 1995), patients with
severe acute pancreatitis were randomised to standard treatment or standard
treatment with selective decontamination of the gut. Mortality in the
decontamination group was significantly reduced 11/50 (22 %) versus 18/52 (35 %).
The difference was mainly caused by a reduction in late mortality due to a
significant reduction in Gram negative infection of the pancreas. In both groups of
patients, all Gram negative aerobic pancreatic infection was preceded by
colonisation of the digestive tract by the same bacteria. A number of studies
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investigating the effect of systemic antibiotic therapy in both experimental and
clinical acute pancreatitis have been reported (Pederzoli, 1993; Widdison, 1994a;
Foitzik, 1996; Johnson, 1996). Reduction in the number of septic complications,
particularly of the pancreas is a constant finding although disappointingly, this has
not translated into a reduction in mortality. The most effective anti-microbial agents
in this respect are those with good penetration into necrotic tissue.
Acute pancreatitis remains a potentially lethal disease. Nevertheless, our
understanding of the pathophysiology of the disease (Formela, 1995) and prediction
of severity (Hedstrom, 1996) is improving while potential therapeutic agents are
under investigation (Skaife, 1996). What is also becoming evident, is the genetic
predisposition in some patients to develop severe disease, sometimes with the rapid
onset of multiple organ failure and death within days of admission (Rinderknecht,
1994). Genetic variation in an individual's immunological response to pancreatic
inflammation is likely as observed in patients with sepsis (Guillou, 1993;
Wakefield, 1993). Furthermore, genetic variation at the level of the pancreatic
acinar cell itself in response to pancreatic injury, in particular, the ability to activate
acinar cell apoptotic programs and regulate the appearance of stem cells may also
influence the outcome for the patient (Iovanna, 1996).
Nevertheless, the future for patients with severe acute pancreatitis is
encouraging as the fruits of research in a variety of areas related to the disease
become realised. Further research into the pathophysiology of the disease will pave
the way to the development of specific treatments for a condition that to date, relies
on supportive therapy alone. More accurate, early disease prediction will allow the
identification of high risk groups, perhaps making use of the immunological and
genetic markers discussed in this thesis. Advances in the care of the critically ill
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and of organ support will also benefit those patients who develop organ failure and
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Proinflammatory cytokine release was measured from
peripheral blood mononuclear cells (PBMCs) isolated
from six volunteers and, on admission, from 16 patients
with acute pancreatitis. Tumour necrosis factor (TNF)
release in patients did not differ significantly from that of
volunteers, whereas both interleukin (IL) 6 and IL-8
release in patients was raised when compared with that in
the volunteer group (mean(s.e.m.) IL-6 20-7(4-6) versus
9-3(1-7) ng/ml, P = 0-03; IL-8 283(40) versus 128(22) ng/ml,
P = 0-04). When variation in white cell count was
accounted for, IL-6 and IL-8 release but not that of TNF
was significantly greater in patients with severe disease
than in those with mild disease. These results point to a
complex upregulation of proinflammatory cytokine release
from PBMCs in patients with acute pancreatitis,
components of which relate to the clinical progress of the
disease.
Acute pancreatitis is a common and potentially fatal
disease which is characterized by a systemic inflammatory
response that may progress to multiple organ failure and
death. It has been proposed1 that organ dysfunction
results from excessive leucocyte activation. Barie and co¬
workers2 have noted that the pulmonary sequelae of
experimental acute pancreatitis in sheep are prevented by
leucocyte depletion before the induction of pancreatitis.
Similarly leucocyte depletion reduces acute lung injury in
experimental acute pancreatitis in rats3. In other models
of pancreatitis, pronounced margination of leucocytes
within the capillaries and venules of the liver and lungs is
an early event in progressive organ dysfunction and
failure4. Research has focused on neutrophil activity, but
other cellular systems may be important in pathogenesis
of the disease. The mechanisms promoting intravascular
leucocyte activation are not clear. Proinflammatory
mediators may be released into the circulation from the
focus of the acutely inflamed pancreas. Endotoxaemia is a
recognized feature of the disease5 and may also mediate
intravascular events.
The evidence for leucocyte activation in acute
pancreatitis in humans has largely been accrued through
indirect means by measurement of surrogate markers of
inflammation in the serum of patients. Neutrophil elastase
released during phagocytosis is rapidly complexed in the
circulation with oq-protease inhibitor. The serum
concentration of this complex is raised in a number of
inflammatory conditions, including acute pancreatitis6, and
is thought to be a crude marker of neutrophil activation.
Other leucocyte products, including proinflammatory
cytokines such as tumour necrosis factor (TNF) and
interleukin (IL) 6, have been measured in patients with
acute pancreatitis. TNF is a short-lived cytokine,
produced early in the disease process, and is thus often
undetectable in the serum of patients following
admission6. However, the level of IL-6 appears to be more
stable and is raised in the serum of patients with acute
pancreatitis, correlating to some degree with the severity
of disease7-8.
This paper investigates whether in vitro pro¬
inflammatory cytokine release by peripheral blood
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mononuclear cells (PBMCs) is associated with disease
severity in vivo. To examine leucocyte activation directly,
the study investigated the spontaneous and endotoxin-
stimulated release of proinflammatory cytokines from
PBMCs isolated from patients with acute pancreatitis.
Cytokine release in vitro was then related to the clinical
course of the patients and to the serum concentration of
the corresponding cytokine. To investigate the influence
of serum factors on cytokine release, PMBCs were
incubated in both autologous serum and fetal calf serum
(FCS). PBMCs are a mixed cell population comprised
largely of monocytes and lymphocytes. These cell types
participate in intercellular signalling which can signifi¬
cantly modify cell function in mixed cultures in
comparison with that in monocultures of cells9. Thus
coincubation of mononuclear cells is important as it may
more accurately reflect their actions in vivo.
Patients and methods
Sixteen consecutive patients with acute pancreatitis were studied.
The diagnosis of acute pancreatitis was based on the presence of
appropriate clinical or radiographic evidence accompanied by
a serum amylase concentration greater than 1000 units/1
(Phadebas; Pharmacia Diagnostics, Uppsala, Sweden; normal
range 70-300 units/1). Peripheral blood was taken from patients
on the first day of admission for isolation of PBMCs, acquisition
of serum and white cell counting. The progress of the patient
was evaluated with regard to the development of pancreatic
complications as defined by the 1992 Atlanta Convention10 or of
multiple organ failure as defined by the Goris score". No patient
was receiving steroids, non-steroidal anti-inflammatory drugs or
other immunosuppressive medication on admission. Six control
subjects were healthy volunteers, taking no medication and with
no known pancreatic pathology. Written informed consent was
obtained from patients and the protocol was approved by the
local ethics committee.
Isolation and culture ofperipheral blood mononuclear cells
PBMCs were cultured in 96-well flat-bottomed tissue culture
plates at 2 X 105 cells per well in 200 p\ RPMI 1640 supple¬
mented with penicillin 50 units/ml, streptomycin 50 /rg/ml,
glutamine 2 mmol/1 and 5 per cent FCS (ICN Flow Laboratories,
Irvine, UK) or 5 per cent autologous serum. In lipopoly-
saccharide (LPS)-stimulated cultures (Escherichia coli 0127 :B9;
Sigma Chemicals, Poole, UK) the final concentration of LPS was
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5 /xg/ml. Supernatants from the cultures were removed after 24 h
and stored at -70°C for subsequent batch cytokine assay. All
cultures were performed at 37°C in the presence of 5 per cent
carbon dioxide.
Assay for interleukins 6 and 8 and tumour necrosis factor
IL-6, 1L-8 and TNF were measured by enzyme-linked immuno¬
sorbent assay (ELISA). The capture antibody was mouse
monoclonal anti-human IL-6 antibody (Boehringer Mannheim,
Lewes, UK) or rabbit polyclonal anti-human IL-8 (AMS
Biotechnology UK, Witney, UK). The detecting antibodies were
goat polyclonal anti-IL-6 or anti-IL-8 antibody (R&D Systems,
Oxon, UK) followed by polyclonal sheep anti-goat immuno¬
globulin G horseradish peroxidase-labelled antibody (Sigma
Immunochemicals, Poole, UK) with tetramethylbenzidine
(Boehringer Mannheim) as substrate. The limits of sensitivity of
the assays were 40 pg/ml for IL-6 and 200 pg/ml for IL-8. Intra-
assay and interassay variation was less than 5 per cent. The
capture antibody for TNF was mouse monoclonal anti-human
TNF and the detecting antibody was peroxidase-conjugated
mouse monoclonal anti-human TNF Fab fragments (Boehringer
Mannheim), used according to the manufacturer's instructions,
rhe limit of sensitivity of the assay was 15 pg/ml. Intra-assay and
interassay variation was less than 4 per cent.
Statistical analysis
Comparison between patient and control groups or between
:hose with mild and severe disease was performed with the
Vlann-Whitney U test. Comparison within patient or control
'roups was made with the paired Student's t test. P<0-05 was
:onsidered significant.
Results
rhere was no significant difference in the mean (range)
ige between patients with acute pancreatitis and controls,
55-8 (23-96) versus 47-5 (26-73) years respectively,
P- 0-41)) with a 1:1 sex ratio in both groups. Five of the
!6 patients were considered to have severe disease: two
vith pancreatic necrosis and three with renal impairment
m admission (scoring 1 on the Goris score for the renal
ystem with a serum creatinine level greater than
70/umol/l), which returned to normal limits with
onservative therapy.
The mean spontaneous and LPS-stimulated TNF
elease from PBMCs of patients with acute pancreatitis,
/hether incubated in FCS or autologous serum, was
imilar to that of the control group (Table 1). In contrast,
he mean spontaneous IL-6 release from PBMCs was
ignificantly increased in the pancreatitis group compared
nth that in controls when cultured in autologous serum,
ut this effect was not seen when the cells were cultured
i FCS (Table 1). The mean LPS-stimulated IL-6 release
rom PBMCs was significantly increased in the patient
roup compared with that in the control group when
ultured with either FCS or autologous serum (Table 1).
'he mean spontaneous and LPS-stimulated release of IL-
from PBMCs was significantly increased in patients with
ancreatitis compared with that in controls, with the
ffect seen whether the cells were incubated with FCS or
utologous serum (Table I).
The release of TNF, IL-6 and IL-8 from PBMCs
dated from patients with acute pancreatitis and healthy
olunteers was significantly increased when the cells were
leubated in the presence of LPS in comparison with
rontaneous cytokine release (Table 1). The mean ratio of
PS-stimulated TNF and IL-6 release to spontaneous
Aokine release was not significantly greater in patients
with pancreatitis than in controls (3-5 (95 per cent
confidence interval (c.i.) 2-4-4-9) versus 2-3 (95 per cent
c.i. 1-4-3-3) for TNF and 2-8 (1-7-4-0) versus 1-7 (1-2-2-5)
for IL-6 respectively.
Incubation of PBMCs with autologous serum in
comparison with FCS produced a greater mean increase
in spontaneous TNF and IL-6 release in patients with
pancreatitis compared with controls (ratio for TNF 3-4 (95
per cent c.i. 2-1-5-0) versus 1-7 (95 per cent c.i. 1-6-1-9),
F = 0-01; IL-6 2-0 (1-6-2-8) versus 1-6 (1-4-1-9), P = 0-04).
IL-8 release was not significantly enhanced in either the
pancreatitis or control group from PBMCs cultured in
media supplemented with autologous serum compared
with FCS (1-4 (0-9-1-8) versus 1-2 (0-8-1-7), P = 0-36).
TNF and IL-6 were detectable on the first day of
admission in the serum of seven patients, five of whom
developed severe disease as described above (Fig. 1).
However, there was no correlation between the serum
TNF and IL-6 concentration and spontaneous PBMC
Table 1 Spontaneous and lipopolysaccharide-stimulated tumour
necrosis factor, interleukin 6 and interleukin 8 release from
peripheral blood mononuclear cells isolated from six healthy
volunteers and during the first day of admission in 16 patients
with acute pancreatitis
Culture condition TNF (pg/ml) IL-6 (ng/ml) IL-8 (ng/ml)
Spontaneous in FCS
Control 1356(376) 6-9(1-5) 103(17)
Pancreatitis 1339(374) 10-6(1-3) 238(26)*
Spontaneous in AS
Control 2053(741) 9-3(1-7) 128(22)
Pancreatitis 2425(441) 20-7(4-6)* 283(40)*
LPS stimulation in FCS
Control 2596(839) 11-5(0-9) 192(20)
Pancreatitis 3554(825) 24-4(2-5)* 427(35)*
LPS stimulation in AS
Control 3994(1199) 17-7(2-6) 135(16)
Pancreatitis 4799(708) 35-8(5-5)* 419(56)*
Cells were incubated in the presence of 5 per cent fetal calf
serum (FCS) or 5 per cent autologous serum (AS). Values are
mean(s.e.m.). TNF, tumour necrosis factor; IL, interleukin; LPS,


















Fig. 1 Serum tumour necrosis factor (TNF) and interleukin (IL)
6 concentration in patients with acute pancreatitis measured on
the first day of admission. •, Patients with severe disease (n = 5);
O, patients with mild disease (n = 11)
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cytokine release (r = 0-10, P = 0-71 and r = 0-22, P = 0-42
for TNF and IL-6 respectively). IL-8 was detected in the
serum of only two patients. TNF, IL-6 and IL-8 were
undetectable in the serum of volunteers.
The spontaneous release of TNF, IL-6 and IL-8 from
PBMCs isolated from patients with acute pancreatitis on
the first day of admission, and cultured at a standard cell
concentration of 106 per ml, is depicted in Fig. 2. PBMC
release of TNF, IL-6 and IL-8 was not significantly
different between the 11 patients with mild and the five
with severe pancreatitis. As an estimation of cytokine
production per unit of blood, allowing for the variation in
white cell count between patients, cytokine production
from the standard cell concentration was multiplied by the
mononuclear cell count (monocyte count plus lymphocyte
count) measured on the first day of admission; these
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Fig. 2 Spontaneous release of a tumour necrosis factor (TNF), b
interleukin (IL) 6 and c IL-8 from peripheral blood mononuclear
cells (PBMCs) in patients with acute pancreatitis on the first day
of admission, comparing patients with severe disease (n = 5) with
those with mild disease (n = 11). Points represent cytokine
release from PBMCs plated at a standard concentration of 106
cells/ml. There were no significant differences between patients
with mild and severe disease
Fig. 3 Spontaneous release of a tumour necrosis factor (TNF), b
interleukin (IL) 6 and c IL-8 from peripheral blood mononuclear
cells in patients with acute pancreatitis on the first day of
admission, comparing patients with severe disease (n = 5) with
those with mild disease (n = 11). Points represent cytokine
release from the standard cell concentration multiplied by the
white cell count. *P = 0T3, tP = 0-04, tP = 0-02 (Mann-Whitney
U test)
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per unit of blood in patients with severe disease was
significantly increased compared with that in mild disease.
However, there was no significant difference in TNF
release from PBMCs between the two groups (Fig. 3).
Discussion
This study demonstrates increased release of IL-6 and
IL-8 from PBMCs in the blood of patients with acute
pancreatitis compared with that in healthy volunteers
(Table 1). While there was no significant difference in
proinflammatory cytokine release per cell when compar¬
ing patients with mild or severe disease (Fig. 2), making
allowance for the white cell count revealed that IL-6 and
IL-8 release per unit of blood was significantly greater in
those with severe disease (Fig. 3). This effect was not
observed for TNF release (Fig. 3) despite the observation
that TNF plays an important early role in the cascade of
inflammatory events12. Although blood was withdrawn
:rom patients as soon after admission as feasible, the
disease process, as manifested by patient symptoms, had
teen present for hours and in some cases days before
idmission. It is thus likely that significant release of TNF
fom PBMCs had already occurred, as indicated by raised
lerum TNF levels in a number of patients (Fig. 1). It is
>erhaps of greater significance, with regard to the
>athogenesis of acute pancreatitis and its complications,
hat PBMCs in patients were still able to mount a similar
nNF response to that in healthy volunteers despite the
aised serum TNF concentration.
Endotoxaemia is a feature of acute pancreatitis. Foulis
nd co-workers5 detected endotoxin in the serum of 13 of
6 patients with acute pancreatitis. More recently a
ignificant fall in the serum levels of endogenous anti-
ndotoxin core antibodies was observed in 28 of 33 cases,
nplying exposure to endotoxin13. Monocyte activation
jllows exposure to bacterial LPS. While monocytes are
ble to recognize LPS directly14, activation is potentiated
hen LPS forms a complex with LPS binding protein,
hich then interacts with the monocyte CD14 receptor15.
PS binding protein is present in human serum but, being
a acute-phase protein, its serum concentration is raised
i patients with acute pancreatitis. The concentration of
PS binding protein in FCS is not known. However, the
resence of LPS binding protein is a consistent finding in
:her animals16 and its presence in FCS is probable. In the
■esent study incubation with endotoxin led to an
creased release of TNF, IL-6 and IL-8 from PBMCs in
)th patient and control groups. While endotoxaemia is
llikely to be the primary event in the pathogenesis of
:ute pancreatitis, its presence could contribute to the
ate of monocyte activation and subsequent development
the systemic inflammatory response syndrome
sociated with the disease.
Culture of isolated PBMCs in either autologous serum
FCS allows comparison between the behaviour of cells
ider the same conditions (FCS) or in the conditions
evailing in vivo (autologous serum). Spontaneous TNF
d IL-6 release from PBMCs in patients with acute
ncreatitis was greater in response to incubation with
tologous serum than with FCS. This finding suggests
at circulating factors in the serum of patients with acute
ncreatitis contribute to the state of PBMC activation
th regard to TNF and IL-6 secretion. Damaged acinar
Is and the leucocyte infiltrate associated with
ncreatitis are known to secrete a wide variety of
proinflammatory agents, including complement factors,
oxygen-derived free radicals, cytokines, platelet activating
factor and leukotrienes1. All these agents affect
endothelial cells and promote circulating leucocyte
activation. Differences in endotoxin concentration
between FCS and autologous serum are unlikely to
account for this observation, as the LPS stimulation
concentration used in this study induced maximal cytokine
release in preliminary studies.
An increase in serum IL-6 concentration early in the
course of acute pancreatitis is well documented8-9. While a
number of immunocompetent cells secrete IL-6 in vivo,
the increased secretion of IL-6 by PBMCs observed in the
present patients may contribute significantly to raised
serum IL-6 concentrations. Studies have reported that
both the concentration on admission and the peak level of
serum IL-6 correlate with disease severity8-9. Faist et a/.17
have shown that monocyte IL-6 secretion is increased
twofold in patients with sepsis. In an intervention study
using a mouse burn-sepsis model, IL-l/f and indo-
methacin administration reduced the production of TNF,
IL-1 and IL-6 by cultured splenocytes towards normal
control levels with a corresponding improvement in the
survival rate18. These results suggest that in inflammatory
conditions such as acute pancreatitis excessive production
of IL-6 from PBMCs may be altered by therapeutic
intervention and could conceivably influence outcome.
Alternatively, IL-6 may simply be a marker of more
important proinflammatory mediators.
IL-8 was detected in the serum on the first day of
admission in only two patients in the present study. The
IL-8 ELISA detection limit of 200 pg/ml and the blood's
capacity for inactivating IL-8 (principally by means of
irreversible binding with red blood cells)19 render serum
IL-8 measurement early in the course of an acute
inflammatory disease a poor reflection of cellular or
PBMC IL-8 production. Similar upregulation of IL-8
release from monocytes has been observed in a study
simulating ischaemia-reperfusion20. The role of IL-8 in
neutrophil-endothelial cell interaction, through chemo-
attraction and potentiation of the action of the
intercellular adhesion molecule 1 on endothelial cells, is
well known21-22. In addition IL-8 can induce neutrophil
shape change and the shedding of l-selectin from the
neutrophil surface, events that appear essential for
neutrophil migration22"24. However, the role of IL-8 in the
propagation of multiple organ failure is not clear. Both
Rot22 and Tanaka et al.25 independently proposed that
bloodborne IL-8 can result in premature activation of
circulating neutrophils, including the release of l-selectin
and activation of the integrin CD11-CD18 ligand. These
events serve to prevent neutrophil emigration by inducing
intravascular neutrophil aggregation and stiffening of the
cell membrane. These prematurely activated neutrophils
are carried in the circulation to sequester in the next
microcirculation they encounter26. This sequence of events
would account for the leucocyte sequestration in
pulmonary capillaries observed in animal models of acute
pancreatitis27 and for the beneficial effect of leucocyte
depletion in preventing pulmonary complications in such
models2-3.
The results of the present study reveal increased
proinflammatory cytokine release from PBMCs in patients
with acute pancreatitis early in the course of the disease.
Further research is required to identify whether this
upregulation results from an imbalance in the production
of inflammatory mediators or a loss of sensitivity to
© 1996 Blackwell Science Ltd, British Journal of Surgery 1996, 83, 1071-1075
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downregulatory signals, and to determine whether early
therapeutic intervention can alter the progress of the
disease.
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Interleukin-4 and Interleukin-10 Increase Endotoxin-Stimulated
Human Umbilical Vein Endothelial Cell Interleukin-8 Release
A.C. DE BEAUX. J.P. MAINGAY, J.A. ROSS, K.C.H. FEARON, and D.C. CARTER
ABSTRACT
The aim of this study was to determine the effect of interleukin-4 (IL-4) and interleukin-10 (IL-10) on
interieukin-8 (IL-8) release from endothelial cells. Confluent monolayers of human umbilical vein endothelial
cells (HUVECs) were incubated in the absence or presence of 10 ng/ml of bacterial lipopolysaccharide (LPS),
with 5% human AB serum and recombinant human IL-4 or IL-10 over a dose range from 50 fg/ml to 50 ng/ml
(final concentration). IL-4 and IL-10 had no effect on HUVEC IL-8 release in the absence of LPS. In the
presence of LPS, IL-4 and IL-10 enhanced IL-8 release by approximately 300% compared with LPS-stimu-
lated cells alone, IL-8 release increasing from 2594 ± 493 pg/ml (no IL-4 or IL-10) to 7892 ± 320 pg/ml (IL-4,
5 pg/ml; p= 0.001) and 8359 ± 712 pg/ml (IL-10, 50 pg/ml; p = 0.002). IL-8 release in response to IL-4 or
IL-10 plateaued above 5 and 50 pg/ml, respectively. This study suggests that IL-4 and IL-10 may be involved in
the complex regulation of endothelial cell cytokine production during the response to endotoxin.
INTRODUCTION
Endothelial cells form a physical but interactive barrierbetween the blood and the tissues and are important in the
pathophysiology of conditions, such as multiple-organ failure
and septic shock.*L2) A variety of circulating factors present in
major sepsis such as bacterial lipopolysaccharide, interleu-
kin-ip (IL-1 (3), and tumor necrosis factor a (TNF-a), have
been shown to induce functional alterations in endothelial cells
in culture, including the synthesis and release of proinflamma¬
tory cytokines, such as IL-6 and 1L-8,13-51 and alterations in the
expression of cell surface structures involved in adhesion.'61
The role of the IL-6 and IL-8 produced by endothelial cells is
not clear, but they appear to influence the inflammatory re¬
sponse by interacting with circulating immune cells to mediate
local cell activation and chemoattraction.17-91 Clearly, if such
proinflammatory events occur unchecked, then this might con¬
tribute to microcirculatory failure and the tissue destruction
seen in severe sepsis. It seems reasonable that the body should
possess mechanisms that downregulate IL-6 and IL-8 release by
endothelial cells.
Of considerable interest in this regard are the actions of IL-4
and IL-10, which have been shown to attenuate proinflamma¬
tory cytokine production from a variety of immunocompetent
cells, including polymorphonuclear cells, monocytes, and mac¬
rophages.'10-l3) Paradoxically, however, IL-4 has been shown
to induced rather than suppress IL-6 production from unstimu¬
lated and endotoxin-stimulated human endothelial cells,
but IL-10 had no effect on lipopolysaccharide (LPS)-stimulated
IL-6 production."61 The purpose of this study was to examine
whether the same pertains with regard to the effects of IL-4 and
IL-10 on the release of IL-8 from endotoxin-stimuiated human
umbilical vein endothelial cells (HUVECs).
MATERIALS AND METHODS
Culture media and reagents
RPMI 1640, penicillin/streptomycin, and fetal bovine serum
(FBS) were purchased from ICN Flow Laboratories (Irvine,
UK) and lipopolysaccharide (Escherichia coli 0127:B9), hu¬
man AB serum (heat inactivated: 56°C for 30 minutes), hydro¬
cortisone, sodium citrate, and sodium acetate from Sigma
Chemicals (Poole, UK). Endothelial serum-free (E-SFM)
growth and plating medium and recombinant human epidermal
growth factor (rEGF) were obtained from GIBCO BRL (Pais¬
ley, UK). Endothelial cell growth factor (ECGF), collagenase
H, and tetramethylbenzidine (TMB) were purchased from Boe-
hringer Mannheim (Lewes, UK). Recombinant human IL-4,
IL-10, and recombinant human endothelial cell-derived IL-8
Department of Surgery, University of Edinburgh. Royal Infirmary. Lauriston Place. Edinburgh. UK EH3 9YW.
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were obtained from Genzyme (West Mailing, UK). Sulfuric
acid was obtained from BDH. Ltd. (Poole, UK).
Human umbilical vein endothelial cell cultures
HUVECs were obtained by a modification of the method of
Jaffe et al."7) In brief, human umbilical veins were obtained
fresh, cannulated. and treated with collagenase. The vein was
flushed with RPMI 1640, and the cells obtained were washed
first in RPMI and then in E-SFM growth media. Cells were then
cultured in 75 cm3 plastic flasks (Costar, High Wycombe, UK)
in E-SFM plating media supplemented with penicillin (50 IU/
ml), streptomycin (50 p.g/ml), hydrocortisone (1 fig/ml),
ECGF (50 p-g'ml), and rEGF (10 ng/mi). Primary cultures were
detached by trypsin-EDTA, washed in RPMI supplemented
with 10% FBS, and then washed in E-SFM growth media
before being plated on to 96-well flat-bottomed tissue culture
piates (Costar, High Wycombe, UK) in E-SFM plating media
supplemented as before and the cells grown to confluence. All
HUVEC cell lines were characterized by the expression of von
Wiilebrand factor and were used for experiments between the
second and fourth passages.
Experiment protocol
Confluent HUVECs were incubated in the present or absence
of LPS at a final concentration of 10 ng/ml with 5% human AB
serum for 5 h. IL-4 or IL-10 were added to the cultures at a final
concentration of 50 fg/ml to 50 ng/ml. After 5 h, the cells were
washed with E-SFM growth media and incubated for a further
12 h in E-SFM growth media. Supernatants from the cultures
were removed after this period and stored at —70°C for subse¬
quent batch cytokine assay. All cultures were performed at
37°C in the presence of 5% CO, and 95% humidified air.
Interleukin-8 Enzyme-linked immunosorbent
assay (ELISA)
IL-8 was assayed using a sandwich ELISA. Supematants
were diluted 1:5 and incubated in duplicate in 96-well ELISA
plates (Costar, High Wycombe, UK) coated with rabbit poly¬
clonal antihuman IL-8 (AMS Biotechnology UK, Ltd., Wit¬
ney, UK). After incubation, wells were incubated sequentially
with goat polyclonal anti-IL-8 antibody (British Biotechnology,
Oxon, UK), polyclonal rabbit antigoat IgG horseradish peroxi-
dase-labeled antibody (Sigma Immunochemicals, Poole, UK),
and the peroxidase substrate TMB in sodium citrate/acetate
buffer (pH 4.9). The reaction was stopped with 1 M H2S04,
and the plates read at 450 nm using the MR5000 ELISA plate
reader (Dynatech, Billinghurst, UK). Concentrations in the
samples were calculated using AssayZap computer software
(Biosoft, Cambridge, UK). The limit of sensitivity of the assay
was 40 pg/ml.
Statistical analysis
One-factor analysis of variance was used to compare the
effect of IL-4 or IL-10 on LPS-stimulated HUVEC IL-8 release
with that of LPS-stimulated HUVEC in the absence of IL-4 or
IL-10.
Incubation time (hours)
FIG. 1. Effect of incubation time on IL-8 release by HUVEC
following exposure to LPS at varying concentrations and time
period. Results from a representative experiment: 5 h, 10 ng/ml
LPS pulse (squares); 5 h, 1 ng/ml LPS pulse (diamonds); 3 h,
10 ng/ml LPS pulse (circles).
RESULTS
A dose-response curve for the endotoxin-stimulated release
of IL-8 from HUVECs was established using LPS over the
range 0.1-100 ng/ml and AB serum over the range 0-10%. The
optimal LPS concentration to induce IL-8 release was 10 ng/ml
with 5% AB serum. HUVECs did not respond to a LPS stimu¬
lus (0.1-100 ng/ml) in the absence of AB serum. The results of
a representative experiment comparing LPS concentration,
length of pulse, and length of further incubation time with
HUVEC IL-8 release is shown in Fig. 1.
Results are expressed as the mean of experiments performed
on four HUVEC lines. Spontaneous HUVEC IL-8 release in the
presence or absence of 5% AB serum was undetectable. IL-4
and IL-10 had no detectable effect on spontaneous IL-8 release
from HUVECs following the 12 h incubation period. In the
presence of LPS and AB serum, the addition of IL-4 to the
culture medium (Fig. 2) led to an initial dose-dependent in¬
crease in the mean IL-8 release by HUVEC, rising from
2594 ± 493 pg/ml (no IL-4) to 7892 ± 320 pg/ml (IL-4; 5
pg/ml; p = 0.001, one-factor analysis of variance). Similarly,
in the presence of LPS, the addition of IL-10 to the culture
medium (Fig. 3) led to a dose-dependent increase in the mean
IL-8 release by HUVEC, rising from 2594 ± 493 pg/ml (no
IL-10) to 8359 ±712 pg/ml (IL-10, 50 pg/ml; p = 0.002, one-
factor analysis of variance).
The addition of IL-4 and IL-10 after the pulse of LPS (at the
start of the 12 h incubation period) had little effect on IL-8
release. In these experiments results are the mean ± standard
error of the mean of two HUVEC lines. LPS-stimulated HU¬
VEC release of IL-8 was 2490 ± 100 pg/ml, and IL-4 at 50
ng/ml following an LPS pulse enhanced the release of IL-8 to
3130 ± 480 pg/ml, and IL-10 at 50 ng/ml following an LPS
fear.-wrmtk TaMKi—anttaaMMIiCC i
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lOOOO-i 10000-i
IL-4 (pg/ml)
FIG. 2. Effect of IL-4 on LPS-stimulated HUVEC IL-8 pro¬
duction. Results are the mean of four HUVEC lines with the
standard error of the mean represented by the error bars.
*p < 0.03 compared with 0 ng/ml of [IL-4] (one-factor analysis
of variance).
IL-10 (pg/ml)
FIG. 3. Effect of IL-10 on LPS-stimulated HUVEC IL-8
production. Results are the mean of four HUVEC lines with the
standard error of the mean represented by the error bars.






pulse increased the release of IL-8 to 3065 ± 95 pg/ml. None of
these increases were statistically significant.
DISCUSSION
The antiinflammatory actions of IL-4 and IL-10 are well
recognized."0-13' For example, both in experimental arthri¬
tis081 and in cancer patients receiving immunotherapy,'19) the
production of the proinflammatory cytokine IL-1 is reduced by
IL-4. In addition, IL-10 protects mice against Staphylococcus
enterotoxin B-induced lethal shock,'20' and IL-4 and IL-10
exhibit synergy to inhibit cell-mediated immunity in a mouse
model of leishmaniasis.'2" IL-8 can be regarded as a proinflam¬
matory cytokine. Thus, in the present study, the enhancement
by ILA and IL-10 of IL-8 release by endothelial cells in the
presence of endotoxin appears somewhat paradoxical.
IL-8 is a potent chemoattractant for circulating leukocytes to
sites of acute inflammation.(9-22-23) Endothelial surface-bound
IL-8 is known to promote the integrin-mediated adhesion be¬
tween neutrophils and endothelial cells.<8'24' In addition, IL-8
induces neutrophil shape change and the shedding of L-selectin
from the surface of neutrophils adhered to endothelial cells,
events that are essential for neutrophil emigration.'25' How¬
ever, Gimbrone and coworkers'5' have shown that although
certain inflammatory stimuli render cultured human endothelial
cells hyperadhesive for neutrophils, this state is transient and
reversible. The mechanism for the attenuation of endothelial
cell-neutrophil interaction was attributed in part to the secretion
by activated endothelial cells of a soluble leukocyte adhesion
inhibitor, identified as IL-877, the extended amino-terminal
IL-8 variant.'5' Furthermore, recombinant human IL-8 inhib¬
ited neutrophil adhesion to IL-1 -activated endothelial monolay¬
ers, protecting the monolayers from neutrophil-mediated dam¬
age.'5' One explanation for the observations reported by
Gimbrone and coworkers is that IL-8, like all chemoattractants,
is an ineffective promoter of neutrophil invasion if the stimulus
is distributed equally between apical and basal compartments,
thereby destroying the concentration gradient. Under normal
conditions of blood flow through a vessel, the IL-8 released by
endothelial cells from the luminal surface may be bound to
antibodies and red cells and removed. However, if neutrophils
come into contact with soluble blood-bome IL-8, they may
undergo shape change and shedding of the L-selectin receptor
before their initial contact with endothelial cells, thus losing
their ability to adhere to the endothelium and migrate.'25' IL-4
and IL-10 may therefore exert an antiinflammatory action on
endothelial cells by inducing shedding of surface-bound IL-8 or
by the secretion of intracellular IL-8. The further synthesis of
IL-8 de novo may not occur because IL-4 in particular has been
shown not to induce IL-8 messenger RNA expression.'26'
The role of proinflammatory cytokines in both acute and
chronic inflammatory diseases is now well recognized, and
successful therapeutic strategies have been developed to reduce
the influence of such cytokines, for example the administration
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of anti-TNF27' or anti-IL-6 antibodies'28' in certain models of
septic shock. The established role of IL-4 and IL-10 in the
downregulation of leukocyte proinflammatory cytokine release
has led to the suggestion that IL-4 and IL-10 could be used to
treat such conditions as septic shock. The results of the present
study indicate that IL-4 and IL-10 augment LPS-mediated IL-8
release from endothelial cells and may indeed provide a means
of altering IL-8 concentration gradients within the local mi-
croenvironment. Further studies are required to determine the
outcome of treatment with IL-4 or IL-10 under various condi¬
tions in vivo.
The findings presented here, together with the earlier work
on endothelial cell IL-6 release,<l4-'5' indicate that IL-4 and
IL-10 may be involved in a complex regulation of endothelial
cell activation following exposure to endotoxin. An acute in¬
flammatory response requires the sequestration of circulating
monocytes, lymphocytes, and neutrophils into sites of inflam¬
mation. Clearly, the attraction and migration of circulating cells
into such sites must be regulated with some precision and spec¬
ificity. The fine-tuning of the cytokines produced by endothe¬
lial cells and the cell surface molecules expressed by these cells,
in the local microenvironment may lend this precision and spec¬
ificity.
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Leucocyte activation and proinflammatory cytokine
release (tumour necrosis factor (TNF) and interleukin 6
(IL-6)) are thought to contribute to the induction of a
systemic inflammatory response, an acute-phase response
and multiple organ failure in patients with acute
pancreatitis. The serum concentration of TNF, soluble
TNF receptors (sTNFR5S and sTNFR75), IL-6 and C-reative
protein (CRP) in 58 patients with acute pancreatitis was
assessed during the first 2 days of admission. Thirty
patients had mild disease and 28 severe disease, of whom
18 developed local pancreatic complications alone
(Atlanta classification) and ten developed organ failure (a
Goris score of 1 or more). TNF was detected in only 17
patients on the first day of admission, while soluble TNF
receptors were detected in all patients and IL-6 in 34. On
the first and second days of admission there was a
progressive and significant (P<0-03) increase in the
median concentration of sTNFR55, sTNFR75 and IL-6 in
patients eventually classified into those with mild disease,
a local pancreatic complication alone, or organ failure.
This pattern was also evident in CRP levels from the
second but not the first day of admission. These findings
suggest that proinflammatory cytokines or their soluble
receptors may be more accurate early predictors of
outcome than CRP. Moreover, markers of inflammation in
the sera of patients with acute pancreatitis are highest in
those who subsequently develop organ failure.
Acute pancreatitis remains a common and potentially
fatal disease in which some patients develop extensive
pancreatic inflammation and necrosis, a systemic
inflammatory response and multiple organ failure1. It has
been proposed that the systemic sequelae of pancreatitis
arise from excessive leucocyte activation with the release
of secondary mediators such as proinflammatory
cytokines, including tumour necrosis factor (TNF) and
interleukin (IL) 62. The central role of TNF (a potent
cytokine produced mainly by activated macrophages) in
orchestrating aspects of the early inflammatory response
in sepsis is well established3. Increased levels of TNF have
been documented in the serum of some groups of patients
with sepsis4 and after exposure to endotoxin5. However,
TNF is often undetectable in the sera of patients with
acute pancreatitis, even those with severe disease6-7. This
may be because of the short half-life of TNF, binding of
TNF to other proteins, or difficulties with the various
methods of measuring TNF in serum. Alternatively, it
may be that TNF is not produced in patients with acute
pancreatitis or is mainly produced in the tissues and only
occasionally spills over into the circulation.
The paracrine and endocrine actions of TNF are
exerted by interaction with membrane-bound TNF
receptors on the surface of target cells8. It appears that
after exposure to substances such as bacterial endotoxin
(and indeed TNF itself), such target cells downregulate
their responsiveness to TNF by shedding the receptor into
the circulation9. Two such soluble receptors have been
identified; a 55-kDa (sTNFR55) and a 75-kDa (sTNFR75)
fragment10. The release of these soluble receptors (which
have a longer half-life in serum than TNF itself) appears
to reflect the degree of TNF-induced inflammation".
Thus, although TNF may be undetectable in blood, the
presence of such soluble TNF receptors may be a useful
index of TNF activity.
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Other cytokines involved in the inflammatory cascade,
such as IL-6, are more often detected in the sera of
patients with acute pancreatitis12"14. Both the serum
concentration of IL-6 on admission and the peak level of
IL-6 have some correlation with the severity of the
disease12"14. One of the many actions of IL-6 is to induce
the production of hepatic acute-phase proteins, such as C-
reactive protein (CRP). The serum concentration of CRP
is also increased in patients with acute pancreatitis and
correlates with the severity of the disease15"17. The rise in
serum CRP concentration lags behind the peak in serum
IL-6 concentration by some 24-48 h18 and this has been
interpreted by some investigators to indicate a cause and
effect relationship.
It has been proposed that a prolonged or excessive
inflammatory response may be one of the mechanisms
whereby patients develop multiple organ failurel9-2". The
major causes of death in acute pancreatitis stem from
either local peripancreatic complications or multiple
organ failure, or a combination of the two. In the present
study, the systemic inflammatory response as measured by
markers of inflammation (TNF, sTNFR55, sTNFR75, IL-6
and CRP) in the serum of patients with acute pancreatitis
have been investigated and related to the development of
local complications and organ failure.
Patients and methods
Patients with acute pancreatitis admitted to the Royal Infirmary,
Edinburgh were studied. The diagnosis of acute pancreatitis was
based on the presence of appropriate clinical or radiographic
evidence accompanied by a serum amylase concentration greater
than 1000 units/1 (Phadebas; Pharmacia Diagnostics, Uppsala,
Sweden; normal range 70-300 units/1). The clinical course of the
patients was followed prospectively, allowing retrospective
categorization of patients into those with mild or severe disease
based on the Atlanta classification21. Twenty-eight patients with
severe disease represented a consecutive series over a 16-month
period. Thirty of 78 patients with mild disease admitted over the
same time period were randomly selected for comparison.
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Patients with severe disease were further subcategorized into
those with local pancreatic complications alone (n = 18) and
those with organ failure (a Goris score" of 1 or more; n = 10).
Six patients with organ failure died during the index admission.
Gallstones were suspected as the aetiology in 26 patients, alcohol
in 18 and the presence of pancreatic cancer in one. Pancreatitis
complicated endoscopic retrograde cholangiography in two
patients and the aetiology was not identified in 11. Venous blood
was sampled on the first and second day of admission and the
serum stored at - 70°C until subsequent batch analysis for TNF,
sTNFR„, sTNFR75, IL-6 and CRP concentration by indirect
enzyme-linked immunosorbant assay (EL1SA).
Assay of cytokines and C-reactive protein
TNF was measured with an ELISA using a murine monoclonal
antihuman TNF antibody and peroxidase-conjugated Fab
fragments of a murine monoclonal antihuman TNF antibody
(Boehringer Mannheim, Lewes, UK). A standard curve was
constructed with recombinant human TNF (British Biotech¬
nology, Abingdon, UK) and calibrated with an international
standard (NIBSC, Potters Bar, UK). The lower limit of detection
of the assay was 15 pg/ml.
Serum sTNFR„ and sTNFR,, were detected by ELISA, with
monoclonal and polyclonal anti-sTNFR,, and anti-sTNFR,,
antibodies. Purified sTNFR« and sTNFR75 were used to
construct standard curves. The lower limit of detection of the
assay was 150 pg/ml for both receptors.
The ELISA for IL-6 used a murine monoclonal antihuman IL-
6 antibody (Boehringer Mannheim) as the capture antibody and
a goat polyclonal (non-enzyme labelled) antihuman IL-6 (R&D
Systems, Oxford, UK) followed by a peroxidase-conjugated sheep
antigoat immunoglobulin G antibody (Sigma Immunochemicals,
Poole, UK) to detect bound IL-6. A standard curve was
constructed with recombinant human IL-6 (British Biotech¬
nology) and calibrated with an international standard (NIBSC).
The lower limit of detection of the assay was 30 pg/ml.
CRP was detected by sandwich ELISA, with rabbit antihuman
CRP and peroxidase-conjugated rabbit antihuman CRP (DAKO,
High Wycombe, UK). A standard curve was constructed with a
human serum CRP calibrator (DAKO). The lower limit of
detection of the assay was 1 mg/I.
Statistical analysis
Results are presented as the median (interquartile range). Initial
comparison among patients with mild disease, a local pancreatic
complication alone and organ failure was performed using the
Kruskal-Wallis test. Thereafter, Mann-Whitney U tests were
applied to compare differences between any two groups;
significance was assumed when P<0-05. Where levels of the
cytokine being measured were below the limit of detection of the
assay, the minimum detection concentration was assigned to the
sample and statistical analysis was performed using this
convention.
Results
None of the 30 patients with mild disease developed
significant complications. In contrast, 18 of 28 with severe
pancreatitis developed local complications alone, while
the remaining ten developed failure of one or more organ
systems, with or without an accompanying local pancreatic
complication. There was no significant difference in the
age (P — 0-29) or sex ratio (F = 0-57) between those with
mild pancreatitis and those with severe pancreatitis.
Serum concentrations of TNF were below the level of
detection in 41 of 58 patients on the first day of admission
(29 of 30 with mild disease, eight of 18 who developed a
local pancreatic complication and four of ten who
developed organ failure) and 50 of 58 on the second day
(all with mild disease, 16 of 18 who developed a local
pancreatic complication and four of ten who developed
organ failure). On the first day of admission, the median
serum concentration of TNF was greater in patients who
developed organ failure (P< 0-001) and in those who
developed a local pancreatic complication (P< 0-001)
than in those with mild disease (Table 1). There was no
significant difference between patients who developed
organ failure and those who developed a local pancreatic
complication alone (P = 0-34). On the second day of
admission, the median serum concentration of TNF was
greater in patients who developed organ failure than in
those who developed a local pancreatic complication
(P <0-006) and in those who had mild disease (P< 0-006)
(Table 1). There was no significant difference between
patients who developed a local pancreatic complication
alone and those who had mild disease (P = 0-07).
Serum sTNFR,, and sTNFR75 were detectable in the 58
patients. On both days 1 and 2 of admission, the median
serum concentration of sTNFR55 was greater in patients
who developed organ failure than in those who developed
a local pancreatic complication (P< 0-003). In both
Table 1 Concentration of serum tumour necrosis factor (TNF)
and serum C-reactive protein (CRP) in patients with acute
pancreatitis on the first and second day of admission
Pancreatic
complication
Mild disease alone Organ failure
(n = 30) (n = 18) (n = 10)
Serum TNF (pg/ml)
Day 1 15-0 (15-0-15-0) 17-8 (15-0-23-8) 22-6 (15-0-75-1)
Day 2 15-0(15-0-15-0) 15-0(15-0-15-0) 21-1(15-0-51-4)
Serum CRP (mg/I)
Day 1 31-4 (10-0-61-5) 11-6 (7-8-36-5) 36-0 (14-9-58-9)
Day 2 36-1 (22-8-84-4) 33-0 (19-7-121-1) 99-9 (79-4-136-2)




















Fig. 1 Median serum concentration of soluble tumour necrosis
factor receptor (55 kDa) (sTNFR,,) on the first and second day
of admission in patients with acute pancreatitis categorized by
mild disease (O; n =30), local pancreatic complication alone (□;
n = 18) and organ failure (■; n = 10). Interquartile range
represented by the error bars
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Fig. 2 Median serum concentration of soluble tumour necrosis
factor receptor (75 kDa) (sTNFR75) on the first and second day
of admission in patients with acute pancreatitis categorized by
mild disease (O; n = 30), local pancreatic complication alone (□;
n = 18) and organ failure (■; n = 10). Interquartile range







Fig. 3 Median serum concentration of interleukin (IL) 6 on the
first and second day of admission in patients with acute
pancreatitis categorized by mild disease (O; n = 30), local
pancreatic complication alone (□; n = 18) and organ failure (■;
n = 10). Interquartile range represented by the error bars. Lower
limit of detection of the assay represented by the dashed line
groups with severe disease, the median serum
concentration of sTNFR55 was greater than that in
patients who had mild disease (P< 0-001 in both cases)
(Fig. 1). Serum concentrations of sTNFR75 showed a
similar distribution among the three groups to that found
for the sTNF55 receptor (Fig. 2).
Serum concentrations of IL-6 were below the level of
detection in 24 of 58 patients on the first day of admission
(20 of 30 with mild disease, three of 18 who developed a
local pancreatic complication and one of ten who
developed organ failure) and in 23 of 58 on the second
day (19 of 30 with mild disease and four of 18 who
developed a local pancreatic complication). On both days
1 and 2 of admission, the median serum concentration of
IL-6 was greater in patients who developed organ failure
than in those who developed a local pancreatic
complication alone (/><0-03), which in turn was greater
than in those with mild disease (P< 0-001) (Fig. 3).
CRP was detectable in the serum of all patients. On the
first day of admission, there was no significant difference
in the median serum levels of CRP among patients who
developed organ failure or a local pancreatic complication
and those who had mild disease (P = 0T5) (Table 1). By
the second day of admission, the median serum
concentration of CRP was greater in patients who
developed organ failure than in those who developed a
local pancreatic complication (P = 0-02) or those who had
mild disease alone (P = 0-003) (Table 1). However, the
median serum CRP level in patients who developed a
local pancreatic complication was not significantly
different from that in those with mild disease (P = 0-80)
(Table 1).
Discussion
The present study demonstrates that during the first 2
days of admission, concentrations of markers of
inflammation in the sera of patients with acute pan¬
creatitis are highest in those who subsequently develop
organ failure.
TNF has been implicated as a key mediator in the
development of multiple organ failure20-23. In the present
study, however (in keeping with previous reports6-7), TNF
was detected in only 17 patients on the first day of
admission and in eight by the second day. This finding
may be accounted for by the short half-life of serum TNF
and the fact that blood for TNF estimation was sampled
only once per day. Other authors have suggested that
TNF appears transiently and repetitively in the circulation
and thus the peak concentration of TNF could easily be
missed by infrequent blood sampling24. In contrast, soluble
TNF receptors were detected in all patients, with a
progressive increase in the median concentration of both
sTNFR55 and sTNFR75 being observed among patients
who had mild disease, those who developed a local
pancreatic complication alone and those who developed
organ failure (Figs 1 and 2). Spinas and co-workers"
demonstrated a significant correlation between peak
serum TNF and sTNFR55 in human volunteers after
intravenous administration of Escherichia coli endotoxin,
suggesting that sTNFR5S may reflect the degree of TNF-
induced inflammation. If this assumption is correct, the
finding in the present study of increased soluble TNF
receptors on admission in patients who subsequently
develop severe acute pancreatitis would support the
contention that TNF is an important central mediator of a
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Circulating Endotoxin, Tumour Necrosis Factor-Alpha, and Their Natural
Antagonists in the Pathophysiology of Acute Pancreatitis
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Inflammatory mediators, such as endotoxin and tumour necrosis factor-alpha (TNF-a) have been
implicated in the pathogenesis of acute pancreatitis. However, serum levels of these mediators in patients
with acute pancreatitis are often not detectable on hospital admission. In contrast, their circulating
antagonists (antiendotoxin antibodies and soluble TNF-a receptors) are detectable in all patients. With
increasing severity of disease, patients are more likely to manifest a fall in antiendotoxin levels,
suggesting exposure to endotoxin. Similarly, there is a stepwise increase in soluble TNF-a receptors with
increasing severity of disease. This suggests that the degree of TNF-a-induced inflammation correlates
with disease severity. The role of endotoxin, TNF-a and their relevant antagonists as markers or
mediators of the systemic complications of acute pancreatitis remains under investigation.
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endotoxin; inflammatory response; tumour necrosis factor-alpha; tumour necrosis factor-alpha receptors
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Inflammatory mediators are thought to be important in the
pathogenesis of the systemic sequelae of acute pancreatitis.
Two such mediators are endotoxin and tumour necrosis
factor-alpha (TNF-a). Endotoxin, released from Gram-
negative organisms following bacterial lysis, is a potent
stimulus for the release of proinflammatory cytokines from
leukocytes and endothelial cells. In acute pancreatitis,
reduced intestinal perfusion resulting in increased intestinal
permeability might allow endotoxin to cross the gut wall and
enter the circulation. Alternatively, endotoxin might enter the
circulation from other infective foci (e.g. a pancreatic
abscess). TNF-a, a major proinflammatory cytokine, is
considered to be important in orchestrating the early events
in the inflammatory response and may contribute to the
induction of organ failure in severe inflammatory states.
ENDOTOXIN
The outermost layer of the bacterial cell surface consists of
Iipopolysaccharide and is chemically unique for each strain
of bacteria. The term, endotoxin, refers to the impure extract
of lipopolysaccharide found in combination with different
proteins. Patients with pancreatitis are prone to develop
hypoxia, hypotension, renal failure, hypocalcaemia and
disseminated intravascular coagulation, all of which can be
produced experimentally by endotoxin. It has been estab¬
lished for some time now that endotoxaemia occurs in a
proportion of patients with acute pancreatitis (1,2). Foulis et
al. (1) studied 26 attacks of acute pancreatitis and detected
endotoxin in 13 of the attacks. Furthermore, endotoxaemia
was found in six of the seven patients defined as having a
severe attack. In this study, blood was sampled only once per
day and endotoxaemia was said to be present if endotoxin
was detected on two consecutive days. The release of
endotoxin is known to be episodic and endotoxin is rapidly
cleared from the circulation. Thus, detection of endotox¬
aemia in patients with acute pancreatitis may not only be
related to disease severity, but also to the timing and
frequency of blood sampling. In another study (2), endotoxin
was detected in only 51% of patients with predicted severe
disease when blood samples were taken on days 1, 3 and 7
following admission. To address this question further,
Kivilaakso et al. (3) measured the levels of antienterobacter¬
ial common antigen antibody. The enterobacterial common
antigen is a component of the cell wall of Gram-negative
bacteria. It is common to all enteric bacteria and is spatially
linked to lipopolysaccharide. At the time of admission,
patients with severe acute pancreatitis were found to have
significantly depressed antienterobacterial common antigen
antibody litres when compared to both patients with mild
disease and to controls. Furthermore, there was a significant
rise in the titre during the course of the illness in those
patients who survived. This rise was not seen in those
patients who died. The exact mechanism for these changes in
antienterobacterial common antigen antibody remains to be
delineated. However, they suggest significant exposure to
enterobacterial common antigen from the portal circulation,
with either binding to circulating antibody and subsequent
removal of the resulting complexes (fail in titre), or the
synthesis of new antibody (rise in titre).
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Table I. Fall in IgM and IgG antiendotoxin antibody response in
patients with predicted mild and severe pancreatitis (*p < 0.001 and
**p < 0.05 Fisher's exact two-tailed test). Reproduced with
permission (4)
IgM antibody IgG antibody
Mild pancreatitis (it = 10) 4 0
Severe pancreatitis (n = 23) 23* 9**
ANTIENDOTOXIN ANTIBODIES
In our study (4), we investigated naturally occurring,
circulating antibodies that react with the core glycolipid
region of endotoxin. We found that the serum concentration
of IgM antiendotoxin antibodies fell (defined as less than the
10th centile of the normal population or a greater than 50%
reduction below the median value) in all patients with
predicted severe pancreatitis (Table I). This change was
independent of any alteration in the total serum immunoglo¬
bulin concentration. In contrast, the serum IgG antiendotoxin
antibody concentration fell in only nine of the 23 patients
with predicted severe pancreatitis, while a significant fall in
IgG class antiendotoxin antibody concentration occurred in
all seven patients who developed multiple organ failure (of
whom five died). This suggests that depletion of the IgG
antiendotoxin antibody pool is physiologically important. A
possible explanation for this association is that low antibody
titres allow increased exposure to free endotoxin. This results
in enhanced activation of systemic responses, such as the
cytokine cascade, which are linked to the development of
multiple organ failure. These findings are similar to those in
our more recent study of sepsis syndrome due to infection, in
which a significantly higher mortality rate (5) was found in
patients, who had depleted IgG antiendotoxin core antibody
upon admission to the intensive care unit.
TUMOUR NECROSIS FACTOR-ALPHA (TNF-a)
Endotoxin has a number of actions that can contribute to the
inflammatory response. It is known to activate the comple¬
ment pathway and C3 catabolism has been demonstrated in
patients with acute pancreatitis (1). It can stimulate immune
competent cells to release a vast array of inflammatory
mediators, including cytokines, free radicals and bioactive
lipids. One of the major cytokine mediators, that can
potentially be released by endotoxin, is TNF-a. It is secreted
predominately by activated monocytes and macrophages, but
lymphocytes, fibroblasts and other cells also produce TNF-a.
The central role of TNF-a in orchestrating an early
inflammatory response in patients with sepsis syndrome is
well established. Elevated levels of TNF-a have been
documented in the serum of patients with sepsis (6) and
following exposure to endotoxin (7). However, TNF-a is
often undetectable in the sera of patients with acute
pancreatitis, even in those with severe disease (2, 8, 9). This
may be due to the short serum half-life of TNF-a, the binding
of TNF-a to other proteins, difficulties with the various
methods of measuring TNF-a in serum, or that TNF-a is
mainly produced in the tissues and only occasionally spills
over into the circulation. TNF-a is also broken down by
neutrophil elastase, which is elevated in patients with acute
pancreatitis (10).
Soluble TNF-a receptors
TNF-a exerts its paracrine and endocrine action by
interaction with membrane-bound TNF-a receptors on the
surface of target cells. Following exposure to substances, such
as bacterial endotoxin and TNF-a itself, such target cells
downregulate their responsiveness to TNF-a by shedding the
receptor into the circulation. Two such soluble receptors have
been identified: a 55 kDa (sTNFR55) and a 75 kDa (sTNFR75)
fragment (11). The biological function of these shed receptors
is not clear, but they may bind to circulating TNF-a and
therefore reduce its bioavailability.
We studied the serum concentration of TNF-a and soluble
TNF receptors in 58 non-consecutive patients with acute
pancreatitis on the first day of admission (12). Thirty of these
patients had mild disease and the remainder had severe
disease as defined by the Atlanta classification (13), of whom
18 subsequently developed a local pancreatic complication
and 10 developed organ failure, as defined by the Goris score
(14). As found by others, TNF-a was detected in a minority of
patients (29%) (Table II). In contrast, soluble TNF-a
receptors were detected in all patients. There was a stepwise
and statistically significant (p < 0.01 Mann-Whitney U test)
increase in the median concentration of both sTNFR55 and
STNFR75 at hospital admission in patients eventually
Table II. Number of patients with acute pancreatitis with detectable TNF-a and soluble TNF receptors on admission. Severity of disease was




































pancreatic acinar cell in an experimental model (18). TNF-a
has also been demonstrated in pneumatocytes in the lung
tissue of patients with acute pancreatitis dying from acute
lung injury (18). However, a cause-and-effect relationship has
not been established for TNF-a.
Both endotoxin and TNF-a are biologically active
compounds that have been implicated as key mediators in
the development of sepsis syndrome and progression to
multiple organ failure. In patients with acute pancreatitis,
detection of such mediators in the serum is variable, even in
patients with severe disease. Nevertheless, the depletion of
serum antibodies to endotoxin and the release of soluble TNF-
a receptors into the circulation suggest that both endotoxin
and TNF-a are involved in the systemic inflammatory
response in acute pancreatitis.
Fig. 1. Median serum sTNFR55 and sTNFR75 concentrations on the
first day of admission in patients with acute pancreatitis categorized
by mild disease (n = 30, O). local pancreatic complication alone
(n = 18, □), and organ failure (n = 10, ■). The interquartile range
is represented by error bars. Reproduced with permission (12).
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classified into those with mild disease, a local pancreatic
complication alone, or organ failure (Fig. 1).
Spinas et al. (15) demonstrated a significant correlation
between peak serum TNF-a and sTNFR55 in human
volunteers after intravenous administration of Escherichia
coli endotoxin, suggesting that sTNFR55 may reflect the
degree of TNF-a-induced inflammation. If this assumption is
correct, the finding of elevated soluble TNF-a receptors on
admission in patients who later develop severe acute
pancreatitis would support the contention that TNF-a is an
important central mediator of the systemic inflammatory
response and may also contribute to the development of
multiple organ failure. Interestingly, polyclonal anti-TNF-a
has been shown to have a therapeutic effect in experimental
acute pancreatitis in rodents (16).
Endotoxin is not the only stimulus for the release of TNF-a.
Hughes et al. (17) induced acute pancreatitis in germ-free rats.
They found that a similar rise occurred in serum TNF-a in
both normal and germ-free rats with acute pancreatitis and
that this rise was significantly greater compared with that in
sham-operated animals. Endotoxaemia was not detected in
any of the study groups. Thus, a stimulus other than endotoxin
must be responsible for the production of TNF-a in this model
of acute pancreatitis. As endotoxaemia and endogenous
antiendotoxin antibody depletion are more prevalent in non-
survivors of pancreatitis, severe disease may compromise the
integrity of the gut mucosal barrier, leading to endotoxin
translocation. However, whether such translocation is simply
a reflection rather than a key mediator of severe pancreatitis
and its sequelae is not known. In support of a role for TNF-a
in the pathogenesis of acute pancreatitis, messenger RNA for
TNF-a and TNF-a itself have been demonstrated in the
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